2020-06-13T01:53:15Zhttps:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi
oai:pubmedcentral.nih.gov:70996592020-04-06pheelsevierpmc-open
Comprehensive Toxicology Comprehensive Toxicology PMC7099659 PMC7099659 7099659 B978-0-08-046884-6.01112-X 10.1016/B978-0-08-046884-6.01112-X Article Immunology of the Testis and Male Reproductive Tract Hedger M.P. Monash University, Melbourne, VIC, Australia McQueen Charlene A. Harrison School of Pharmacy, Auburn University, Auburn, AL, USA 12 7 2010 2010 12 7 2010 189 230 Copyright © 2010 Elsevier Ltd. All rights reserved. 2010 Elsevier Ltd Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

A large body of evidence points to the existence of a close, dynamic relationship between the immune system and the male reproductive tract, which has important implications for our understanding of both systems. The testis and the male reproductive tract provide an environment that protects the otherwise highly immunogenic spermatogenic cells and sperm from immunological attack. At the same time, secretions of the testis, including androgens, influence the development and mature functions of the immune system. Activation of the immune system has negative effects on both androgen and sperm production, so that systemic or local infection and inflammation compromise male fertility. The mechanisms underlying these interactions have begun to receive the attention from reproductive biologists and immunologists that they deserve, but many crucial details remain to be uncovered. A complete picture of male reproductive tract function and its response to toxic agents is contingent upon continued exploration of these interactions and the mechanisms involved.

cytokines immunity immunoregulation inflammation Leydig cell lymphocytes macrophages nitric oxide prostanoids seminal plasma Sertoli cell sperm spermatogenesis steroidogenesis toll-like receptors 16:0a-LPC, 1-palmitoyl-sn-glycero-3-phosphocholine 18:1a-LPC, 1-oleoyl-sn-glycero-3-phosphocholine 18:2a-LPC, 1-linoleoyl-sn-glycero-3-phosphocholine 20:4a-LPC, 1-arachidonyl-sn-glycero-3-phosphocholine AID, acquired immune deviation Aire, autoimmune regulator AP1, activated protein 1 APC, antigen-presenting cell BAMBI, BMP and activin membrane-bound inhibitor BMP, bone morphogenetic protein COX, cyclooxygenase Crry, complement receptor-related protein CTL, cytotoxic T lymphocyte EAO, experimental autoimmune orchitis EDS, ethane dimethane sulfonate eNOS, endothelial NOS FADD, Fas-associated death domain protein FasL, Fas ligand FSH, follicle-stimulating hormone GC, glucocorticoid hCG, human chorionic gonadotropin HLA, human leukocyte antigen HMGB1, high mobility group box chromosomal protein 1 ICE, IL1 converting enzyme IFN, interferon IFNAR, IFNα receptor IL, interleukin IL1R, interleukin 1 receptor IL1ra, IL1 receptor antagonist iNOS, inducible nitric oxide synthase IRF, interferon regulatory factor Jak/Stat, Janus kinase/signal transducers and activators of transcription Jnk, Jun N-terminal kinase LH, luteinizing hormone LPC, lysoglycerophosphatidylcholine LPS, lipopolysaccharide MAP, mitogen-activated protein MHC, major histocompatibility complex MIF, macrophage migration inhibitory factor MyD88, myeloid differentiation primary response protein 88 NFκB, nuclear factor kappa B NK, cell natural killer cell NKT cell, natural killer T cell NLR, Nod-like receptor nNOS, neuronal NOS Nod, nucleotide binding oligomerization domain P450c17, 17α-hydroxylase/C17-C20 lyase P450scc, cholesterol side-chain cleavage complex PAF, platelet-activating factor PAMP, pathogen-associated molecular pattern PC, phosphocholine PG, prostaglandin PGES, PGE synthase PGI, prostacyclin PLA2, phospholipase A2 PMN, polymorphonuclear phagocyte PPARγ, peroxisome proliferator-activated receptor γ RIG, retinoic acid-inducible gene RLH, RIG-like helicase ROS, reactive oxygen species StAR, steroidogenic acute regulatory TCR, T cell receptor TGF, transforming growth factor Th cell, helper T cell TIR, Toll/IL1R TLR, Toll-like receptor TNF, tumor necrosis factor TNFR, TNF receptor Tr1, T regulatory 1 TRADD, TNFR-associated death domain protein TRAF, tumor necrosis factor receptor-associated factor Treg, regulatory T cell TRIF, TIR domain-containing adaptor protein inducing interferon β Tx, thromboxane TxAS, thromboxane A synthase
Background

In the decade since this chapter was first published (Hedger 1997), there has been considerable progress in the understanding of the regulation of immunity. Advances such as the emergence of the innate immune system as a major theme in immunity following the discovery of the toll-like receptor (TLR) family (O’Neill and Dinarello 2000), the formalization of multiple macrophage phenotypes corresponding to the type 1 and 2 helper T (Th) cell subsets (Mantovani et al. 2005), the rehabilitation of suppressor and regulatory T cells (Piccirillo and Thornton 2004), and the identification of new lymphocyte subsets, including Th3, Th17, and natural killer T (NKT) cells (Godfrey et al., 2000, MacDonald, 1998, Romagnani, 2008), also have had considerable influence on the concept concerning the immunology of the male reproductive tract. Nonetheless, while there have been advances in our understanding of the interface between the male reproductive tract and the immune system, there is still much we simply do not know. The need to understand this interface and the potential implications for reproductive toxicology continues to be just as important as ever.

There is no doubt that the testis and the male germ cells in particular are susceptible to immunological damage. Clinically significant testicular autoimmunity, most commonly indicated by the presence of antisperm antibodies in the serum or ejaculate, is implicated in the case of 5–12% of all male infertility patients within the developed world (Baker et al., 1983, Pattinson and Mortimer, 1987), but the incidence is much higher in populations where access to reproductive health care is limited (Ekwere 1995). Common factors suspected to contribute to testicular autoimmunity include reproductive tract infections, physical trauma, immune system dysfunction, and genetics. The release of spermatogenic antigens from the reproductive tract following vasectomy generally results in autoimmune responses, ranging in severity from sperm antibodies to orchitis, in both humans and experimental animals (Alexander and Anderson, 1979, Flickinger et al., 1990a, Kojima and Spencer, 1983, Tung and Alexander, 1980). The potential for spontaneous testicular autoimmune disease in otherwise normal men remains poorly characterized, although studies in animals clearly indicate the possibility of such reactions in humans (Furbeth et al., 1989, Tung et al., 1981). Complicating matters is the fact that the testis is an immunologically privileged tissue, in the sense that foreign tissue grafts into the testes of experimental animals survive for prolonged periods (Barker and Billingham, 1977, Head et al., 1983a, Whitmore and Gittes, 1978). This dichotomy between immune susceptibility and privilege is indicative of a highly specialized interaction between the male reproductive system and the immune system, with potentially important implications for both systems. The objective of this chapter is to provide an overview of the current state of knowledge and to highlight issues for further consideration that may be of relevance to male reproductive toxicology.

The Interface between the Immune System and the Reproductive Tract

The immune system is the body’s protective arsenal against disease. It operates via the detection of potential aggressors, recognized through conserved motifs found on pathogenic organisms (innate immunity) or confrontation by completely novel (i.e., foreign) molecular structures (adaptive immunity) (Vivier and Malissen, 2005, Zinkernagel, 2000). Immunity involves specialized cells possessing highly developed recognition and activation abilities (macrophages and dendritic cells) and the cells that carry out the protective responses: T and B cells in the case of adaptive immunity and NK cells and mononuclear or polymorphonuclear phagocytes (PMNs) in the case of innate immunity. Many of these cells play roles in both the recognition and effector arms of the immune response and in both innate and adaptive immunities (Figure 1). Innate immunity provides the rapid response elements of the immune system, but is limited in its attack repertoire. Adaptive immunity is much more flexible in its responses, but requires some time to become effective. Once the adaptive arm has been activated toward a particular pathogen, however, it can respond rapidly in the future due to the persistence of memory lymphocytes, which form the basis of immunization (McGhee et al., 1993, Schittek and Rajewsky, 1990).

Polarization in the immune system. The immune system is conceptually divided into innate and adaptive arms, with adaptive immunity further subdivided into type 1 (cell-mediated) and type 2 (antibody-mediated) responses. Triggering of the immune response involves the induction of inflammation by various agents, which may include infections, particulates, debris from damaged cells, or noxious agents. Innate immunity involves fixed pattern-recognition receptors, such as the Toll-like receptors, whereas adaptive immunity depends upon highly polymorphic receptors expressed by T cells (T cell receptors) and B cells (membrane-bound and secreted immunoglobulin). In general, type 1 responses are associated with cellular immunity, autoimmune reactions, and graft rejection. Type 2 responses involve antibody production by the B cells, but also play a more complex role in allergy, immunoregulation, and control of tolerance, favoring immune privilege. Within these divisions, various cell types, cytokines, chemokines, bioactive lipids, and other molecules interact to integrate or mediate the responses. The direction of the adaptive immune response type is determined primarily by the activity of the antigen-presenting cells (primarily dendritic cells) under the influence of cells with immunoregulatory capacity, such as macrophages, NK cells, and NKT cells, and either type 1 or type 2 cytokines produced locally. Several cell types and molecules play multiple roles within different functional divisions. Abbreviations: Mo, monocyte; NK, natural killer cell; PMN, polymorphonuclear cell; Th; helper T cell; B, B cell; Treg, regulatory T cell; M, macrophage; NKT, natural killer T cell; CTL, cytotoxic T cell; APC, antigen-presenting cell, ROS, reactive oxygen species; IFN, interferon; PGE, prostaglandin E; COX, cyclooxygenase; iNOS, inducible nitric oxide synthase; TNFα, tumor necrosis factor α; IL, interleukin; IL1ra, interleukin 1 receptor antagonist; TGFβ, transforming growth factor β; GC, glucocorticoid; MIF, macrophage migration inhibitory factor.

The Innate Immune Response

The innate immune system operates upon recognition by specific pattern-recognition receptors of specific motifs found on bacterial, viral, fungal, and protozoan pathogens. Functionally, these receptors have evolved to recognize pathogen-associated molecular patterns (PAMPs), such as bacterial lipopolysaccharides (LPSs), lipoproteins, peptidoglycans, and viral nucleic acids (Bianchi, 2007, Roach et al., 2005). Unlike classical ligand receptors, these receptors respond to multiple ligands possessing related, but not necessarily identical, structures. The largest and best-studied class of pattern-recognition receptors is the TLRs, which are members of a larger family of proteins that include the interleukin (IL) 1 receptor (IL1R), and which share a conserved cytoplasmic domain called the Toll/IL1R (TIR) domain (Akira and Takeda, 2004, O’Neill and Bowie, 2007). In humans, 10 functional TLRs (TLR1–10) have been identified (Figure 2). Mammalian TLRs 11–13 are known from laboratory rodent species, but are either pseudogenes or absent in humans (Roach et al. 2005). Although they are particularly associated with cells of the monocyte lineage (i.e., macrophages and dendritic cells), these receptors are also found on certain T and B cells, as well as many fibroblastic and epithelial cells, including those of the male urogenital tract (Lauw et al., 2005, Zhang et al., 2004). Significantly, ligands for some of the TLRs include endogenous molecules of mammalian origin (Barrat et al., 2005, Karikó et al., 2004, Tsan and Gao, 2004, Yasuda et al., 2005, Yu et al., 2006). TLR signaling occurs through engagement of crucial adaptor proteins, specifically myeloid differentiation primary response protein 88 (MyD88) or TIR domain-containing adaptor protein inducing interferon β (TRIF), via TIR domain interactions, leading to activation of tumor necrosis factor (TNF) receptor-associated factor 3 and 6 (TRAF3, TRAF6) (Akira and Takeda, 2004, O’Neill and Bowie, 2007, O’Neill and Dinarello, 2000). Based on the TLR engaged, this results in nuclear translocation of the inflammatory transcription factor, nuclear factor kappa B (NFκB), activation of the Jun N-terminal kinase (Jnk) and p38 mitogen-activated protein (MAP) kinases, and induction of type 1 interferon (IFNα and IFNβ) production (Hertzog et al., 2003, Malmgaard, 2004, Nakano, 2004).

The Toll-like receptors: major pathogenic ligands, adaptor proteins, signaling, and cytokine production. There are 10 active human Toll-like receptors (TLR1–10). TLR11–13 are present in rodents, and TLR11 is specific to the urogenital tract. The TLRs respond to a variety of pathogen-related molecules, usually forming homo- or heterodimers during signaling: for example, TLR2 can self-associate or combine with either TLR1 or TLR6 to mediate responses to various bacterial lipoprotein classes. TLR4 forms a complex with the receptor cofactor CD14, to facilitate binding of bacterial lipopolysaccharide (LPS). The TLRs can be subdivided into cell surface receptors, which largely respond to bacterial proteins, lipoproteins, and lipopolysaccharides, and intracytoplasmic receptors, which recognize single-stranded and double-stranded RNA (ssRNA and dsRNA) and CpG-containing DNA of viral or bacterial origin. Most TLRs signal via the adaptor protein MyD88 (myeloid differentiation primary response protein 88), except TLR3, which acts through the adaptor protein TRIF (TIR domain-containing adaptor protein inducing interferon β). Uniquely, TLR4 can interact with either MyD88 or TRIF, through engagement of the adaptor proteins Mal (MyD88 adaptor-like) or TRAM (TRIF-related adaptor molecule). Downstream signaling involves the tumor necrosis factor receptor-associated factors 3 and 6 (TRAF3 and TRAF6), activation of the transcription factors nuclear factor kappaB (NFκB) and interferon regulatory factor 1 (IRF1), or activation of the mitogen-activated protein kinases (MAP kinases) Jun N-terminal kinase (Jnk) and p38 to produce the Fos/Jun transcription factor activated protein 1 (AP1). These transcription factors interact to induce the expression of multiple proinflammatory genes, including interleukin (IL) 1α, tumor necrosis factor α (TNFα), inducible nitric oxide (iNOS), cyclooxygenase 2 (COX2), and interferon γ (IFNγ), or the type 1 interferons (IFNα, IFNβ) and TNFα. Note that many details of the signaling pathways have been omitted or truncated for the sake of simplicity.

The pattern-recognition receptor family also includes the nucleotide binding and oligomerization domain (Nod)-like receptor (NLR) family and the retinoic acid-inducible gene (RIG)-like helicases (RLHs) (Becker and O’Neill, 2007, Thompson and Locarnini, 2007). The NLRs detect various bacterial PAMPs within the cytosol. Some NLRs, such as Nod1 and Nod2, act via NFκB, while other NLRs work through induction of the cysteine protease caspase 1, which activates the proinflammatory cytokines IL1β and IL18 and initiates caspase-mediated proapoptotic pathways within the target cell. The RLHs, which detect the presence of viral RNA in the cytosol, activate both NFκB and production of type 1 IFNs.

Activation of innate immunity leads to inflammation, characterized by increased blood and lymphatic flow within the affected tissue and recruitment of immune cells to the site through production of chemokines and expression of vascular leukocyte adhesion molecules (Moser and Loetscher, 2001, Picker and Butcher, 1992). This mobilization of immune cells is accompanied by activation of complement, production of proinflammatory cytokines and acute-phase proteins, and stimulation of phagocytosis and killing of pathogens and infected cells by macrophages, PMNs, and NK cells, through production of proteases and other lytic proteins, and cytotoxic reactive oxygen species (ROS) and induction of apoptotic pathways (Rosenberg and Gallin 2003). Moreover, activation of innate immunity is responsible for initiation of the adaptive immune response, through production of regulatory cytokines and stimulation of the antigen-presenting cell (APC) abilities of dendritic cells, macrophages, and some B cells (Kelsall and Rescigno, 2004, Spörri and Reis e Sousa, 2005).

Among the cell types that mediate the innate immune response, NK cells represent a special case. These cells are of the lymphocytic lineage, but they are capable of spontaneously attacking target cells without prior sensitization by exposure to antigen (Mori et al., 2001, Westermann and Pabst, 1992). Through a complex of specific receptors on their surface, NK cells are able to recognize and directly target transformed cells, such as virally infected or tumor cells (Lanier, 2001, Mori et al., 2001). In this, NK cells provide a first-line of lymphocyte defense within the context of the innate immune response, but activated NK cells also participate in adaptive immunity, both as regulators and as effector cells of the response (Mocikat et al., 2003, Raulet, 2004).

The Adaptive Immune Response

Highly specific interactions between APCs and T cells, mediated via the polymorphic proteins of the major histocompatibility complex (MHC; the human leukocyte antigen (HLA) complex in humans) and antigen-specific T cell receptors (TCRs), are crucial to the adaptive immune response. The APCs process exogenous foreign proteins into short antigenic peptides, which are then incorporated into a structural groove on the external surface of the MHC protein complex during its assembly within the cell (Cresswell et al., 1999, Sant et al., 1999). The TCR on the surface of a T cell that has specificity for the antigen binds to the antigen–MHC complex on the APC surface, which results in activation and proliferation of the T cell. Circulating T cells express one of two coreceptors, CD4 and CD8, as part of the TCR, which direct them to recognize antigens associated with either MHC class II or I proteins, respectively (Janeway 1992). Antigens are presented to CD4+ T cells by the so-called professional APCs that express MHC class II antigens (i.e., dendritic cells, macrophages, and B cells) (Heath and Carbone, 2001, Unanue, 1984). The CD8+ T cells recognize antigens presented in the context of MHC class I proteins, which are expressed by almost all cell types in the body. Activation of the T cell also requires physical interaction between the APC and T cell involving costimulatory ligand–receptor pairs, particularly CD28:B7 and CD40:CD40L, as well as the production of either type 1 cytokines (IFNγ, IL2, and IL12) or type 2 cytokines (IL4, IL5, IL10, and IL13) (Constant and Bottomly, 1997, Heath and Carbone, 2001, Moser and Murphy, 2000). As a consequence, the activated T cell can have a number of different fates depending on the costimulatory molecules engaged and cytokines produced: activated CD4+ T cells may become type 1 helper (Th1) cells, which direct development of the cellular immune response involving cytotoxic CD8+ T cells, or they may become type 2 helper (Th2) cells, which promote the development of B cells into antibody-secreting plasma cells following interaction with their antigen (DeFranco 1987). Recently, a new Th effector cell subset (Th17) developmentally related to Th1 cells, but producing IL17, IL21, and IL22 has been described (Ouyang et al., 2008, Romagnani, 2008). These Th17 cells direct a number of responses involved in protection against extracellular pathogens, including recruitment and activation of the major circulating PMN subset, the neutrophils, differentiation of B cells, and inflammatory reactions of epithelial cells. However, this cell subset has also been implicated in the development of autoimmune diseases and, along with Th2 cells, in allergy (Oboki et al., 2008, Ouyang et al., 2008). The absence of appropriate costimulatory molecule interactions and/or the presence of specific regulatory cytokines may also lead to T cell inactivation and deletion or generation of regulatory (i.e., suppressor) T cell subsets (Gilliet and Liu, 2002, Nossal, 1994, Piccirillo and Thornton, 2004, Thompson and Thomas, 2002). Finally, at least some activated T and B cell clones persist as memory cells following the resolution of the immune response (Dutton et al., 1998, Schittek and Rajewsky, 1990).

The initial antigen presentation and lymphocyte activation events generally occur in the secondary immune tissues, the local lymph nodes and spleen. Consequently, an effective lymphatic drainage is usually necessary for immune responses to develop in a particular tissue. However, since leukocytes recirculate through tissues, many of the important events, including antigen exposure and processing, antigen recognition by antigen-exposed lymphocytes, and lymphocyte maturation and proliferation, also occur at the reaction site itself (Ascher et al., 1983, Gruber, 1992, Pedersen and Morris, 1970). Moreover, while it is generally accepted that the adaptive immune system is activated by the presence of foreign antigens, there is an alternative activation model that combines elements of both the innate and adaptive immune systems. This is encapsulated by the ‘danger hypothesis,’ which proposes that APCs respond to substances that cause or signal damage, rather than to those that are simply foreign (Matzinger 1994). These danger signals include CD40L, the early proinflammatory cytokines IL1β and TNFα, IFNs, and heat-shock proteins as well as substances that are normally found only inside cells (e.g., nucleotides, unmethylated CpG sequences in mammalian double-stranded DNA) and hyaluron breakdown products (Gallucci and Matzinger 2001). In this model, activation of the immune system occurs as a response to evidence of an extant threat, rather than toward a specific feature of the threat itself. This mechanism may contribute to the onset of certain autoimmune diseases.

Immunological Tolerance

While an effective immune response is essential for protection of the host from a range of threats, the immune system also has its dark side. The capacity of the immune system for destructiveness is expressed in chronic inflammatory and autoimmune diseases, including those that affect the male reproductive tract (Roper et al., 1998, Schuppe and Meinhardt, 2005, Schuppe et al., 2008, Suominen, 1995). These examples of an immune system seemingly out of control highlight the crucial importance of effective immunoregulation. At the center of immunoregulation is the concept of tolerance, or the capacity of the immune system to ignore certain molecular patterns, and the systems that restrain the immune response once its usefulness has expired.

Tolerance is the ability of the immune system to discriminate self from nonself. It is fundamentally based on the removal, inactivation, or suppression of self-reactive lymphocyte subsets, so that the immune system becomes effectively incapable of recognizing and reacting to these antigens. Induction of tolerance comprises both central and peripheral mechanisms. The central mechanism involves clonal deletion of T and B cell subsets that are potentially autoreactive, a process that normally occurs during gestation as part of the early maturation of the immune system (Kappler et al., 1987, Nossal, 1994). Many details of this editing process remain incompletely understood, although the process involves broad expression by thymic medullary cells of self-antigens, including many endocrine tissue-specific antigens under the control of the transcription factor autoimmune regulator (Aire) (Liston et al. 2003). Lymphocytes that recognize these self-antigens within the thymus during this process are targeted for destruction, effectively removing them from the lymphocyte repertoire. In addition, there are a number of complex mechanisms of peripheral tolerance, which involve the inactivation of antigen-specific lymphocytes in peripheral lymphoid organs by weak antigen stimulation in the absence of appropriate costimulation and the production of lymphocytes with immunoregulatory activities (Gilliet and Liu, 2002, Piccirillo and Thornton, 2004, Thompson and Thomas, 2002). Peripheral immunoregulation involves several antigen-specific regulatory or suppressor T cell types, most notably the CD4+CD25+ regulatory T cell (Treg) subset. These cells selectively produce the immunosuppressive cytokines transforming growth factor β (TGFβ) and IL10, but also appear to act via direct contact with the cell being suppressed (Nakamura et al., 2001, Piccirillo et al., 2002). Other T cell subsets implicated in immunosuppression through their ability to produce TGFβ and IL10 include Th3 cells, Tr1 (T regulatory 1) cells, and γδ T cells, the latter being a minor T cell subset that is generally associated with epithelia (Kuhnlein et al., 1994, MacDonald, 1998, Seo et al., 2001). The NKT cells, which are T cells with NK activity that possess unique restriction to glycolipid antigens presented by the MHC-like molecule CD1d, play a role in promoting graft survival and development of CD8+ regulatory/suppressor T cells through production of IL4 and IL10 (Godfrey et al., 2000, Nakamura et al., 2003, Sonoda et al., 2001). The frontline NK cells are able to modulate adaptive immune responses by inducing dendritic cell death through contact-mediated lysis, but are also capable of producing IFNγ to stimulate the antigen-presenting activity of dendritic cells (Laouar et al., 2005, Raulet, 2004).

It is the absence of tolerance that inhibits graft success in the very artificial condition of tissue transplantation. The immune cells of both the graft recipient and the donor tissue respond to one another, particularly with respect to polymorphic differences of the MHC proteins, leading to rejection of tissues that are not antigenically matched (Gould and Auchincloss 1999). Even under normal conditions, failure of preexisting tolerance may occur through a number of mechanisms, leading to autoimmune disease. Somatic mutation of the antigen receptor expressed by a T or B cell may result in the creation of new self-reactive clones, subverting central tolerance (Burrows et al. 2000). Autoimmunity may also occur when the inflammatory response to an infection damages or overwhelms normal mechanisms of self-tolerance, or where the infection involves organisms that express antigens that may cross-react with self-antigens (molecular mimicry) (Merkler et al., 2006, Regner and Lambert, 2001).

In addition to lymphocyte-mediated tolerance already discussed, the immune system possesses a repertoire of mechanisms that control and limit inflammatory and immune responses once they have commenced. Inflammation triggers the production by the adrenal gland of corticosteroids, which inhibit the production of proinflammatory cytokines and other immune mediators, reduce the expression of leukocyte adhesion molecules, and induce lymphocyte apoptosis (Buckingham et al., 1996, Kapcala et al., 1995). During inflammation, immune cells themselves produce anti-inflammatory and immunosuppressive molecules, including prostaglandins D and J and the lipoxins (Herlong and Scott, 2006, Levy et al., 2001). Moreover, activated lymphocytes have a limited lifespan, undergoing a process of activation-induced cell death following upregulation of the extrinsic apoptotic signal mediated by interaction of the Fas receptor (CD95) with its ligand (Fas ligand: FasL or CD95L), eventually leaving behind a relatively small number of long-lived memory cells (Dutton et al., 1998, Schittek and Rajewsky, 1990). Likewise, there are mechanisms to inhibit antibody activity and promote antibody clearance (Isaacs 1990).

The Concept of Immune Privilege

Classically, the term immune privilege applies to organs or tissues where survival of foreign grafts may be prolonged (Barker and Billingham 1977), but more accurately, the term denotes tissues where immune responses are inhibited or suppressed (Hedger 2007). Privileged tissues include the brain, eye, pregnant uterus, and the testis. Initially, privilege was attributed to deficient lymphatic drainage in such tissues, or physical barriers that prevented immune cells from gaining access (Barker and Billingham 1977). Several privileged tissues do possess highly specialized epithelial or endothelial cell barriers that may sequester antigens away from the normal immune surveillance: the best characterized of these are the blood–brain barrier and the trophoblast in the pregnant uterus (Hunt, 2006, Streilein, 1993). However, physical exclusion is now considered an overly simplistic explanation for immune privilege, given that lymphocyte and antibody responses to introduced antigens occur even in sites where grafts can survive for extended periods (Head et al., 1983b, Kaplan and Streilein, 1978, Tafuri et al., 1995). Although barrier mechanisms and altered lymphatics may be contributory factors in some tissues, immune privilege is a consequence of tissue-specific specialized systems for controlling, subverting, or preventing local inflammatory or immune activation responses (Hedger 2007).

Testicular Organization and Immunity

The male reproductive tract comprises the paired testes, associated epididymis and vas deferentia, accessory glands (chiefly the prostate and seminal vesicles), and the urethra. These tissues represent a diversity of structures and, consequently, the immunology of each tissue retains distinctive features (Hedger and Hales 2006). Best studied in this context is the testis, which comprises two discrete tissue compartments, the seminiferous tubules and the interstitial tissue. The interstitial tissue contains the blood supply and lymphatics, as well as the innervation of the testis (Fawcett et al., 1973, Setchell et al., 1994). The epithelium of the seminiferous tubules is entirely avascular. Within the seminiferous epithelium, spermatogenesis is supported and maintained by the Sertoli cells, which remain in physical contact with the developing germ cells at all times. During spermatogenesis, a stem cell spermatogonium sitting on the basement membrane of the seminiferous tubule becomes committed to a series of mitotic divisions, producing a cohort of spermatocytes. The spermatocytes subsequently move toward the tubule lumen, passing through tight junctions between adjacent Sertoli cells, into the highly specialized environment of the adluminal compartment (Wang and Cheng 2007). Within this compartment, the spermatocytes divide meiotically to produce haploid spermatids and then undergo differentiation into spermatozoa, which are ultimately released into the lumen of the tubule leaving behind the majority of their cytoplasm to be digested by the Sertoli cells as residual bodies. The released spermatozoa are swept by fluid secreted from the Sertoli cells toward the rete testis, a collecting structure lined by a simple epithelium that is connected to the adjacent epididymis by a series of efferent ducts. Sperm mature and are stored in the epididymis, until they are either released through the vas deferentia at the time of ejaculation or removed by epididymal phagocytes (Barratt and Cohen, 1987, Roussel et al., 1967).

The process of spermatogenesis is highly organized, with multiple generations of developing germ cells in each region of the epithelium maintaining distinct, progressing cellular associations or stages, which comprise the cycle of the seminiferous epithelium (14 stages in the rat, 12 stages in the mouse, 6 stages in man). These stages are arranged in sequence along the length of each seminiferous tubule, creating waves of coordinated spermatogenic development (Clermont 1972). Spermatogenesis is maintained and controlled by follicle-stimulating hormone (FSH) and testosterone, the latter being produced by the Leydig cells in the interstitial tissue under the influence of luteinizing hormone (LH). Importantly, FSH and testosterone act upon Sertoli cells and not directly on the germ cells (McLachlan et al. 1996). These hormones determine the efficiency of the spermatogenic process largely by controlling germ cell survival, that is, the balance between differentiation and apoptosis (Matthiesson et al., 2006, Ruwanpura et al., 2008). In order to maintain the cycle of the seminiferous epithelium, the developing germ cells and Sertoli cells are engaged in continuous intercellular communication, although the precise nature of this communication remains very poorly understood.

The testis, and spermatogenesis in particular, presents a unique challenge for the immune system. Although there are reports of direct drainage of some lymphatic vessels to the thoracic duct, there is no evidence of any structural or functional deficiency in the efferent lymphatics of the testis, and allogeneic cells injected into the rat testis induce typical immune responses in the draining lymph nodes (Fawcett et al., 1973, Head et al., 1983b, Itoh et al., 1998a, Moller, 1980). Nonetheless, the vast majority of spermatogenic differentiation occurs long after central tolerance is established and, while thymic expression of some testicular antigens is under the control of the Aire transcription factor, it is obvious from clinical and experimental studies that germ cells express multiple autoreactive antigens and are highly immunogenic when brought into contact with the immune system (Itoh et al., 1991, Tung, 1975). Surprisingly, this is a problem for a relatively small cohort of men only, and autoimmune orchitis or epididymitis is rarely reported in humans, except in the context of local infection (Krieger 1984). Even allowing for the possibility that most cases of spontaneous autoimmune reactions against the developing germ cells are never diagnosed, since they would occur early in reproductive life, and would simply present as spermatogenic failure during infertility work-ups (Schuppe and Meinhardt, 2005, Schuppe et al., 2008), why are such reactions not more common?

The Role of the Blood–Testis Barrier and Immune Ignorance

It is widely believed that the blood–testis barrier plays a role in protecting testicular antigens from the immune system. However, as a result of a common misunderstanding of the nature of this vitally important structure, its actual role is usually overestimated. Critically, the blood–testis barrier involves highly specialized occluding or tight junctions between adjacent Sertoli cells, which separate the spermatogonial and early meiotic cells from the majority of meiotic and postmeiotic germ cells (Dym and Fawcett, 1970, Setchell et al., 1969). The structure and functions of the barrier do not need to be discussed in detail here, as this topic is covered in much more detail in other chapters in this volume (see Chapter 11.05). By preventing the passage of most molecules between adjacent Sertoli cells, the blood–testis barrier allows the creation of a highly specialized biochemical environment essential for meiotic development (Cheng and Mruk, 2002, Griswold, 1988). It also blocks access by lymphocytes, complement, and antibody (Ben et al., 1986, Yule et al., 1988). By contrast, the vascular endothelium and peritubular cells surrounding the tubules play a negligible role in maintaining the blood–testis barrier in practical terms, and immune cells and proteins have relatively free access to the interstitium and basal seminiferous epithelium (Mahi-Brown et al., 1988, Yule et al., 1988). Thus, this barrier is quite different in properties and function from the blood–brain barrier, located on the vascular endothelium, or the trophoblastic barrier of pregnancy, which entirely segregates the developing fetal tissues from the maternal host.

A reinterpretation of the blood–testis barrier as a series of cellular elements that protects the germ cells from harmful influences has been proposed more recently (Bart et al. 2002). In this model, the blood–testis barrier consists not only of the structural elements already discussed, but also the efflux pump barrier system involving the drug transport proteins p-glycoprotein and the multidrug resistance-associated protein-1 expressed on the capillary endothelium, peritubular myoid cells, and the basal aspect of the Sertoli cells (Bart et al., 2004, Melaine et al., 2002). While these elements may certainly be important for protection of the testis against toxic agents, their contribution to immunoregulation is probably marginal.

Several lines of evidence indicate that the blood–testis barrier cannot account for all manifestations of immune privilege in the testis. The barrier does not prevent exposure of germ cell antigens to the immune system, as antibodies and lymphocytes specific for spermatogenic antigens appear to be a normal feature of the circulating immune repertoire even under normal conditions (Turek and Lipshultz 1994). Spermatogenic cell autoantigens are not confined behind the Sertoli cell tight junctions, and are expressed by spermatogonia and the early spermatocytes (Mahi-Brown et al., 1987, Mahi-Brown et al., 1988, Yule et al., 1988). Moreover, the barrier does not extend into the rete testis or beyond. Significantly, orchitis can be passively transferred to naive mice using lymphocytes obtained from mice with active autoimmune orchitis, with the initial reaction concentrated in the interstitial tissue around the rete testis (Mahi-Brown et al., 1987, Tung et al., 1987). A similar initial pattern of development of orchitis within the rete testis region has been observed in mice actively immunized with viable germ cells (Itoh et al. 1995a). In many seasonally breeding species, annual regression of the blood–testis barrier occurs without inducing overt inflammation or autoimmunity (Pelletier, 1986, Tung et al., 1981). Finally, the blood–testis barrier cannot explain the enhanced survival of grafts within the interstitial tissue (i.e., outside the barrier) and does not explain survival of autoantigenic sperm in the epididymis, or remainder of the male reproductive tract. However, while the blood–testis barrier does not explain immune privilege in the testis, the breach of the tight junctions comprising the barrier remains a critical event in the development of any autoimmune destruction of the seminiferous epithelium during orchitis (Mahi-Brown and Tung, 1989, Mahi-Brown et al., 1987).

Recognition of antigen in association with MHC is essential to normal adaptive immune responses, and reduced expression of MHC class I (HLA-A, HLA-B, and HLA-C in humans) and class II proteins (HLA-D) appears to be an important feature of immune-privileged tissues and tumors (Garrido et al., 1997, Haas et al., 1988, Head and Billingham, 1985, Wekerle et al., 1987). Reduction in class I and II expression reduces the likelihood of immune-activating events involving CD4+ helper T cells and cytotoxic CD8+ T cells in the tissues. Studies indicate a characteristic absence of expression of MHC proteins on the cells of the seminiferous epithelium under normal conditions (Haas et al., 1988, Head and Billingham, 1985, Lustig et al., 1993, Tung et al., 1987), although both MHC classes are expressed in human spermatozoa (Martín-Villa et al. 1996). There is evidence from studies on mouse Sertoli cells in culture that MHC class II expression can be upregulated in these cells by IFNγ (Dal Secco et al. 2008). In contrast to the seminiferous epithelium, both MHC class I and II proteins are expressed throughout the testicular interstitial tissue: MHC class I is expressed on most interstitial cells, including the Leydig cells (Haas et al., 1988, Pöllänen and Maddocks, 1988), while testicular macrophages and dendritic cells express MHC class II (Haas et al., 1988, Head and Billingham, 1985, Hedger and Eddy, 1987, Mahi-Brown et al., 1987, Tung et al., 1987). Thus, it appears unlikely that a lack of APCs is a contributing factor in testicular immune privilege, although differences in the number and distribution of MHC class II-expressing cells in the interstitial tissue of different species or strains may help to explain differences in susceptibility to autoimmune orchitis (Flickinger et al., 1990b, Kojima and Spencer, 1983, Teuscher et al., 1987).

The fact that the testis is not isolated from the immune system, yet can tolerate both endogenous (auto-) antigens associated with spermatogenesis and exogenous (allo- or xeno-) antigens expressed by grafts, is evidence of tissue-specific inhibition of the immune response. The question then arises: if immune responses against exogenous and endogenous antigens are inhibited in the testis environment, does the testis display a reduced capacity to deal with infections and greater susceptibility to certain kinds of tumors? There is evidence that immunity may be compromised in some situations, for example, the tendency toward relapsing acute lymphocytic leukemia in the testes (Hudson et al. 1985), and several systemic viral and mycobacterial infections target the testis, including mumps, human immunodeficiency virus, tuberculosis, and the severe acute respiratory syndrome virus (Krieger, 1984, Nistal et al., 1986, Xu et al., 2006). However, the testis does not appear to be immunodeficient. Even in comparison with the rest of the male reproductive tract, orchitis due to ascending infections is relatively rare (Krieger, 1984, Ness et al., 1997). Moreover, the extremely variable level of success of experiments by different groups using different transplant models has shown that immune privilege of the testis is both limited and conditional (Dobrinski, 2005, Head et al., 1983a, Maddocks and Setchell, 1988, Selawry and Whittington, 1984, Setchell et al., 1995). Just what are these necessary conditions, however, remains poorly defined. Studies indicate that the effector arm of the immune response is intact within the testis, and it is the ability to recognize and react toward foreign antigens and/or mount a normal inflammatory response that is suppressed (Head and Billingham, 1985, Head et al., 1983a, Mahi-Brown and Tung, 1989, Mahi-Brown et al., 1987).

In summary, there appears to be a potentially unique functional interaction between the testis and the immune system, which involves control of the mechanisms normally involved in immune activation, in order to limit adaptive immune responses without drastically compromising the ability of the testis to protect itself when required.

Testicular Leukocytes

Although their presence and influence is almost universally neglected, macrophages, lymphocytes, and PMNs have varying degrees of access to the interstitial tissue of the testis (Table 1). They are generally excluded from the seminiferous epithelium under normal conditions. Over the past 10 years, studies have started to fill in some of the details concerning these cells.

Leukocytes of the normal mammalian testis

Cell typeCharacteristicsLocal functions
Monocytes/macrophagesNumerous, multiple subsetsPhagocytosis, tissue remodeling, Leydig cell development, innate immunity (antimicrobial), immunoregulation
Dendritic cellsPresentAntigen presentation, immunoregulation
T cellsCD4+, CD8+, and NK T subsetsAdaptive immunity, immunosurveillance, immunoregulation
NK cellsPresentInnate immunity, immunosurveillance, immunoregulation
Mast cellsSpecies-specific distributionVascular control, innate immunity
EosinophilsSpecies-specific distributionVascular control, innate immunity
NeutrophilsNot normally presentInflammation, phagocytosis, innate immunity (antimicrobial)

Macrophages

Macrophages are by far the most prominent immune cells in the testis. They are found in the testes of all mammalian species so far examined, but are particularly numerous in human, rat, and mouse testes (Frungieri et al., 2002, Hume et al., 1984, Mendis-Handagama et al., 1987, Miller et al., 1984, Vergouwen et al., 1993, Wang et al., 1994). Typically, macrophages arise from myeloid precursors in the bone marrow and circulate in the blood as monocytes. They are capable of adopting a broad range of structural and functional phenotypes that are largely dictated by the tissues in which they become resident (Mantovani et al., 2005, van Furth, 1988). Characteristically, they are robustly phagocytic and possess a potent arsenal of antimicrobial and cytotoxic activities, such as the ability to generate large amounts of ROS. They produce many immunoregulatory products, including cytokines, eicosanoids (prostaglandins, thromboxanes, leukotrienes, and lipoxins), and nitric oxide, all of which are important in establishing and controlling the inflammatory process, but also have important roles in tissue remodeling, healing, and normal homeostasis. All macrophage lineages can express MHC class II antigens and have the capacity to present to CD4+ helper or Treg cells (Unanue 1984). Thus, macrophages are the cells that link innate and adaptive immunity, and dendritic cells are a highly specialized macrophage subset that is particularly effective in this role (Heath and Carbone 2001).

Testicular macrophages have been most extensively studied in the rat, with a few studies also in the mouse and human. Studies in the rat indicate that they are heterogenous in their morphology and functions (Bryniarski et al., 2004, Gerdprasert et al., 2002a, Itoh et al., 1995b, Wang et al., 1994). Their absolute numbers are primarily under Leydig cell control, but evidence suggests that FSH acting via the Sertoli cell has a role in regulating their functional activity (Duckett et al., 1997a, Duckett et al., 1997b, Gaytan et al., 1994c, Wang et al., 1994). Macrophages accumulate within the interstitial tissue at the time of puberty, and play critical roles in the normal development of the testis, particularly by promoting the proliferation and maturation of the Leydig cell population (Cohen et al., 1997, Gaytan et al., 1994a, Gaytan et al., 1994b, Hardy et al., 1989, Itoh et al., 1999, Raburn et al., 1993, Vergouwen et al., 1993). Through their ability to produce a broad array of growth factors, prostanoids, and vasoactive regulators, other developmental and homeostatic roles within the testis may be predicted as well.

Data concerning the immunological functions of testicular macrophages are based on a relatively small number of studies in either the rat or the mouse, and are patchy at best. Indeed, there is some evidence for distinct differences even between these two closely related species. In general, testicular macrophages have intact phagocytic, cytotoxic, and antimicrobial functions (Miller et al., 1984, Wei et al., 1988). Rat testis macrophages express MHC class II antigens (Head and Billingham, 1985, Hedger and Eddy, 1987, Wang et al., 1994), but display a reduced capacity for lymphocyte activation in vitro (Kern and Maddocks 1995). Testicular macrophages in the human and mouse also express MHC class II, although expression in the mouse appears to be more restricted (Haas et al., 1988, Itoh et al., 1995b, Pöllänen and Niemi, 1987, Tung et al., 1987). A lack of expression of the essential costimulatory molecules, B7-1 (CD80) and B7-2 (CD86), has been reported in the mouse testis as well (Sainio-Pöllänen et al. 1996). Studies also indicate that macrophages from the rat testis have a significantly reduced ability to produce proinflammatory cytokines, such as IL1β and TNFα, following activation (Gerdprasert et al., 2002a, Hayes et al., 1996, Kern and Maddocks, 1995, Kern et al., 1995, Meinhardt et al., 1996), and stimulated mouse testicular macrophages produce the anti-inflammatory/immunosuppressive cytokines IL10 and TGFβ1 in vitro (Bryniarski et al., 2004, Bryniarski et al., 2005). While the data suggest that testicular macrophages may have a predominantly anti-inflammatory and/or immunosuppressive phenotype, this has yet to be formally established. Furthermore, dendritic cells, which are a highly specialized macrophage subset also found within the testicular interstitium (Fijak et al., 2005, Hoek et al., 1997, Itoh et al., 1995b, Rival et al., 2006a), presumably play a more important role in controlling immune responses to antigens within the testis (Fijak et al., 2005, Rival et al., 2006a, Rival et al., 2007).

In the rat testis, macrophages can be discriminated by their differential expression of two molecular markers recognized by the antibodies ED1 and ED2. Antibody ED1 recognizes the lysosomal protein CD68, which is associated with antigen processing and presentation (Groisman et al. 2002), while ED2 recognizes the scavenger receptor CD163 (Fabriek et al. 2005). CD163 is involved in the clearance of hemoglobin:haptoglobin complexes and the resolution of inflammation (Philippidis et al. 2004). About 80–85% of rat testicular macrophages express this scavenger receptor and about half of these cells also lack expression of CD68 (Gerdprasert et al., 2002a, Meinhardt et al., 1998, Wang et al., 1994). In the human testis, most macrophages appear to be CD68+, but expression of CD163 is a feature of a subset of these cells as well (Frungieri et al. 2002). The heterogeneous expression of these two markers points to the existence of multiple populations of testicular macrophages, and evidence suggests that these phenotypic differences also correspond to functional differences. In the normal and inflamed adult rat testis, CD163+ cells lack expression of the key inflammatory mediators IL1β and inducible nitric oxide synthase (iNOS), as measured by double-label immunohistochemistry, but these molecules are detectable in CD68+ cells that do not express CD163 (Gerdprasert et al., 2002a, O’Bryan et al., 2005). Indeed, purification of CD163+ macrophages from the rat testis using immunomagnetic beads confirms that these cells have reduced capacity to produce IL1β, IL6, or NO upon stimulation, although they retain the ability to produce prostaglandins (Gerdprasert et al. 2002a; Hedger, unpublished data). This suggests that the CD163+ macrophages have reduced proinflammatory activities, while the CD163-negative testicular macrophage population retains normal proinflammatory functions. This observation is important because macrophages that express CD163 and produce IL10, but display reduced expression of CD80, CD86, iNOS, TNFα, and IL1β, are polarized toward the immunoregulatory M2 subset (Mantovani et al., 2005, Sica et al., 2008). The M2 macrophage subset is analogous to the Th2 subset among T cells, and is associated with late-stage inflammation and its resolution, as well as tumors and other immunologically privileged tissue sites. It would appear that a significant proportion of the resident macrophages of the testis possess an immunoregulatory phenotype that is consistent with immune privilege. The functional roles of this macrophage population, as well as those of the macrophages that appear to retain normal inflammatory (i.e., M1 subset) properties, demand particular attention if we are to understand the unique immunological environment of the testis.

Lymphocytes

While the functions and regulation of lymphocytes within the testis have yet to be properly characterized, by their presence alone these cells will have significant effects on testicular events. It may also be assumed that, in contrast to the largely resident population of testicular macrophages, lymphocytes circulate through the testis. This may be because they possess specificity for testicular antigens, or because they have been activated during earlier intratesticular inflammatory or infectious events (Czerkinsky et al., 1999, Springer, 1994). Quantitative studies in the rat indicate that, at any given time, lymphocytes are approximately 10% as numerous as the macrophages in the normal testis (Hedger and Meinhardt, 2000, Hedger et al., 1998b, Wang et al., 1994). In the rat and mouse, intratesticular lymphocytes express T cell and NK cell markers, and comprise distinct T cell, NK cell, and NKT cell subsets (Tompkins et al. 1998; Hedger, unpublished data). Both T cell and NK cell markers are expressed by lymphocytes in the human testis as well (Hedger, unpublished data). B cells are not usually observed in normal tissues, and this includes the testis. In the rat, many T cells possess a memory phenotype, as would be expected (Hedger et al., 1998b, Tompkins et al., 1998). Reanalysis of the data for individual animals across several studies suggests that their numbers tend to be proportional to the numbers of macrophages, but gradually increase with the age of the animal (Hedger et al., 1998b, Hedger and Meinhardt, 2000, Wang et al., 1994). Among the T cells of the testis, there is a strong bias toward the CD8+ (i.e., MHC class I restricted, largely cytotoxic) subset (Hedger et al., 1998b, Pöllänen and Niemi, 1987, Ritchie et al., 1984, Tompkins et al., 1998, Wang et al., 1994). The prominence of NK cell subsets in the testis is also intriguing given the reduced MHC class I antigen expression in the seminiferous compartment, which would tend to make these cells more susceptible to NK cells (Lanier 2001). Consistent with the anti-inflammatory/immunosuppressive phenotype of the major testicular macrophage subset, T cells and NKT cells in the rat testis constitutively produce IL10 (Hedger, unpublished data). While much remains to be discovered, the existing data concerning the types and activity of testicular lymphocytes are consistent with maintaining immune privilege (i.e., the presence of immunoregulatory lymphocytes) and increased innate immunity (i.e., cytotoxic cell activity).

Polymorphonuclear Cells

Evidence that PMNs are important in testicular function comes from the fact that mast cells and eosinophils are significant elements of the interstitial tissue in many species. In the rat, mouse, dog, cat, bull, and deer, both cell types are largely absent from the testicular parenchyma, but are associated with blood vessels in the testicular capsule (Anton et al. 1998). Mast cells are found throughout the interstitial tissue in equine and human testes (Anton et al., 1998, Nistal et al., 1984, Yamanaka et al., 2000), and both mast cells and eosinophils are present in porcine species (Anton et al. 1998). The role of these cells in vascular control and innate immunity can be predicted, but they may also play immunoregulatory roles, as mast cells do in other tissues (Galli et al. 2005).

In humans, testicular mast cell numbers are increased in infertility (Meineke et al., 2000, Nagai et al., 1992, Yamanaka et al., 2000), but decline with advancing age (Nistal et al. 1984). The possibility that they accumulate due to past immune events needs to be considered, but they also appear to be actively regulated. In the adult rat testis, mast cell proliferation is under the control of the Leydig cells, suggesting that these cells produce an inhibitor of mast cell activity (Gaytan et al., 1990, Wang et al., 1994). Neonatal estrogen treatment increases mast cell numbers in the rat testis (Gaytan et al., 1989, Gaytan et al., 1990), and a relationship with elevated Leydig cell aromatase activity is suggested by the prevalence of these cells in boar and equine testes (Eisenhauer et al., 1994, Raeside and Renaud, 1983). Neutrophils are found in the testis only under conditions of testicular inflammation or damage (Gerdprasert et al., 2002a, Kohno et al., 1983a, O’Bryan et al., 2000b).

Immunity in the Epididymis, Accessory Glands, and Urogenital Tract

The majority of this chapter deals with the testis because it is the primary source of male gametes and hormones, and damage to this organ tends to have more significant consequences for fertility. The remainder of the male reproductive tract comprises the epididymis, vas deferens, accessory glands, and the urethra, which are all epithelial-lined ductal tissues of varying complexity. The immunology of these tissues appears to be quite distinct from that of the testis. While it is true that sperm spend relatively little time within most of these tissues, mature sperm reside within the epididymis for extended periods without provoking an overt immune response, and inflammation and immune cell activity can nonetheless have damaging effects in this organ.

Significantly, these tissues possess normal interepithelial cell junctions, but lack a completely occluding intercellular structure analogous to the blood–testis barrier (Levy and Robaire, 1999, Pelletier, 2001). Secreted IgA, which lacks the ability to bind complement and possesses principally anti-inflammatory properties as a result, plays an important role in the male urogenital tract (Clifton et al., 1992, Politch et al., 2007, Pudney and Anderson, 1995), and the immunology of these organs tends to more closely resemble that of other elements of the mucosal immune system, such as the gastrointestinal and respiratory tracts (Beagley et al., 1998, Clifton et al., 1992, Mestecky et al., 2005). In the absence of the specialized mucosal-associated lymphoepithelial tissue normally found in the gastrointestinal and respiratory tracts, it is likely that the epithelial cells themselves, together with the numerous intraepithelial and stromal macrophages and lymphocytes that are normally found within these tissues, mediate local immunoregulatory mechanisms (Barratt and Cohen, 1987, Dym and Romrell, 1975, el-Demiry et al., 1985, Ritchie et al., 1984, Pudney and Anderson, 1995, Theyer et al., 1992, Yeung et al., 1994). A better understanding of the immunology of these tissues is important. Inflammation, infection, and physical damage can lead to immune reactions against the sperm, which in turn may compromise fertility. Moreover, many men suffer from chronic pelvic pain, generally manifesting as epididymitis or prostatitis in the absence of a detectable infection, a condition that almost certainly involves chronic inflammatory processes within the male reproductive tract.

Immunoregulation in the Male Reproductive Tract

As outlined in the preceding sections, the testis is able to support immune privilege without sacrificing immune surveillance and protection. The mechanisms responsible for this immunological balancing act are still far from understood, but a number of inflammatory and immunoregulatory systems that operate within the testis have been investigated in varying degrees of detail. It is perhaps not very surprising that many of these regulatory systems also impact upon normal testis physiology, in addition to their immunological and pathological roles.

The Immunoregulatory Roles of Testicular Somatic Cells and Germ Cells

Given that the types and properties of leukocytes found within the testis environment are consistent with immunoregulation and enhanced innate immunity, the focus should be on which testicular elements are involved in creating this potentially unique immunological environment. Most attention in this regard has been directed toward the highly versatile Sertoli cell.

Evidence that the Sertoli cell possesses specialized immunoregulatory properties comes from cotransplantation studies. Sertoli cells from immature rat, murine, or porcine testes display extended survival as allografts or xenografts, and cotransplantation of Sertoli cells or testis cell mixtures containing these cells confers increased survival on neural cell xenografts, and pancreatic islet allografts and xenografts (Sanberg et al., 1996, Selawry and Cameron, 1993, Suarez-Pinzon et al., 2000). The ability to form a physical barrier through inter-Sertoli tight junctions and the fact that Sertoli cells have reduced MHC expression (Haas et al., 1988, Kohno et al., 1983b, Sanberg et al., 1996, Turek et al., 1996) undoubtedly enhance their potential to avoid T cell activation both in the intact testis and in engraftment studies. Moreover, a soluble form of the nonclassical MHC class Ib molecule HLA-G is produced by the Sertoli cells, as well as spermatocytes, spermatids, and some interstitial cells, in the rhesus monkey testis (Ryan et al. 2002). This molecule has been implicated in apoptosis of alloreactive CD8+ cytotoxic T cells (Fournel et al. 2000). Sertoli cells display lymphocytotoxic activities and produce molecules with immunosuppressive activity, such as TGFβ1 (De Cesaris et al., 1992, Suarez-Pinzon et al., 2000, Wyatt et al., 1988, Yin et al., 2006) and FasL (Bellgrau et al., 1995, Yin et al., 2006). An active immunoregulatory role has also been suggested: murine Sertoli cells treated with IFNγ increase expression of MHC class II molecules and the negative costimulatory ligand B7-H1, and stimulate Treg numbers in culture (Dal Secco et al. 2008). The ability of the Sertoli cell to suppress other critical inflammatory events through expression of complement regulatory proteins (Lee et al. 2007) and secretion of inhibitors of lymphocyte cytotoxic activities (Sipione et al. 2006) is also likely to be important. Finally, Sertoli cells possess an enormous capacity for phagocytosis of senescent cells, cell debris, and other potentially antigenic complexes, which could otherwise activate an immune response.

Data concerning immunoregulatory roles of other testicular cells are less comprehensive. The evidence clearly indicates a role for Leydig cells in recruiting macrophages into the testis, although testicular macrophage function may actually be determined by the Sertoli cells (Duckett et al., 1997a, Duckett et al., 1997b, Gaytan et al., 1994c, Wang et al., 1994). Leydig cells also produce various steroids, proteins, and other factors with immunosuppressive activity, and inhibit lymphocyte activity in vitro (Born and Wekerle, 1982, Hedger et al., 1990). Peritubular cells, like Sertoli cells, produce immunoregulatory TGFβ family members (Konrad et al., 2000, Mullaney and Skinner, 1993, Okuma et al., 2005b). The possibility that the germ cells themselves have a direct effect on immune cells has also been considered (Hurtenbach and Shearer 1982), although it seems more likely that germ cells may influence immune responses indirectly by inducing immunoregulatory activities of the Sertoli cells and other somatic cells.

Immunoregulatory Systems in the Testis Toll-like receptors

The relatively recent discovery of the TLRs has radically expanded our understanding of innate immunity and promises to do the same for testicular immunology. In addition to their predictable expression on testicular macrophages and dendritic cells, TLR mRNA, protein, and/or ligand responses have been described in several other testicular cells. Rat and mouse Sertoli cells express TLR2, 3, 4, and 5 (Bhushan et al., 2008, Riccioli et al., 2006, Starace et al., 2008, Wu et al., 2008). TLR1, 10, and 11 mRNA expression has been observed in rat Sertoli cells (Bhushan et al. 2008), and low levels of TLR6, 7, and 13 mRNA have been detected in mouse Sertoli cells (Riccioli et al., 2006, Wu et al., 2008). In the rat, germ cells also produce mRNA for TLR2, 3, and 4 in a stage-specific manner, and the peritubular cells express TLR3 and 11, along with low levels of TLR2, 4, and 6 (Bhushan et al. 2008). Rat Leydig cells express TLR2 mRNA and low levels of TLR10 (Bhushan et al. 2008). However, the cytoplasmic receptors TLR8 and 9 have yet to be observed in any nonmyeloid testicular cell type. Of the other pattern-recognition receptors, Nod1 mRNA has been detected in rat Sertoli cells, peritubular cells, and spermatogonia, while Nod2 was detected in spermatogonia only (Bhushan et al. 2008).

Expression of TLRs and other pattern-recognition receptors in the testis is obviously important for responses toward intratesticular pathogens. Infections and inflammation, both systemic and localized, have negative effects on testicular function, resulting in reduced androgen production, lowered sperm counts, and temporary loss of fertility (Adamopoulos et al., 1978, Baker, 1998, Carlsen et al., 2003). Presumably, TLRs expressed by the Sertoli cells and germ cells are necessary to detect pathogens that ascend the reproductive tract and, as a consequence, lie behind the blood–testis barrier. This expression within the seminiferous epithelium also suggests a mechanism whereby inflammation can directly inhibit spermatogenesis. Activation of Sertoli cells by TLR ligands induces production of inflammatory mediators, such as IL1α, IL6, and NO, which have direct effects on germ cell development and Leydig cell steroidogenesis (Gérard et al., 1992, Stéphan et al., 1995, Stéphan et al., 1997, O’Bryan and Hedger, 2008, Riccioli et al., 2006, Wu et al., 2008). Moreover, while inhibition of Leydig cell steroidogenesis during inflammation may involve indirect effects at the level of the pituitary, or the actions of inflammatory mediators produced by the testicular macrophages and Sertoli cells, there is evidence that these cells can also respond directly to TLR ligands (Bhushan et al., 2008, Xiong and Hales, 1993a).

Although the TLRs have evolved to recognize pathogen-derived molecules, such as LPS (TLR4) and bacterial lipoproteins (TLR2), recent data show that they can also be activated by certain endogenous molecules. The ability of preparations of some endogenous molecules, such as heat-shock proteins, to activate TLR signaling is now attributed to contamination of these preparations by bacterial products (Tsan and Gao 2004), but there is convincing evidence that mammalian mRNA is a ligand for TLR3 (Karikó et al. 2004) and mammalian CpG DNA can activate TLR9 (Yasuda et al. 2005). The high mobility group box chromosomal protein 1 (HMGB1), produced by both spermatogonia and Sertoli cells, is a TLR2 and 4 ligand (Yu et al., 2006, Zetterström et al., 2006). Expression of TLRs by the Sertoli cells under normal conditions, therefore, suggests a potential role for these receptors in responding to these endogenous ligands.

The interleukin 1 family

IL1 is the best studied of all the cytokines normally expressed in the testis. It is produced in two forms, α and β, which are encoded by separate genes and share approximately 25% sequence homology. Both forms act through the same receptor complex (IL1R1), and exert a similar range of proinflammatory and physiological effects (Dinarello, 1996, O’Neill and Dinarello, 2000). Most IL1 signaling occurs through activation of the MyD88/TRAF and Jnk/p38 MAP kinase pathways, thereby regulating many proinflammatory genes through stimulation of the transcription factors NFκB and activated protein 1 (AP1) (Medzhitov et al. 1998). The IL1s are synthesized as precursor proteins, which are cleaved to produce 17 kDa active proteins. In the case of IL1α, the precursor possesses low-level biological activity, but the IL1β precursor protein is inactive (Black et al., 1988, Watanabe and Kobayashi, 1994). The precursor of IL1β is cleaved by the IL1 converting enzyme (ICE, caspase 1) during the process of secretion, whereas IL1α is cleaved by the calcium-dependent membrane-associated cysteine protease (calpain) or by extracellular proteases (Thornberry and Molineaux, 1995, Watanabe and Kobayashi, 1994). IL1β is produced by activated monocyte/macrophages and is the main secreted form during inflammation, whereas IL1α is more commonly found within the cell, where it may act as an autocrine or paracrine growth factor involved in direct cell-to-cell communication.

In addition to the prototypical IL1α and IL1β, the IL1 family comprises a number of structurally related proteins, which appear to have arisen by gene duplication (Dunn et al. 2001). The closest structurally to IL1α/β is IL18, which is processed by caspase 1 activity, but acts via a separate receptor rather than IL1R1 (Gracie et al. 2003). Another member of the family, which does bind to IL1R1 but lacks the ability to transduce a signal, blocks IL1α/β action and is called IL1 receptor antagonist (IL1ra) (Arend 1991).

Production of IL1α is constitutively high in the normal testis, as IL1α is produced by the Sertoli cells in a cyclical manner within the mature seminiferous epithelium (Jonsson et al., 1999, Söder et al., 1991). Its production is driven by the developing germ cells and by phagocytosis of the residual cytoplasm cast off by the spermatids at the time of their release into the tubule lumen (Gérard et al., 1992, Syed et al., 1995). Sertoli cell IL1α production is also stimulated by LPS, but not by FSH (Stéphan et al. 1997). Production of IL1β by the normal testis is low, but is upregulated in a subset of testicular macrophages and the Leydig cells during inflammation (Gérard et al., 1991, Jonsson et al., 1999, O’Bryan et al., 2005). Curiously, the majority of this secreted testicular IL1β exists as the precursor (O’Bryan et al. 2005).

The receptor IL1R1 has been localized to germ cells and Sertoli cells (Gomez et al. 1997). IL1α stimulates DNA synthesis in spermatogonia (i.e., mitosis) and early spermatocytes (i.e., meiosis), proliferation of immature Sertoli cells, and a number of activities of the mature Sertoli cell that support spermatogenesis, such as the production of lactate and transferrin (Hakovirta et al., 1993b, Hoeben et al., 1996, Nehar et al., 1998, Parvinen et al., 1991, Pöllänen et al., 1989, Söder et al., 1991). It also regulates the ability of the Sertoli cell to maintain contact with other Sertoli cells and the developing germ cells, by altering the Sertoli cell cytoskeleton (Sarkar et al. 2008). In the interstitium, both IL1α and IL1β suppress LH-stimulated androgen production by adult Leydig cells through inhibition of steroidogenic enzyme activity (Hales, 1992, Xiong and Hales, 1994, Xiong and Hales, 1997). IL1ra is produced by the Sertoli cell, and is stimulated by FSH, IL1, and LPS (Zeyse et al. 2000). Presumably, its role is to regulate the activity of IL1α/β within the testis.

Both IL18 and its receptor have been found in the seminiferous epithelium, with IL18 mRNA and protein localized to spermatocytes and round spermatids (Strand et al. 2005). As is the case for IL1β, the majority of IL18 produced within the testis is in the precursor form, indicating that the processing of these cytokines by caspase 1 in the testis is an area requiring more investigation. IL18 stimulates spermatogonial DNA synthesis in cultures of rat seminiferous tubules, without influencing germ cell apoptosis (Strand et al. 2005). Another member of the family localized to the testis is IL1F8, although its function there is entirely unknown (Kumar et al. 2000).

Tumor necrosis factor α and Fas ligand

TNFα and FasL are transmembrane and secreted cytokines with typically trimeric structures and they interact with specific receptors to mediate a cell death signal (Ju et al., 1995, Schütze et al., 2008). They are implicated in both immunoregulation and the control of normal spermatogenic function in the testis.

TNFα is a 17 kDa glycosylated polypeptide and is a major early product of activated monocytes and macrophages. It binds to either of two TNF receptor subsets (TNFR1 and TNFR2) and plays a central role in initiating the inflammatory response by stimulating the production of IL1 and IL6 (Basak and Hoffmann, 2008, Bradley, 2008). Whether TNFα exerts proinflammatory or cytotoxic effects depends on the receptor subtype engaged and the expression of specific adaptor proteins within the target cell (Basak and Hoffmann, 2008, Chung et al., 2002, Hsu et al., 1996, Mak and Yeh, 2002). Consistent with its name, TNFα exerts a cell death signal via TNFR1, through interaction with the TNFR-associated death domain protein (TRADD) or the Fas-associated death domain protein (FADD), and activation of the caspase-dependent apoptotic pathway (Schütze et al. 2008). However, interaction with TRADD can also result in recruitment of other adaptor proteins leading to the binding of TRAF2 and activation of the NFκB pathway and/or the MAP kinases Jnk or p38 (Chung et al. 2002). Moreover, TNFR2 and its related receptors, which include CD40, do not contain a death domain, and instead associate with the TRAFs leading to activation of cell signaling events (Bradley, 2008, Mak and Yeh, 2002).

In the mouse testis, TNFα is expressed by round spermatids, pachytene spermatocytes, and testicular macrophages, and mRNA for TNFR1 has been located on both Sertoli and Leydig cells (De et al. 1993). In porcine Sertoli cells, TNFα receptor subunit protein expression is stimulated by FSH (Mauduit et al. 1996). There is no evidence that TNFα is produced by the Sertoli cell, but expression of TNFα by the germ cells within the seminiferous epithelium, like that of IL1α and IL6, is cyclical. Within the seminiferous epithelium, TNFα produced by the germ cells appears to play a complex role in the control of both Sertoli cell function and spermatogenesis. TNFα reduces spontaneous germ cell degeneration in cultured human and rat seminiferous tubules, suggesting a germ cell survival effect presumably mediated through the Sertoli cell (Pentikäinen et al., 2001, Suominen et al., 2004). Conversely, TNFα disrupts Sertoli cell tight junction assembly by inhibiting the production of junction proteins and by regulating matrix metalloprotease and protease inhibitor activity (Siu et al. 2003). TNFα also stimulates plasminogen activator inhibitor expression in rat testicular peritubular cells (Le Magueresse-Battistoni et al. 1997). Similar to IL1, TNFα stimulates basal lactate production by cultured Sertoli cells, but TNFα generally antagonizes the actions of FSH on Sertoli cell function, including the stimulation of aromatase activity and lactate production (Mauduit et al., 1993, Nehar et al., 1997, Riera et al., 2001). However, Delfino et al. (2003) have shown that TNFα stimulates androgen receptor expression in Sertoli cells via upregulation of NFκB, which binds to several enhancer motifs in the androgen receptor promoter. TNFα also stimulates the expression of inflammatory cytokines, chemokines, and leukocyte adhesion molecules in both Sertoli cells and peritubular cells (Aubry et al., 2000, De Cesaris et al., 1998, Stéphan et al., 1997). In testicular pathology, TNFα has been implicated as a major causative agent in the development of experimental autoimmune orchitis (EAO) (Yule and Tung 1993). There is a significant increase in the number of TNFα-positive testicular macrophages and the number of TNFR1-positive germ cells undergoing apoptosis during EAO in rats (Suescun et al. 2003). Within the interstitium, TNFα acts as an effective regulator of Leydig cell steroidogenesis, by inhibiting LH receptor binding and steroidogenic gene expression (Li et al., 1995, Mauduit et al., 1991b, Mauduit et al., 1998, Xiong and Hales, 1993b, Xiong and Hales, 1994).

No intratesticular cytokine has excited more controversy than the cell death signaling ligand FasL. Interactions between FasL and its receptor on activated T cells are important in the regulation of the immune response (Ju et al. 1995). The death domain in the cytoplasmic region of the Fas receptor recruits the FADD adaptor protein and induces T cell death via caspase-dependent apoptosis (Schütze et al. 2008). There is evidence that FasL expression on epithelial cells in immune-privileged tissues, including Sertoli cells, may be responsible for deleting activated T cells within the tissue, thereby suppressing adaptive immunity (Bellgrau et al., 1995, Griffith et al., 1996, Saas et al., 1997, Stuart et al., 1997). However, this hypothesis has been challenged by the observation that increased FasL expression on cells such as tumor cell lines and pancreatic islet cells does not increase protection in transplantation studies, but actually provokes a massive inflammatory reaction and rejection (Allison et al., 1997, Kang et al., 1997). Moreover, FasL appears to be abundantly expressed in the epithelia of several human tissues that lack any evidence for immunological privilege (Xerri et al. 1997), while absence or inhibition of Fas or FasL does not automatically cause failure of immune privilege (Rogers et al., 1998, Suarez-Pinzon et al., 2000, Wahlsten et al., 2000). It seems unlikely that FasL expression on its own is a fundamental explanation for immune privilege, although it may contribute through interaction with other immunoregulatory processes (Chen et al. 1998).

Localization of FasL and Fas in the testis under normal conditions also has proven controversial, which may be attributed to differences in detection methods, limitations of some of the reagents that have been used, and the fact that these molecules are inducible (D’Alessio et al., 2001, Restifo, 2000). Studies have shown FasL to be present in rat, mouse, porcine, and human Sertoli cells and absent in most germ cells (Bellgrau et al., 1995, Brændstrup et al., 1999, D’Abrizio et al., 2004, Lee et al., 1997), but other studies have reported that FasL expression in the rat seminiferous epithelium is confined to the germ cells (Celik-Ozenci et al., 2006, D’Alessio et al., 2001). The receptor Fas has been found on isolated mouse Sertoli cells (Riccioli et al. 2000), but in intact testes has been localized to spermatogonia and spermatocytes from the pubertal period onward (Celik-Ozenci et al., 2006, Lee et al., 1997, Lizama et al., 2007, Ogi et al., 1998). In germ cells, Fas expression is associated with cells that are undergoing apoptosis (Lee et al., 1997, Lizama et al., 2007), and Fas is induced by TNFα and IFNγ in the Sertoli cell (Riccioli et al. 2000). Curiously, in one study using fragment cultures of human seminiferous tubules, TNFα downregulated FasL expression and inhibited apoptosis of germ cells (Pentikäinen et al. 2001). Less controversially, Fas and FasL expression is upregulated in various models of seminiferous epithelium damage, indicating that this mechanism is important in regulating germ cell apoptosis in cases of physical and toxicological insult (Lee et al., 1997, Ogi et al., 1998).

Interleukin 6 and the gp130 family

Members of the IL6 family of cytokines exert their actions via binding to specific receptors that associate with a common membrane signal transducer gp130, leading to the activation of the Janus kinase/signal transducers and activators of transcription (Jak/Stat) and MAP kinase cascades (Heinrich et al. 2003). In addition to their functions in inflammation and the immune response, these cytokines play crucial roles in hematopoiesis, liver and neuronal regeneration, embryonic development, and fertility. Members of this family that have been detected in the testis are leukemia inhibitory factor, oncostatin M, ciliary neurotropic factor, IL11, and IL6 itself (de Miguel et al., 1996, de Miguel et al., 1997, Du et al., 1996, Jenab and Morris, 1998, Okuda et al., 1994, Stéphan et al., 1997). The principal roles of most of these cytokines in the testis appear to lie in regulating Leydig cell development and the onset of spermatogenesis. A role in testicular immunology is most likely for IL6, which possesses both proinflammatory and anti-inflammatory properties, and regulates the acute-phase response as well as several aspects of immune cell development and activity (Kopf et al., 1994, Tilg et al., 1997).

Sertoli cells, Leydig cells, and peritubular cells have been shown to produce IL6 in vitro (Cudicini et al., 1997b, Okuda et al., 1994, Syed et al., 1993, Syed et al., 1995). In rat Sertoli cells, IL6 production is stimulated by FSH, testosterone, phagocytosis, and other inflammatory stimuli, including IL1α, IL1β, TNFα, and LPS (Cudicini et al., 1997a, Cudicini et al., 1997b, Okuda et al., 1994, Okuda et al., 1995, Stéphan et al., 1997, Syed et al., 1995). Production of IL6 by cultured mouse Sertoli cells is inhibited by INFγ (Riccioli et al., 2000, Stéphan et al., 1997). Within the seminiferous epithelium, endogenous production of IL6 follows a cyclical pattern that corresponds with the changes in the stages of the spermatogenic cycle, most probably under the influence of IL1α and FSH (Hakovirta et al., 1995, Syed et al., 1993, Syed et al., 1995). Both the IL6-specific receptor subunit (IL6R) and the gp130 mRNA are expressed in rat Sertoli cells, and are stimulated by IL1 and IL6, but only the IL6R subunit is stimulated by FSH (Fujisawa et al. 2002). IL6 increases basal and FSH-induced transferrin and cyclic GMP secretion by the Sertoli cell, and inhibits meiotic DNA synthesis in preleptotene spermatocytes (Boockfor and Schwarz, 1991, Hakovirta et al., 1995, Hoeben et al., 1997). In models of EAO, IL6 appears to play an ameliorative or protective role within the seminiferous epithelium (Li et al., 2002, Rival et al., 2006b). Leydig cells are also active producers of IL6 following stimulation by LH, LPS, or IL1β in vitro, and evidence suggests that these cells actually may be the major testicular source (Boockfor et al., 1994, Cudicini et al., 1997b, Okuda et al., 1994, Okuda et al., 1995).

Interleukin 10

Several studies have implicated IL10 as a key player in testicular immunology. Testicular IL10 production is preferentially induced by systemic LPS treatment in the adult rat testis (O’Bryan et al. 2005), and macrophages and T cells isolated from the rat testis constitutively produce IL10, which may contribute to testicular immune privilege (Hedger, unpublished data). In a mouse model of EAO, elevation of endogenous IL10 levels by adenoviral-mediated transfection of human IL10 was found to significantly reduce the incidence of immune activation, orchitis, and spermatogenic damage (Watanabe et al. 2005). Although male mice deficient in IL10 do not show evidence of male fertility problems, intratesticular immune responses have yet to be examined in these animals (Kühn et al. 1993).

Nitric oxide and oxygen metabolites

Production of ROS, particularly by macrophages, is an important component of the early response to infection (Takemura and Werb 1984). Significant ROS include the superoxide anion (O2−), hydrogen peroxide (H2O2), the hydroxyl radical (HO·), nitric oxide (NO·), and the peroxynitrite anion (ONOO−). Most are products of normal cellular metabolism, but their production is stimulated during inflammation through the activity of the enzymes NADPH oxidase (nicotinamide adenine dinucleotide phosphate-oxidase) and iNOS (Forman and Torres, 2002, Nathan, 2006). These small molecules are cytotoxic to many microorganisms, although some play a more complex role in cell signaling processes. They also interact with crucial intracellular macromolecules, such as proteins, lipids, and DNA, causing oxidative damage. Although there are endogenous repair systems to correct oxidative damage, excessive production of ROS contributes to the pathology of many diseases.

Among the ROS, nitric oxide represents a special case. At high levels, NO is highly cytotoxic, especially as a precursor of the peroxynitrite anion, but at low levels NO acts as an intracellular and extracellular signaling molecule (Bogdan, 2001, Schmidt and Walter, 1994). It is produced by one of three related enzymes, neuronal NOS (nNOS or NOS1), inducible NOS (iNOS or NOS2), and endothelial NOS (eNOS or NOS3), which catalyze the conversion of l-arginine to l-citrulline and NO (Alderton et al. 2001). The NOS enzymes are homodimeric proteins encoded by three separate genes (Table 2). Both nNOS and eNOS are constitutively expressed enzymes whose activity is regulated through a calcium–calmodulin-mediated mechanism, whereas iNOS is a constitutively activated enzyme that is regulated at the transcriptional and translational levels by various inflammatory mediators, including LPS, IL1, and TNFα (Wolkow 1998).

Major inflammatory enzymes – properties and distribution in the testis

EnzymePropertiesPrincipal cellular expression in normal testis
Neuronal nitric oxide synthase (nNOS, type I)Ca/calmodulin regulated, constitutively expressedSertoli cell, Leydig cell, vascular endothelium
Inducible nitric oxide synthase (iNOS, type II)Constitutively active, transcriptionally and translationally regulatedSertoli cell, Leydig cell, peritubular cell, pachytene spermatocytes and elongating spermatids, macrophage subset
Endothelial nitric oxide synthase (eNOS, type III)Ca/calmodulin regulated, constitutively expressedSertoli cell, Leydig cell, peritubular cell, vascular endothelium
Phospholipase A2Multiple classes and groups, various propertiesUbiquitous expression
Cyclooxygenase 1 (COX1)Constitutively expressed, not induced by inflammationUbiquitous expression
Cyclooxygenase 2 (COX2)Induced by inflammationSertoli cell, Leydig cell, peritubular cell, all spermatogenic cells

In studies in various species, NOS has been found in Sertoli cells, Leydig cells, peritubular cells, germ cells, testicular macrophages, and vascular endothelial cells (Kim et al., 2007, Lee and Cheng, 2004). The nNOS gene also produces a testis-specific isoform, TnNOS, which has been localized to Leydig cells (Wang et al. 1997). In the normal rat seminiferous epithelium, iNOS is expressed by elongating spermatids and pachytene spermatocytes, particularly during the stages immediately following sperm release, with relatively lower levels of expression in Sertoli cells and peritubular cells throughout the entire cycle (O’Bryan et al. 2000a). In the interstitium, macrophage expression of iNOS appears to be largely confined to the minority of CD163-negative macrophages of the testis, and is not detectable in the majority of resident macrophages even during inflammation (O’Bryan et al., 2000a, Gerdprasert et al., 2002a). Testicular cell iNOS expression and NO production are increased by inflammatory events induced by LPS, testicular torsion, or testicular heating (Lue et al., 2003, O’Bryan et al., 2000a, Shiraishi et al., 2001).

Production of NO by germ cells, in particular, is implicated in the control of the formation and disassembly of the Sertoli cell junctions that constitute the blood–testis barrier, as well as the junctional complexes involved in Sertoli–germ cell adhesion (Lee and Cheng, 2003, Lee et al., 2005). Moreover, pachytene and round spermatid apoptosis is significantly reduced in iNOS null mice, leading to an increase in daily sperm output and indicating a key role for iNOS in limiting germ cell survival and/or the carrying capacity of the Sertoli cells (Lue et al. 2003). NO inhibits Leydig cell steroidogenesis directly, an action that is probably mediated through oxidative damage, and treatment with NOS inhibitors counteracts the normal decrease in testosterone associated with sepsis or stress (Del Punta et al. 1996; Sharma et al. 1998; Welch et al. 1995). Similarly, production of other ROS has been implicated in the loss of steroidogenic function in various inflammatory models and in Leydig cell cultures (Georgiou et al., 1987, Quinn and Payne, 1984). Last but not least, NO is a potent vasodilator, and plays a role in the endogenous control of testicular blood flow and formation of the interstitial fluid (Lissbrant et al., 1997, O’Bryan et al., 2000a). Production of NO is an important mediator of germ cell death in testicular torsion (Moon et al., 2005, Shiraishi et al., 2001), and may be involved in the testicular damage associated with varicocele (Santoro et al., 2001, Türker Köksal et al., 2004).

Inflammatory Signaling Pathways in the Seminiferous Epithelium

It is evident that the major inflammatory signaling pathways mediated via NFκB and the p38/Jnk MAP kinases play important, albeit complex, intratesticular roles. Notably, NFκB has been implicated as an apoptosis-inducing signal for germ cells in numerous studies (Lysiak et al., 2005, Pentikäinen et al., 2002, Rasoulpour and Boekelheide, 2005, Starace et al., 2005), even though it stimulates androgen receptor expression in the Sertoli cell (Delfino et al. 2003). Activation of p38/Jnk is implicated in the stimulation of proliferation by immature Sertoli cells and the regulation of blood–testis barrier dynamics, steroidogenesis, and multiple inflammatory responses, including the production of IL6, iNOS, monocyte chemoattractant protein 1, and leukocyte adhesion molecules, in the mature Sertoli cell (De Cesaris et al., 1998, De Cesaris et al., 1999, Ishikawa and Morris, 2006, Ishikawa et al., 2005, Petersen et al., 2005, Riccioli et al., 2006). While these pathways mediate many of the effects of inflammation on the testis, endogenous regulation of these pathways also appears to be involved in the normal functions of the seminiferous epithelium, as will be discussed later.

Interferons

The IFNs are functionally related cytokines with antiviral activity and they comprise three main groups (α, β, and γ), based on their structural relationships and major cellular sources (Hertzog et al., 2003, Malmgaard, 2004). The type I IFNs (IFNα and β) are produced by a variety of cell types in addition to leukocytes, and exert primarily antiviral and antiproliferative effects via the IFNα receptor (IFNAR). The type II IFNγ is produced by NK and NKT cells, activated T cells and, under certain conditions, by macrophages and dendritic cells (Schoenborn and Wilson, 2007, Varma et al., 2002). It acts through a separate receptor, and regulates the activity of APCs as part of the adaptive immune response in addition to its antiviral functions. Hence, IFNγ is a type II IFN, but a type 1 cytokine.

Type I IFN production is stimulated through TLR3, which detects double-stranded viral RNA, and TLR4, the bacterial LPS receptor (Hertzog et al. 2003). These two TLRs, which are expressed in the testis (Bhushan et al., 2008, Riccioli et al., 2006, Starace et al., 2008, Wu et al., 2008), are able to induce the IFN transcription factor IRF3, via engagement of the TRIF adapter protein (Akira and Takeda, 2004, Hertzog et al., 2003, O’Neill and Bowie, 2007). The regulation of IFNγ is cell specific and complex, but involves Jak/Stat signaling and various transcription factors, including NFκB and AP1 (Schoenborn and Wilson, 2007, Varma et al., 2002). Its production is stimulated by type I IFNs and by IL18, among other cytokines. Viral infections stimulate type 1 IFN and, somewhat more surprisingly, IFNγ production by Sertoli cells, peritubular cells, Leydig cells, and testicular macrophages, leading to typical antiviral responses in the testis (Dejucq et al., 1995, Dejucq et al., 1998a, Dejucq et al., 1998b, Hu et al., 1998, Starace et al., 2008). A role for IFNγ in maintaining testicular immune privilege has been indicated by the observation that mouse Sertoli cells upregulate their expression of the negative costimulatory ligand B7-H1 in response to IFNγ in vitro, but remain devoid of positive costimulatory molecules (Dal Secco et al. 2008). On the other hand, in vivo studies have identified IFNγ as a causative factor in EAO in mice (Itoh et al. 1998b). Moreover, IFNγ stimulates Sertoli cell production of Fas and caspase 1, and is implicated as the mediator of Sertoli cell and germ cell apoptosis under various conditions (Kanzaki and Morris, 1998, Riccioli et al., 2000). These disparate observations are indicative of a complex relationship between IFNγ, the local immune system, and spermatogenesis.

IFN production also affects testicular steroidogenesis. Normal healthy men treated with human IFNα had significantly decreased serum testosterone levels in conjunction with normal serum gonadotropins, and both IFNα and IFNγ inhibit testosterone production in primary cultures of Leydig cells (Orava et al. 1986). Studies using porcine Leydig cells indicate that IFNγ exerts its inhibitory effect on testosterone production at the level of cholesterol transport into the mitochondria, and inhibits expression of the steroidogenic acute regulatory (StAR) protein and the P-450 steroidogenic enzymes, cholesterol side-chain cleavage complex (P450scc) and 17α-hydroxylase/C17–C20 lyase (P450c17) (Orava et al., 1985, Orava et al., 1989). These data indicate that IFNs may contribute to the decline in steroidogenic function of patients with viral infections, in particular. However, Dejucq et al., 1995, Dejucq et al., 1998a have shown that an increase in IFNα and IFNγ expression in Sertoli and Leydig cells of rats infected with Sendai virus was actually associated with an increase in testosterone production. These results suggest that indirect or secondary stimulatory effects on testicular steroidogenesis may be involved, providing further evidence that IFNs play a complex role in testicular function.

Transforming growth factor β and activin A

The three TGFβ family members that are expressed in mammals (TGFβ1, TGFβ2, and TGFβ3) are the archetypes of a much larger superfamily of mostly homo- and heterodimeric proteins, which includes the activins, the bone morphogenetic proteins (BMPs), inhibin, and anti-Müllerian hormone (Lin et al. 2006). The TGFβs themselves are multifunctional growth and differentiation factors involved in many aspects of tissue remodeling and repair as well as regulation of the immune system (Ashcroft, 1999, Chang et al., 2001, Licona-Limón and Soldevila, 2007). Nearly all cells synthesize a form of TGFβ and possess functional receptors for these cytokines. Most TGFβ family ligands act via dual transmembrane serine/threonine kinase receptors, called type I and type II, which interact upon ligand binding (Cárcamo et al., 1994, Ebner et al., 1993, Massagué et al., 1992). Signals are transduced from the membrane to the nucleus through phosphorylation of the regulatory Smad signaling proteins, with Smads 2, 3, and 4 responsible for mediating TGFβ and activin signaling (Datto et al., 1999, de Caestecker et al., 1998).

All three mammalian TGFβ forms are differentially expressed by Sertoli cells, peritubular cells, and Leydig cells in the fetal and immature testis, but production declines considerably during sexual maturation (Avallet et al., 1994, Gautier et al., 1994, Mullaney and Skinner, 1993, Olaso et al., 1997). In the postpubertal testis, they have also been localized to the germ cells (Caussanel et al., 1997, Teerds and Dorrington, 1993), and TGFβ receptors are found in both somatic and germ cells (Caussanel et al., 1997, Goddard et al., 2000, Le Magueresse-Battistoni et al., 1995). The TGFβs appear to be involved in testicular development by controlling, among other things, apoptosis of undifferentiated spermatogonia (gonocytes) (Olaso et al. 1998), seminiferous tubule formation, and Leydig cell differentiation (Cupp et al., 1999, Dickson et al., 2002, Khan et al., 1992a, Konrad et al., 2000). In the adult testis, TGFβ2 and TGFβ3 regulate Sertoli cell tight junction dynamics, indicating a role in regulating the permeability of the blood–testis barrier to facilitate the passage of spermatocytes across the barrier during spermatogenesis (Lui et al., 2003, Xia et al., 2006). However, the TGFβs are also potent inhibitors of the activity of immune cells, especially T cells, B cells, and NK cells (Ahmad et al., 1997, Ashcroft, 1999, Cousins et al., 1991, Licona-Limón and Soldevila, 2007, Wahl et al., 2006), suggesting a prominent role in creating testicular immune privilege. Accordingly, TGFβ1 contributes to the lymphocyte inhibitory activity of testis extracts (Pöllänen et al. 1993) and to the immunoprotective properties of Sertoli cells in cotransplantation studies (Suarez-Pinzon et al. 2000).

Activins are homodimers or heterodimers of homologous subunits, designated βA–βE, which are structurally related to the TGFβs (Chang et al., 2001, de Kretser et al., 2002). Homodimers of βA form activin A, which is widely expressed and has been extensively studied. Relatively less is known about the other activin forms, which appear to be both less abundant and less widely distributed. Activin A is a multifunctional growth factor and inflammatory regulator (Phillips et al. 2001), although activins were originally named for the ability of activin A and B, in particular, to stimulate pituitary FSH secretion (Corrigan et al., 1991, Ling et al., 1986). Heterodimers of either βA or βB subunits with a homologous α subunit, are called inhibin A and inhibin B, respectively, and act as feedback inhibitors of FSH secretion from the pituitary (Robertson et al. 1986). Unlike the activins, inhibins are not widely produced, and their chief source is the Sertoli cell, the cellular target of FSH action (de Kretser et al., 2004, Meunier et al., 1988).

Activin functions are highly regulated. Like the TGFβs, they act via specific type I and type II transmembrane serine/threonine kinase receptors, linked to the Smad signaling pathway (Ethier and Findlay, 2001, Vale et al., 2004). The inhibins are competitive inhibitors of activin receptor binding, but activin homodimers and heterodimers comprising the βB and βC subunits also appear to act as weak competitive agonists of activin A (Brown et al., 2000, Makanji et al., 2008, Mellor et al., 2003). These interactions are modulated and/or facilitated by specific inhibitory coreceptor proteins, such as betaglycan and the BMP and activin membrane-bound inhibitor (BAMBI) (Lewis et al., 2000, Makanji et al., 2008, Onichtchouk et al., 1999). Moreover, activin bioactivity can be effectively neutralized in the circulation by the high-affinity activin binding protein, follistatin (Nakamura et al. 1991).

Activin A is abundantly produced in the testis, particularly during early testicular development (Barakat et al., 2008, Buzzard et al., 2004). Even in the adult rat, intratesticular fluid levels of activin A are 5–10 times higher than normal circulating concentrations (O’Bryan et al. 2005). The Sertoli cells appear to be the main source in the adult testis, although the βA subunit is expressed in most germ cells (Buzzard et al., 2004, Kaipia et al., 1992), and activin A protein is present in the resident macrophages and mast cells (Okuma et al., 2005b, Okuma et al., 2006). Activin A is expressed at low levels throughout the cycle of the seminiferous epithelium, but there is a distinct peak of production immediately following spermiation, which is driven by the surge of ILα produced by the Sertoli cell at this time (Kaipia et al., 1992, Okuma et al., 2006). Activin receptors are expressed by most, if not all, of the somatic and germ cells in the testis (Cameron et al., 1994, de Winter et al., 1992, Feng et al., 1993, Kaipia et al., 1993). Activin A exerts a complex regulation of germ cell, Sertoli cell, and Leydig cell proliferation and/or differentiation during development and in the adult (Barakat et al., 2008, Buzzard et al., 2003, Mather et al., 1990, Mauduit et al., 1991a, Meehan et al., 2000, Meinhardt et al., 2000), and disorders of activin signaling are implicated in the onset of testicular cancer (Dias et al. 2008).

Activin A is produced by activated monocytes, macrophages, dendritic cells, bone marrow stromal cells, and some lymphocytes (Erämaa et al., 1992, Ogawa et al., 2006, Robson et al., 2008, Yamashita et al., 1992), and plays a facilitating role in early inflammation responses (Jones et al. 2007). Consistent with its homology to the TGFβ proteins, however, activin A also possesses a repertoire of anti-inflammatory and immunoregulatory activities, and displays characteristics of a type 2 cytokine (Hedger et al., 1989, Ogawa et al., 2006, Wang et al., 2008, Yu et al., 1998). In various experimental systems, activin A has been found to antagonize the production and actions of IL1 and IL6, to inhibit critical T cell and B cell activation responses, and to induce macrophages to polarize toward the M2 phenotype (Brosh et al., 1995, Gribi et al., 2001, Ogawa et al., 2006, Russell et al., 1999). Both Sertoli cells and testicular macrophages in culture respond to LPS by increasing activin A production (Okuma et al. 2005a) (Hedger, unpublished data), and IL1 is a very potent stimulus for activin A production by the Sertoli cell (Okuma et al., 2005b, Okuma et al., 2006). The actual role of activin A in testicular inflammation remains unclear, since the high intratesticular levels of activin A are not affected by LPS treatment in vivo (O’Bryan et al. 2005), but a role for activin A in modulating testicular immune responses can be predicted.

Steroids

Androgens produced by the Leydig cells have immunosuppressive properties that contribute to differences in immunity between the sexes (Cutolo et al., 2004, Miller and Hunt, 1996). The majority of these effects are believed to be exerted at the level of the immune tissues, rather than by direct effects on circulating leukocytes, which lack classical androgen receptors (Grossman et al., 1979, Sasson and Mayer, 1981). Recently, however, it has been discovered that steroids can interact with membrane-bound G-protein-coupled receptors to trigger nongenomic responses (Braun and Thomas, 2004, Rahman and Christian, 2007). Studies have shown that androgens alter [Ca] fluxes in lymphocytes and macrophages via such membrane-mediated interactions, affecting gene expression and function in the target cells (Benten et al., 2004, Walker, 2003, Wunderlich et al., 2002). Although studies of the role of androgens in suppressing immune responses, such as graft rejection, in the testis have been somewhat equivocal (Cameron et al., 1990, Selawry and Whittington, 1988, Whitmore and Gittes, 1978), the observation that immune cells can respond directly to androgens has resurrected the intriguing possibility that androgens, and possibly other testicular steroids, may directly regulate immune cell activity within the testis and adjacent draining lymph nodes.

Glucocorticoids play an important role in modulating both testicular immunity and steroidogenesis via a complex extratesticular regulatory loop. During inflammation, proinflammatory cytokines activate the hypothalamic–pituitary–adrenal axis leading to increased secretion of glucocorticoids, which act through the ubiquitously expressed glucocorticoid receptors (Buckingham et al., 1996, Sapolsky et al., 2000). Glucocorticoids suppress innate and acquired immunity at multiple levels and are an essential control in the inflammatory/immune response. They inhibit the inflammatory response primarily by repression of NFκB, suppressing the production and actions of the proinflammatory cytokines, reducing adhesion molecule expression, and stimulating the production of anti-inflammatory cytokines (Auphan et al., 1995, Brack et al., 1997, Kapcala et al., 1995). Glucocorticoids also exert inhibitory effects at all levels of the hypothalamic–pituitary–Leydig cell axis (Bambino and Hsueh, 1981, Hales and Payne, 1989, Hardy et al., 2005, Monder et al., 1994), thereby contributing to the inhibition of androgen production that accompanies local and systemic inflammatory events.

Bioactive lipids: Prostanoids and phospholipids

Prostaglandins (PGD, PGE, and PGF), prostacyclins (PGI), and thromboxanes (Tx), collectively called the prostanoids, are fundamental to many physiological processes, including inflammation and immunity. Prostanoids arise from hydrolysis of membrane glycerophospholipids to release the free fatty acid arachidonic acid through the action of one of the more than 20 enzymes with phospholipase A2 (PLA2) activity (Kudo and Murakami, 2002, Schaloske and Dennis, 2006). Arachidonic acid is in turn directed down the prostanoid synthetic pathway by the action of the cyclooxygenase (COX; also called prostaglandin-endoperoxide synthase) enzymes (Figure 3). There are two COX enzymes, which are the products of different genes: the constitutively expressed COX1 and an inflammation-induced form, COX2 (Table 2) (Smith et al., 2000, Tanabe and Tohnai, 2002). While conversion of arachidonic acid to the prostanoid precursor PGH2 by COX is the rate-limiting step, production of specific prostanoids depends on the activity of the prostaglandin synthases, that is, PGE synthase (PGES), PGIS, PGDS, PGFS, and thromboxane A synthase (TxAS) (Helliwell et al., 2004, Ueno et al., 2005). Each prostanoid acts via one or more specific receptors to regulate cell growth, vascular smooth muscle constriction or relaxation, vascular permeability, and immune cell activity (Bos et al., 2004, Hata et al., 1990). Several prostanoids exert both proinflammatory and immunosuppressive actions through different receptor interactions, or through metabolism to other active immunoregulatory metabolites, such as 15-deoxy-PGJ2, a ligand for the peroxisome proliferator-activated receptor γ (PPARγ) (Jiang et al. 1998). An alternative synthetic pathway, catalyzed by the lipoxygenases, converts arachidonic acid to the related leukotrienes and lipoxins, which also possess diverse metabolic, vascular, and inflammation-regulating actions (Samuelsson et al., 1987, Takano et al., 1997).

Prostanoid and lysophosphatidylcholine synthesis and targets. Synthesis of the prostanoids commences through the action of phospholipase A2 (PLA2) on arachidonyl-containing phospholipids (usually a 1-acyl-2-arachidonyl-glycerophospholipid) to produce the free fatty acid arachidonic acid and the corresponding lysophospholipid. Arachidonic acid is converted into the prostanoid precursor prostaglandin H2 (PGH2) by the action of cyclooxygenases and this is further converted into the various prostanoid subtypes, prostaglandins (PGD, PGE, and PGF), prostacyclins (PGI), and thromboxanes (Tx), by the action of specific prostaglandin and thromboxane synthases. Synthesis of lipoxins and leukotrienes from arachidonic acid occurs via the activity of a separate lipoxygenase enzyme (not shown). The prostanoids interact with their various receptor subtypes: there are two PGD receptors (DP1–2) and four PGE receptors (EP1–4). It is the cellular expression of these receptor subtypes that ultimately determines the eventual biological responses; for example, different prostanoid and receptor combinations may produce either proinflammatory or anti-inflammatory responses, or may have opposing vasodilatory and vasoconstrictive effects. When the phospholipid is a phosphatidylcholine, a lysophosphatidylcholine (LPC) is formed, which may interact with cells via G-protein-coupled receptor-mediated or direct membrane interactions, or may undergo further enzymatic modification to form other bioactive lipids.

Most of the enzymes responsible for prostanoid production are ubiquitously expressed, and this includes the male reproductive tract (Gerena et al., 2000, Lazarus et al., 2002, Takahashi et al., 1995, Winnall et al., 2007). In fact, the levels of E series prostaglandins in human seminal plasma are remarkably high (Cooper and Kelly 1975). Most testicular cells express both COX forms, and possess the capacity to produce prostaglandins in vitro (Winnall et al. 2007), although there appear to be cell type-specific and species-specific differences in the relative levels of expression (Balaji et al., 2007, Frungieri et al., 2006, Lazarus et al., 2004). In the normal rat testis, COX2 is responsible for the majority of prostaglandin production (Winnall et al. 2007), although intratesticular PGE2 levels are only marginally affected by acute inflammation (Winnall et al. 2008). This is probably due to the fact that macrophages in the rat testis express COX2 at very low levels, but are the only testis cell type to respond to an inflammatory stimulus with a significant increase in COX2 activity (Winnall et al. 2007). These data point toward a previously unanticipated maintenance role for the so-called inducible COX2 enzyme in testicular function, as well as an anomalous inflammatory response of testicular COX2, consistent with an altered capacity of this organ to initiate and support inflammatory reactions.

Fertility is retained in male mice lacking either COX1 or COX2, whereas double deletions are lethal (Langenbach et al., 1999, Lim et al., 1997, Sales and Jabbour, 2003). Studies on male fertility and spermatogenesis using prostaglandins, or nonsteroidal anti-inflammatory drugs such as aspirin and indomethacin, which act primarily via inhibition of COX activity, have produced conflicting conclusions (Abbatiello et al., 1975, Biswas et al., 1978, Sanyal et al., 1980, Winnall et al., 2008). These diverse outcomes indicate the complexity of the roles of prostanoids in controlling various aspects of testicular function. Prostaglandins, particularly PGE2 and PGF2α, have been implicated in the control of Leydig cell development in the immature testis, production of proinflammatory cytokines by the Leydig and Sertoli cells, autoregulation of steroidogenesis in the adult, and the decline in Leydig cell function that occurs during aging (Baker and O’Shaughnessy, 2001, Cooke et al., 1991, Haour et al., 1979, Ishikawa et al., 2005, Walch and Morris, 2002, Wang et al., 2005). Production of PGE2 and PGF2α by COX2 also mediates the effects of IL1 on protein and lipid regulation by the Sertoli cell involved in supporting spermatogenesis and inflammation in the testis (Ishikawa and Morris, 2006, Ishikawa et al., 2005). In addition, PGE2 and PGF2α produced by mature spermatozoa play a role in the acrosome reaction (Breitbart et al., 1995, Joyce et al., 1987). Products of the lipoxygenase pathway, such as leukotriene B4, are also produced by the testis, where they intervene in the regulation of Leydig cell steroidogenesis by LH (Papadopoulos et al., 1987, Sullivan and Cooke, 1985), but other functions can be expected.

Direct evidence for the anticipated roles of prostanoids or lipoxygenase products in testicular inflammation and immunity is lacking. Initially, there was some evidence to suggest that PGE2 might be responsible for the immunosuppressive phenotype of resident testicular macrophages (Kern and Maddocks, 1995, Kern et al., 1995). This now seems unlikely, because testicular macrophages produce little PGE2 under normal conditions, and blocking COX2 activity in vivo or in vitro does not affect the production of proinflammatory cytokines in the testis in response to LPS (Gerdprasert et al., 2002a, Winnall et al., 2007, Winnall et al., 2008). In the rat, chronic inhibition of COX2 inhibited interstitial fluid formation in normal testes, but ameliorated the loss of fluid that usually occurs during LPS-induced inflammation (Winnall et al. 2008). The latter data would seem to indicate roles for products of COX2 in the control of vascular tone in the normal and inflamed testis and this deserves further exploration.

When phosphocholine (PC)-containing phospholipids are used as the substrate for PLA2 action, lysophosphatidylcholines (LPCs) are also produced (Aoki et al., 2002, Snyder, 1990). LPCs usually comprise a glycerophosphocholine backbone, a single long-chain fatty acid, and a free hydroxyl group (Khaselev and Murphy 2000). The platelet-activating factors (PAFs) are a subset of LPCs with an acetyl group in place of the hydroxyl group, which facilitates binding to the PAF receptor (Snyder 1990). The effective concentrations of these phospholipid-derived molecules in biological fluids are normally tightly controlled by binding to albumin and lipoproteins (Croset et al. 2000), since some LPCs, particularly those derived from the saturated C16 and C18 fatty acids, cause cell lysis at high concentrations (Weltzien 1979). At physiological concentrations, however, LPCs induce specific responses in various cell types, including most immune cell types. Nonacetylated LPCs are chemotactic toward macrophages, T cells, and NK cells, and stimulate COX2 expression by macrophages, cytokine production by T cells, and the cytotoxic activity of NK cells (Légrádi et al., 2004, Radu et al., 2004, Whalen et al., 1999, Yang et al., 2005). In addition, LPCs induce apoptosis in T cells, indicating a role in immunosuppression as well (Kabarowski et al., 2002, Takeda et al., 1982). The details of the mechanisms involved are poorly understood. While there is evidence for involvement of specific G-protein-coupled receptors (Flemming et al., 2006, Lin and Ye, 2003, Radu et al., 2004, Soga et al., 2005, Yang et al., 2005), LPCs may interact with G-proteins, membrane kinases, and ion channels directly, thereby bypassing the need for any specific receptor–ligand interactions.

The interstitial fluid of the testis has long been known to possess potent lymphocyte-inhibiting activity in vitro (Hedger et al., 1998a, Pöllänen et al., 1988). The molecules responsible for this activity have now been isolated and identified as the specific LPCs: 1-palmitoyl-sn-glycero-3-phosphocholine (16:0a-LPC), 1-oleoyl-sn-glycero-3-phosphocholine (18:1a-LPC), a 18:2a-LPC (putatively, 1-linoleoyl-sn-glycero-3-phosphocholine), and a 20:4a-LPC (putatively, 1-arachidonyl-sn-glycero-3-phosphocholine) (Foulds et al. 2008). These molecules inhibit T cell proliferation in response to activation and induce apoptosis of these cells in a time- and dose-dependent manner at physiologically relevant concentrations. Although PAF activity has also been found in the testis (Muguruma et al. 1993), these acetylated LPCs did not appear to contribute significantly to the T cell inhibitory activity. The emergence of LPCs as regulators of critical immune events in the testis opens up new avenues of inquiry into the origins of autoimmune infertility and more general mechanisms of peripheral immunoregulation. These molecules may also have other roles in testis biology that demand consideration.

Cell surface regulatory molecules: Complement inhibitors and nonclassical MHC

Inhibition of complement activation is an important mechanism for reducing transplant rejection, particularly in the early phase. Membrane complement inhibitors, such as CD46, CD55, CD59, and the complement receptor-related protein (Crry), are expressed in several immune-privileged tissues and have been implicated in suppression of inflammation in the eye and placenta (Bora et al., 1993, Bulla et al., 2005). CD46 and CD55 appear to be confined to spermatids in the adult rat testis, Crry is expressed on early spermatocytes and interstitial cells, but CD59 is widely expressed throughout the seminiferous epithelium and interstitium (Mizuno et al. 2006). A role for CD59 expression by the Sertoli cells in prolonging the survival of these cells in transplantation studies has been suggested (Lee et al. 2007). Moreover, complement regulators both in seminal plasma and on the surface of the spermatozoa (CD46, CD55, and CD59) may contribute to complement evasion by the spermatozoa in the female tract (Harris et al. 2006).

Classical MHC class I molecules (HLA-A, HLA-B, and HLA-C) are expressed on nearly all cell types, and facilitate antigen presentation by these cells and activation of cytotoxic T cells (Cresswell et al., 1999, Janeway, 1992, Sant et al., 1999). By contrast, the nonclassical MHC class Ib molecules (HLA-E, -F, and -G) are much less widely expressed, and are associated with suppression of the adaptive immune response. Membrane-bound and soluble variants of these MHC class Ib molecules have been implicated in the apoptosis of alloreactive cytotoxic T cells, inhibition of NK cell cytolytic activity, suppression of T cell proliferation, and deviation of type 1 to type 2 responses, most notably in pregnancy (Bainbridge et al., 2000, Fournel et al., 2000, Ishitani et al., 2006, Kapasi et al., 2000, Kanai et al., 2001, Riteau et al., 1999). HLA-G has been found in the rhesus monkey testis (Ryan et al., 2002, Slukvin et al., 1999), and HLA-E is expressed on germ cells in the human testis (Fiszer et al. 1997), indicating that these molecules may contribute to immune privilege in the testis.

Immune System–Testis Interactions in Normal Function and Pathology

From the evidence outlined in the previous sections, it should be evident that proinflammatory and immunoregulatory processes are involved in both normal testicular function and testicular pathophysiology. In the normal testis, roles in the maintenance of immune privilege, the control of Leydig cell development, and the fine regulation of spermatogenesis are indicated (Figure 4). Contributions to pathology include the development of autoimmunity within the male reproductive tract, disruption of steroidogenesis and spermatogenesis during systemic and local inflammatory events, and the response to vascular disturbances.

Inflammatory and immunoregulatory signaling in the control of intratesticular interactions. Sertoli cells are primarily regulated by the hormones follicle-stimulating hormone (FSH) and testosterone, the latter being produced by the Leydig cells on stimulation by luteinizing hormone (LH). Sertoli cells and germ cells interact through production of various inflammatory mediators, including interleukin (IL) 1α, IL6, activin A, tumor necrosis factor α (TNFα), and NO, to facilitate and coordinate critical events throughout the cycle of the seminiferous epithelium. The development and activity of the Leydig cells and the resident macrophages involve a close mutual interaction, mediated by mechanisms that remain to be completely defined. The Sertoli cell and the resident macrophages, in turn, influence the activity of the antigen-presenting cells (APC; e.g., dendritic cells) and lymphocytes within the interstitial tissue to control local immune events, such as the maintenance of an immunologically privileged environment. This communication involves the immunoregulatory cytokines transforming growth factor β (TGFβ), activin A, and IL10, although other mechanisms may also be involved.

Normal testicular function

Direct evidence that immune privilege is due to a specialized immune environment originally comes from studies involving the central nervous system. Injection of soluble antigen into the compartments of the eye or brain produces antigen-specific suppression of cell-mediated immunity, specifically type 1 reactions (Kaplan and Streilein, 1978, Wenkel et al., 2000). This phenomenon is called acquired immune deviation (AID), and it is possible to elicit similar inhibition of antigen-specific immune responses by prior injection of antigens into the testis (Ditzian-Kadanoff, 1999, Li et al., 1997, Veräjänkorva et al., 2002). The Sertoli cell and Leydig cell are almost certainly central to this process, although contributions from other testicular cells are to be expected. The mechanisms responsible presumably involve the recruitment and functional deviation of macrophages (and possibly dendritic cells) within the testis (Hedger 2002), the subsequent recruitment of immunoregulatory lymphocyte subsets (Tompkins et al. 1998), the production of immunoregulatory cytokines, such as TGFβ family members and IL10 (O’Bryan et al., 2005, Suarez-Pinzon et al., 2000), local high concentrations of androgenic steroids, prostanoids, and other bioactive lipids (Foulds et al., 2008, Winnall et al., 2007), complement inhibitors (Lee et al., 2007, Mizuno et al., 2006), and testicular expression of inhibitory MHC and costimulatory molecules (Dal Secco et al., 2008, Fiszer et al., 1997, Ryan et al., 2002).

Macrophages play an important role in Leydig cell development and function. There is a close temporal link between the maturation of the adult Leydig cell population and the increase in the number of testicular resident macrophages during puberty (Hardy et al., 1989, Raburn et al., 1993, Vergouwen et al., 1993). Reductions in intratesticular macrophages due to specific depletion methods or in the macrophage-deficient (op/op) mouse lead to disorders of Leydig cell development and mature function (Cohen et al., 1997, Gaytan et al., 1994a, Gaytan et al., 1994b), and testicular macrophage-conditioned medium stimulates Leydig cell steroidogenesis under certain conditions (Nes et al., 2000, Yee and Hutson, 1985). These supportive functions of the testicular macrophages may involve production of cytokines and other secreted mediators (Khan et al., 1992b, Warren et al., 1990), as well as the distinctive intercytoplasmic specializations that develop between the two cell types (Hutson, 1992, Miller et al., 1983). It has also been shown that testicular macrophages support basal steroidogenesis in the Leydig cells by providing 25-hydroxycholesterol as a substrate for testosterone biosynthesis (Nes et al. 2000).

Endogenous regulation of inflammatory pathways within the seminiferous epithelium appears to be involved in the fine control of spermatogenesis. Studies in the rat and mouse indicate that nuclear localization (i.e., activation) of the key proinflammatory transcription factor NFκB, and expression of the inflammation-responsive genes, IL1α, TNFα, IL6, activin A, and iNOS, in the Sertoli cell and the germ cells describe cyclical patterns within the seminiferous epithelium that coincide with critical events in the cycle of the seminiferous epithelium (O’Bryan and Hedger 2008). Most notably, release of spermatozoa from the epithelium (spermiation) in the rat testis is followed by an increase in the production of IL1α, IL6, and activin A by the Sertoli cells and of TNFα and iNOS by the spermatocytes (De et al., 1993, Hakovirta et al., 1995, Kaipia et al., 1992, Söder et al., 1991, Syed et al., 1993, O’Bryan et al., 2000a, Okuma et al., 2006). In the mouse, spermiation is accompanied by a period of elevated nuclear NFκB levels in spermatocytes (Delfino and Walker 1998). These responses coincide with a peak of DNA synthesis by preleptotene spermatocytes and type A spermatogonia prior to meiotic and mitotic division, and reorganization of Sertoli cell tight junctions to allow the meiotic cells to enter the adluminal compartment (O’Bryan and Hedger 2008). Given that IL1α, IL6, and activin A are regulators of spermatogonial proliferation and meiotic progression (Hakovirta et al., 1993a, Hakovirta et al., 1995, Mather et al., 1990, Meehan et al., 2000, Meinhardt et al., 2000, Parvinen et al., 1991, Söder et al., 1991), while TNFα and iNOS/NO induce the disassembly of the intercellular tight junctions (Lee and Cheng, 2003, Lee et al., 2005, Li et al., 2006a, Siu et al., 2003), this concurrence of events is unlikely to be a coincidence. It would appear that release of the spermatozoa and/or phagocytosis of the residual cytoplasm triggers elements of the inflammatory machinery within the seminiferous epithelium. A role for TLRs or other pattern-recognition receptors in this process may be postulated, and similar regulatory networks may also operate throughout the remainder of the cycle. Many questions regarding the details of this functional regulation await clarification, and it must be noted that there is a curious lack of concordance between the content of NFκB in the Sertoli cell nucleus observed across the cycle in the mouse (Delfino and Walker 1998) and inflammatory cytokine production by these same cells in the rat (De et al., 1993, Hakovirta et al., 1995, Kaipia et al., 1992, O’Bryan et al., 2000a, Okuma et al., 2006, Söder et al., 1991, Syed et al., 1993). Regardless of the questions that remain, however, key elements of the inflammatory response appear to play essential roles in the physiological regulation of the seminiferous epithelium, which are entirely separate from their roles in pathology.

Testicular pathology

Although it is a common assumption that male reproductive failure caused by local or systemic illness, infection, and chronic inflammatory disease is due to the negative effects of raised body temperature on spermatogenesis, there is little clinical or experimental evidence to support this belief (O’Bryan et al. 2000b). There is much more convincing evidence that the damage is due to activation of local inflammatory pathways and the activity of immune cells recruited during inflammatory events. As already outlined in the previous sections, inflammatory mediators such as IL1, ROS, TNFα, and NO, as well as glucocorticoids produced in response to inflammation, have mostly negative effects at all levels of the hypothalamic–pituitary–Leydig cell axis (Bambino and Hsueh, 1981, Del Punta et al., 1996, Hales, 1992, Hales and Payne, 1989, Hardy et al., 2005, Li et al., 1995, Mauduit et al., 1991b, Mauduit et al., 1998, Monder et al., 1994, Sharma et al., 1998, Welch et al., 1995, Xiong and Hales, 1993b, Xiong and Hales, 1994, Xiong and Hales, 1997). The subsequent reduction in androgen production may lead to reduced spermatogenic capacity, but may also exacerbate the effects of inflammation on spermatogenesis itself. Expression of TLRs on the Sertoli cells is obviously important in protective responses against pathogens, but also provides a mechanism whereby pathogens can directly inhibit spermatogenesis. Thus, TLR activation and the production of inflammatory mediators almost certainly alter Sertoli cell functions, and this will affect the ability of these cells to support and regulate spermatogenesis, as well as activate signaling pathways that promote germ cell apoptosis (Lysiak et al., 2005, Pentikäinen et al., 2002, Rasoulpour and Boekelheide, 2005, Starace et al., 2005).

Inflammatory events play a role in testicular damage due to vascular disturbance. Spermatogenesis is an energy intensive process, and the seminiferous epithelium is not vascularized. Consequently, unobstructed blood flow to the testis is essential and even minor anomalies in the testicular vasculature, such as varicocele, have cumulative negative effects on sperm production (Jarow 2001). The deleterious effects of cadmium on fertility through disruption of the testicular vasculature are well known (Schrag and Dixon 1985). In experimental animals, transient torsion of the spermatic cord that renders the testis ischemic followed by reperfusion causes an increase in TNFα and IL1β expression, activation of the stress-related Jnk/p38 MAP kinase signaling pathway, neutrophil recruitment and infiltration into the testis, increased oxidative stress, germ cell apoptosis, and significantly decreased serum testosterone levels (Lysiak, 2004, Lysiak et al., 2001, Rodriguez et al., 2006). A specific role for testicular nitric oxide in mediating damage in both the testicular torsion and human varicocele models has been implicated (Moon et al., 2005, Santoro et al., 2001, Shiraishi and Naito, 2007, Shiraishi et al., 2001, Türker Köksal et al., 2004).

Administration of high doses of human chorionic gonadotropin (hCG), a treatment used to correct delayed testicular descent in young boys, causes a hyperstimulation syndrome in rats comprising increased testicular blood flow and pressure, increased vascular permeability, and accumulation of interstitial fluid (Hjertkvist et al., 1993, Setchell and Sharpe, 1981, van Vliet et al., 1988). These vascular changes are accompanied by accumulation of intravascular and interstitial neutrophils in the testis (Bergh et al., 1986, Widmark et al., 1987), and spermatogenic damage (Kerr and Sharpe, 1989a, Kerr and Sharpe, 1989b). The responses to hCG can be eliminated by depletion of either the Leydig cells or the neutrophils (Setchell and Rommerts, 1985, Widmark et al., 1987), and IL1β is able to replicate most of the effects (Bergh and Söder, 1990, Bergh et al., 1996), suggesting that the response involves an inflammatory event mediated via IL1β secreted by the Leydig cells. Thus, it appears that disruption of the seminiferous epithelium in both the ischemia/reperfusion model and hCG hyperstimulation models is directly linked to local recruitment of neutrophils. Exactly how these cells exert damage on the germ cells is not yet known, but increased oxidative stress is obviously involved. The responses are quite different from those observed in LPS-induced inflammation, which paradoxically causes a large reduction in interstitial fluid volume and an increase in mononuclear cells in the rat testis (O’Bryan et al., 2000b, Gerdprasert et al., 2002a, Gerdprasert et al., 2002b), although the germ cell damage is similar in both models.

In summary, different testicular inflammation models have direct effects on spermatogenic development, in addition to causing damage to the steroiodogenic function of the Leydig cells. It should also be noted that, as in most other tissues, inflammation responses within the testis do not automatically lead to autoimmune complications, but damage to various testicular functions that may be less readily apparent may lead to longer-term consequences for reproductive health (Schuppe and Meinhardt, 2005, Schuppe et al., 2008, Suominen and Soderstrom, 1982).

The Epididymis, Vas Deferens, Accessory Glands, and Urogenital Tract

As already noted above, the immune environment of the remainder of the male tract is quite distinct from that of the testis, or even from that of other mucosal tissues. The mechanisms whereby sperm within the male reproductive tract are protected from the immune system remain largely unknown, but an intact tract is obviously important. In humans, vasectomy leads to sperm antibody formation in approximately 70% of cases, and sperm antibodies are also associated with obstructive azoospermia and congenital absence of the epididymis and/or vas (Alexander and Anderson, 1979, de Kretser et al., 1998, Hellema et al., 1979, Patrizio et al., 1992). The incidence of antibody formation in humans appears to be directly related to the distance of the lesion from the testis, implying a limited role for elements of testicular immune privilege in preventing immune reactions. There is evidence from patients and animal models that vasectomy can have deleterious effects on the testis and epididymis as well, and that at least some of these effects may have an immunological basis (Aitken et al., 1999, Bigazzi et al., 1976, Flickinger et al., 1990a, Raleigh et al., 2004). In certain strains of rats, mice, and rabbits, vasectomy rapidly leads to orchitis and sterility, so it is not clear why this degree of damage is so rare in humans. In reality, the immunology of the male reproductive tract has yet to be investigated in depth, but two areas of recent interest are worth highlighting: the TLRs and the defensins.

Given the exposure to the external environment, it is not surprising that the TLRs as well as many essential TLR-related genes, such as MyD88, are expressed throughout the male reproductive tract, including the epididymis, vas deferens, and accessory glands (Nishimura and Naito, 2005, Palladino et al., 2007, Quintar et al., 2006, Rodrigues et al., 2008). Expression is found on both epithelial cells and leukocytes in these tissues. Moreover, weak expression of TLR11, originally localized to the urinary tract of experimental rodents, has been detected in the epididymis and vas deferens of the rat (Lauw et al., 2005, Palladino et al., 2007, Zhang et al., 2004). The importance of these molecules in acute and chronic inflammation, and the response to infection, in the male reproductive tract is an important area for future studies. Moreover, changes in susceptibility to inflammation through polymorphisms in the TLRs have been associated with differences in susceptibility to the onset of cancer in the prostate (Sun et al., 2005, Zheng et al., 2004).

Defensins are small (3–4 kDa) positively charged peptides that are able to disrupt bacteria, fungi, parasites, and some enveloped viruses by forming multimeric pores in the pathogen membrane (Selsted and Ouellette 2005). The β-defensins are produced by most mucosal epithelial tissues, including the testis and epididymis (Com et al. 2003), and their production is stimulated via TLR activation and cytokines. A number of epididymal-specific β-defensins have been identified in the mouse and the rat (Li et al., 2001, Jalkanen et al., 2005, Yamaguchi et al., 2002, Yenugu et al., 2004, Zhou et al., 2004), and a role for androgen in their regulation has been indicated (Jalkanen et al., 2005, Yenugu et al., 2004). Apart from their obvious role in protection against pathogens, defensins may have other functions in the reproductive tract. The novel β-defensin, Bin1b, which is exclusively produced and secreted by the rat caput epididymis, binds to sperm (Li et al., 2001, Zhou et al., 2004), and blocking Bin1b reduces sperm motility in vivo, suggesting a novel role for this molecule in sperm maturation (Zhou et al. 2004).

Sperm, Semen, Seminal Leukocytes, and Cytokines

In humans, semen is the most accessible window into the health of the male reproductive system, as it is the number and quality of sperm in the semen that provide the principal foci for male reproductive toxicity outcomes. However, semen is a complex secretion, comprising many components, including leukocytes, immunoglobulins, cytokines, prostaglandins, and various immunosuppressives. Changes in the number or activity of these immunological components of the semen are also potential indicators of toxic actions within the tract.

Elevated numbers of leukocytes in the semen are generally considered to be an indication of infection, but leukocytes are present even in the semen of men with normal fertility (Aitken and Baker, 1995, Barratt et al., 1991). The origin of these cells is somewhat obscure. Evidence suggests that the epididymis or vas may be a major source (Anderson et al., 1991, Schwartz, 1990), but the main leukocyte subset present in most semen samples are neutrophils, which are not a normal feature of the tissues of the genital tract (Aitken and Baker, 1995, el-Demiry et al., 1986, Wolff and Anderson, 1988). The impact of these cells on fertility is also poorly understood. Some studies have shown a relationship between leukocytospermia and impaired sperm function (Auroux, 1984, Aziz et al., 2004, Berger et al., 1982, Wolff et al., 1990), and some data suggest that these cells might be a cause of sperm damage due to production of ROS and cytokines (Hill et al., 1987, Tomlinson et al., 1992a). Moreover, leukocytes may attack the sperm directly, particularly in the presence of sperm autoantibodies, and may provoke or mediate hostile responses in the female tract. Other studies, however, have failed to confirm a clear link between seminal leukocytes and infertility or sperm antibody formation (Aitken et al., 1995, Barratt et al., 1990, Tomlinson et al., 1993), and it has even been suggested that leukocytes might play a beneficial role by removing abnormal sperm or by assisting in sperm capacitation (Tomlinson et al., 1992b, Tomlinson et al., 1993).

Molecules with immunomodulatory properties in seminal plasma include immunoglobulins, cytokines, and immunosuppressives. Both IgG and IgA are the major constituents of seminal plasma, and there appears to be a negative correlation between IgA concentrations and lymphosuppressive activity in seminal plasma (Eggert-Kruse et al., 1996, Imade et al., 1997, Moldoveanu et al., 2005). These antibodies may play either protective roles in the control of immunity and infection, or destructive roles, when directed against functional elements of the sperm. Proinflammatory cytokines such as IL1α, IL2, IL6, IL8, IL12, IL17, TNFα, and IFNγ are found in all seminal plasma samples, even those from men with apparently normal fertility (Eggert-Kruse et al., 2001, Huleihel et al., 1999, Koumantakis et al., 1998, Maegawa et al., 2002, Naz and Evans, 1998, Politch et al., 2007). This is not particularly surprising, as these cytokines are present in most biological fluids and are modulated by the general health status of the individual. Soluble IL2 and IL6 receptors, molecules that modulate the activity of their respective cytokines, have also been found in seminal plasma (Huleihel et al. 1999). Numerous studies have shown that proinflammatory cytokines are dramatically elevated in patients with inflammation and/or leukocytospermia (Eggert-Kruse et al., 2001, Krause et al., 2003, Maegawa et al., 2002, Miller et al., 2002, Rajasekaran et al., 1996). However, specific positive and negative associations with other forms of infertility have also been reported (Eggert-Kruse et al., 2001, Gruschwitz et al., 1996, Huleihel et al., 1999, Loras et al., 1999, Naz and Evans, 1998).

Seminal plasma has profoundly immunosuppressive properties, as defined by the ability to inhibit various T cell and NK cell activities in vitro. This inhibitory activity has been attributed to a number of seminal factors, including prostasomes (Kelly et al. 1991), oxidized polyamines (Allen and Roberts 1986), prostaglandins of the E series (Skibinski et al. 1992), nonspecific lymphocyte-suppressing proteins (Maccioni et al., 2001, Veselský et al., 2002), and immunoregulatory cytokines (Anderson et al., 1998, Huleihel et al., 1999, Loras et al., 1999, Miller et al., 2002, Nocera and Chu, 1993, Rajasekaran et al., 1996, Srivastava et al., 1996). The main cytokines with immunosuppressive activity in human seminal plasma are TGFβ1, TGFβ2, IL10, and activin A. Immunosuppressives are believed to play a role in preventing lymphocyte responses against sperm autoantigens in the male and female reproductive tracts (Robertson et al., 2003, Ochsenkühn et al., 2006).

General and Toxicological Issues

In the current state of understanding of the interactions between the male reproductive tract and the immune system, many questions still remain. Nonetheless, it is clear that the mammalian testis in particular displays a special, if not unique, relationship with the immune system, involving distinctive cell–cell interactions and shared cytokines. Recently, microarray analysis of testicular gene expression signatures in human spermatogenic failure were found to correspond with gene sets usually associated with inflammation and autoimmune disease (Spiess et al. 2007). This relationship between reproduction and immunology impacts upon normal function, since perturbations in one system caused by toxicants will almost certainly impinge upon the other system. This extends into the characteristic responses of the testis to toxins and various pathologies (Figure 5). The complexity and potential consequences of these interactions may be appreciated by consideration of the following propositions:

If leukocytes play a role in maintaining normal testicular function, then drugs and toxicants that reduce macrophage and lymphocyte function or numbers may also have an indirect effect on testicular function. The effect of dichloromethylene diphosphonate on macrophages in the rat provides a good experimental example of this possibility, by demonstrating that the loss of functioning macrophages leads to a decline in androgen levels and retarded Leydig cell development (Bergh et al., 1993, Gaytan et al., 1994a). Inhibition of macrophage and lymphocyte functions or numbers may also compromise the immune-privileged status of the testis, potentially leading to testicular autoimmune disease. A related subset would involve chemicals that have direct action on both the immune system and testicular function, such as cyclosporin and cyclophosphamide (Cavallini et al., 1990, Meistrich, 1984, Seethalakshmi et al., 1990, Wetzels, 2004), which are commonly used to suppress graft rejection response and in the treatment of some autoimmune diseases.

Drugs or toxicants that induce inflammation may interfere with normal testicular function. The serious consequences for testicular function associated with immune activation and inflammation are illustrated by the experimental model of LPS administration, which leads to Leydig cell dysfunction and testicular failure (Christeff et al., 1987, Wallgren et al., 1993, O’Bryan et al., 2000b). Any drug or toxicant that induces macrophage activation (e.g., bacterial toxins, carbon monoxide, sulfur dioxide) has the potential to induce testicular production of inflammatory cytokines, such as IL1β, TNFα, and IFNγ, as well as ROS, which may interfere with Leydig cell function and spermatogenic development, or local immunoregulation. The danger hypothesis model of autoimmune disease may be particularly relevant in this instance (Matzinger 1994). At least one of the putative ‘danger’ molecules (i.e., TNFα) is endogenously produced in the testis, potentially presenting a continuous challenge to the testicular immune system.

Drugs or toxicants that induce autoimmune disease or allergy may also induce testicular autoimmune disease. There are many drugs that induce polysystemic autoimmune disease and this may also include reactions against the germ cells. An example here is polyarteritis nodosa, a necrotizing vasculitis of small arteries, which frequently involves the testis (Fauci et al. 1978). Sulfonamides, penicillin, phenytoin, arsenicals, thiouracil, iodides, and thiazides are frequently suspected as causes of this condition (Nusinow et al. 1985). Likewise, mutagens and other toxins that may alter T and B cell receptor repertoires to create self-reactive lymphocytes could also contribute to the onset of autoimmune disease in the male reproductive tract.

Drugs or toxicants that affect testicular cell development or viability may also induce immune responses. There are drugs or toxicants that affect Sertoli–Sertoli and Sertoli–germ cell junction stability, as well as agents that damage the Sertoli cell or germ cells directly, resulting in massive germ cell death, which may overwhelm the normal immunoregulatory capacity of the testis. Examples of this interaction are seen after testicular heating, serotonin administration, or treatment with ethane dimethane sulfonate (EDS) or other testicular toxicants, which are frequently followed by transient immune and/or inflammatory events (Creasy et al., 1983, Hedger et al., 1995, Padmanabhan and Singh, 1981, Wang et al., 1994). Even if the epithelium recovers fully, there is the potential for sperm antibody development, leading to reduced fertility. Increased exposure to estrogenic compounds is associated with activation of immune cells in the testis, most notably the macrophages, providing evidence for a mechanism whereby environmental estrogens may affect male fertility indirectly via effects on local immunity (Li et al. 2006b).

Testicular toxicants that alter steroidogenic cell function will have a direct effect on the immune system. Toxicants that damage Leydig cells and reduce steroid production possibly could alter thymus function, leading to an enhanced susceptibility to autoimmune disease. Balanced against this is the likelihood that other androgen-deficiency symptoms are far more likely to be manifest and treated. All these interactions, however, illustrate to one degree or another the difficulty of separating direct effects of toxic agents on the immune cells and on the testis.

Model of toxicant actions and potential immunological consequences in the testis. Toxicants may damage or alter the function of somatic cells (in particular the Sertoli and Leydig cells), immune cells, or germ cells, thereby inhibiting androgen production and spermatogenesis, leading to increased germ cell death. This damage may lead to an overt inflammatory event (orchitis) through activation of the proinflammatory activities of local macrophages, which may exacerbate or prolong the testicular dysfunction. These events may be followed by a full or partial recovery of normal function, but intratesticular immune cell numbers and activity may become permanently altered, with possible implications for future toxic or inflammatory episodes. In certain circumstances, which may depend upon the severity of the initial damage caused or the genetic background of the patient, the antigen-presenting activity of intratesticular dendritic cells or macrophages may also be activated. This may lead to recruitment and activation of testicular antigen-specific T cells, development of cytotoxic T cells (CTL), and B cell antibody (Ig) production. This subsequent autoimmunity may have a more permanent effect on testis or sperm function (epithelial destruction or sperm antibody formation).

Conclusions

There is a dynamic relationship between the male reproductive tract and the immune system that should be considered when assessing the effects of various toxicants on male fertility and reproductive development. The effects of toxicants on male reproductive functions, most notably the production of androgenic steroids, will in turn impinge upon the functions of the immune system. Many mechanisms underlying these interactions have begun to emerge in recent years, but a complete picture remains hidden. Further studies will no doubt lead to important new concepts concerning this relationship and its implications for reproductive toxicology.

This work was supported by a fellowship from the National Health and Medical Research Council (NHMRC Grant 436601), an NHMRC Program Grant (143786), and a Discovery Grant (DP0664729) from the Australian Research Council.

References Abbatiello E.R. Kaminsky M. Weisbroth S. Int. J. Fertil. 20 1975 177 182 4399 Adamopoulos D.A. Lawrence D.M. Vassilopoulos P. Contoyiannis P.A. Swyer G.I. Br. Med. J. 1 1978 1177 1180 346165 Ahmad S. Choudhry M.A. Shankar R. Sayeed M.M. FEBS Lett. 402 1997 213 218 9037198 Aitken H. Kumarakuru S. Orr R. Reid O. Bennett N.K. McDonald S.W. Clin. Anat. 12 1999 250 263 10398384 Aitken R.J. Baker H.W. Hum. Reprod. 10 1995 1736 1739 8582971 Aitken R.J. Buckingham D.W. Brindle J. Gomez E. Baker H.W. Irvine D.S. Hum. Reprod. 10 1995 2061 2071 8567843 Akira S. Takeda K. Nat. Rev. Immunol. 4 2004 499 511 15229469 Alderton W.K. Cooper C.E. Knowles R.G. Biochem. J. 357 2001 593 615 11463332 Alexander N.J. Anderson D.J. Fertil. Steril. 32 1979 253 260 114428 Allen R.D. Roberts T.K. Am. J. Reprod. Immunol. Microbiol. 11 1986 59 64 3740349 Allison J. Georgiou H.M. Strasser A. Vaux D.L. Proc. Natl. Acad. Sci. USA 94 1997 3943 3947 9108084 Anderson D.J. Politch J.A. Martinez A. Van Voorhis B.J. Padian N.S. O’Brien T.R. Lancet 338 1991 573 574 Anderson R.A. Evans L.W. Irvine D.S. McIntyre M.A. Groome N.P. Riley S.C. Hum. Reprod. 13 1998 3319 3325 9886507 Anton F. Morales C. Aguilar R. Bellido C. Aguilar E. Gaytan F. Zentralbl. Veterinarmed. A 45 1998 209 218 9697421 Aoki J. Taira A. Takanezawa Y. Kishi Y. Hama K. Kishimoto T. Mizuno K. Saku K. Taguchi R. Arai H. J. Biol. Chem. 277 2002 48737 48744 12354767 Arend W.P. J. Clin. Invest. 88 1991 1445 1451 1834696 Ascher N.L. Hoffman R. Hanto D.W. Simmons R.L. Transplantation 35 1983 193 197 6340271 Ashcroft G.S. Microbes Infect. 1 1999 1275 1282 10611755 Aubry F. Habasque C. Satie A.P. Jégou B. Samson M. Biol. Reprod. 62 2000 1427 1435 10775197 Auphan N. DiDonato J.A. Rosette C. Helmberg A. Karin M. Science 270 1995 286 290 7569976 Auroux M. Arch. Androl. 12 1984 197 201 6508427 Avallet O. Vigier M. Leduque P. Dubois P.M. Saez J.M. Endocrinology 134 1994 2079 2087 8156908 Aziz N. Agarwal A. Lewis-Jones I. Sharma R.K. Thomas A.J. Jr. Fertil. Steril. 82 2004 621 627 15374705 Bainbridge D.R. Ellis S.A. Sargent I.L. J. Reprod. Immunol. 48 2000 17 26 10996380 Baker H.W. Endocrinol. Metab. Clin. North Am. 27 1998 831 850 9922910 Baker H.W. Clarke G.N. Hudson B. McBain J.C. McGowan M.P. Pepperell R.J. Clin. Reprod. Fertil. 2 1983 55 71 6640475 Baker P.J. O’Shaughnessy P.J. Reproduction 122 2001 553 559 11570962 Balaji T. Ramanathan M. Padmanabhan Menon V. Prostaglandins Leukot. Essent. Fatty Acids 76 2007 341 348 17624748 Bambino T.H. Hsueh A.J. Endocrinology 108 1981 2142 2148 6262050 Barakat B. O’Connor A.E. Gold E. de Kretser D.M. Loveland K.L. Reproduction 136 2008 345 359 18515316 Barker C.F. Billingham R.E. Adv. Immunol. 25 1977 1 54 345773 Barrat F.J. Meeker T. Gregorio J. Chan J.H. Uematsu S. Akira S. Chang B. Duramad O. Coffman R.L. J. Exp. Med. 202 2005 1131 1139 16230478 Barratt C.L. Cohen J. J. Reprod. Fertil. 81 1987 377 384 3430459 Barratt C.L. Harrison P.E. Robinson A. Cooke I.D. Int. J. Androl. 13 1990 50 58 2138139 Barratt C.L. Harrison P.E. Robinson A. Kessopoulou E. Cooke I.D. Br. J. Urol. 68 1991 531 536 1747731 Bart J. Groen H.J. van der Graaf W.T. Hollema H. Hendrikse N.H. Vaalburg W. Sleijfer D.T. de Vries E.G. Lancet Oncol. 3 2002 357 363 12107023 Bart J. Hollema H. Groen H.J. de Vries E.G. Hendrikse N.H. Sleijfer D.T. Wegman T.D. Vaalburg W. van der Graaf W.T. Eur. J. Cancer 40 2004 2064 2070 15341980 Basak S. Hoffmann A. Cytokine Growth Factor Rev. 19 2008 187 197 18515173 Beagley K.W. Wu Z.L. Pomering M. Jones R.C. J. Reprod. Fertil. Suppl. 53 1998 235 245 10645283 Becker C.E. O’Neill L.A. Semin. Immunopathol. 29 2007 239 248 17805544 Bellgrau D. Gold D. Selawry H. Moore J. Franzusoff A. Duke R.C. Nature 377 1995 630 632 7566174 Ben K. Alexander N.J. Huso N. Am. J. Reprod. Immunol. Microbiol. 12 1986 33 37 3491547 Benten W.P. Guo Z. Krucken J. Wunderlich F. Steroids 69 2004 585 590 15288774 Berger R.E. Karp L.E. Williamson R.A. Koehler J. Moore D.E. Holmes K.K. Fertil. Steril. 37 1982 557 564 6896033 Bergh A. Damber J.E. Hjertkvist M. Int. J. Androl. 19 1996 229 236 8940661 Bergh A. Damber J.E. van Rooijen N. J. Endocrinol. 136 1993 407 413 8473830 Bergh A. Söder O. J. Reprod. Immunol. 17 1990 155 165 2338674 Bergh A. Widmark A. Damber J.E. Cajander S. Endocrinology 119 1986 586 590 3732138 Bhushan S. Tchatalbachev S. Klug J. Fijak M. Pineau C. Chakraborty T. Meinhardt A. J. Immunol. 180 2008 5537 5547 18390738 Bianchi M.E. J. Leuk. Biol. 81 2007 1 5 Bigazzi P.E. Kosuda L.L. Hsu K.C. Andres G.A. J. Exp. Med. 143 1976 382 404 129498 Biswas N.M. Sanyal S. Patra P.B. Andrologia 10 1978 137 141 646143 Black R.A. Kronheim S.R. Cantrell M. Deeley M.C. March C.J. Prickett K.S. Wignall J. Conlon P.J. Cosman D. Hopp T.P. J. Biol. Chem. 263 1988 9437 9442 3288634 Bogdan C. Nat. Immunol. 2 2001 907 916 11577346 Boockfor F.R. Schwarz L.K. Endocrinology 129 1991 256 262 1905226 Boockfor F.R. Wang D. Lin T. Nagpal M.L. Spangelo B.L. Endocrinology 134 1994 2150 2155 8156916 Bora N.S. Gobleman C.L. Atkinson J.P. Pepose J.S. Kaplan H.J. Invest. Ophthalmol. Vis. Sci. 34 1993 3579 3584 7505007 Born W. Wekerle H. Am. J. Reprod. Immunol. 2 1982 291 295 6984293 Bos C.L. Richel D.J. Ritsema T. Peppelenbosch M.P. Versteeg H.H. Int. J. Biochem. Cell Biol. 36 2004 1187 1205 15109566 Brack A. Rittner H.L. Younge B.R. Kaltschmidt C. Weyand C.M. Goronzy J.J. J. Clin. Invest. 99 1997 2842 2850 9185506 Bradley J.R. J. Pathol. 214 2008 149 160 18161752 Brændstrup O. Bols B. Jensen L. APMIS 107 1999 431 436 10230699 Braun A.M. Thomas P. Biol. Reprod. 71 2004 146 155 14985249 Breitbart H. Shalev Y. Marcus S. Shemesh M. Hum. Reprod. 10 1995 2079 2084 8567845 Brosh N. Sternberg D. Honigwachs-Sha’anani J. Lee B.C. Shav-Tal Y. Tzehoval E. Shulman L.M. Toledo J. Hacham Y. Carmi P. J. Biol. Chem. 270 1995 29594 29600 7494003 Brown C.W. Houston-Hawkins D.E. Woodruff T.K. Matzuk M.M. Nat. Genet. 25 2000 453 457 10932194 Bryniarski K. Szczepanik M. Maresz K. Ptak M. Ptak W. Am. J. Reprod. Immunol. 52 2004 27 35 15214939 Bryniarski K. Szczepanik M. Ptak M. Ptak W. J. Immunol. Methods 301 2005 186 189 15982664 Buckingham J.C. Loxley H.D. Christian H.C. Philip J.G. Pharmacol. Biochem. Behav. 54 1996 285 298 8728570 Bulla R. Bossi F. Fischetti F. De Seta F. Tedesco F. Chem. Immunol. Allergy 89 2005 149 157 16129961 Burrows P.D. Suematsu S. Watanabe T. Rev. Immunogenet. 2 2000 38 51 11324692 Buzzard J.J. Farnworth P.G. de Kretser D.M. O’Connor A.E. Wreford N.G. Morrison J.R. Endocrinology 144 2003 474 483 12538607 Buzzard J.J. Loveland K.L. O’Bryan M.K. O’Connor A.E. Bakker M. Hayashi T. Wreford N.G. Morrison J.R. de Kretser D.M. Endocrinology 145 2004 3532 3541 15070852 Cameron D.F. Whittington K. Schultz R.E. Selawry H.P. Transplantation 50 1990 649 653 2171164 Cameron V.A. Nishimura E. Mathews L.S. Lewis K.A. Sawchenko P.E. Vale W.W. Endocrinology 134 1994 799 808 8299574 Cárcamo J. Weis F.M. Ventura F. Wieser R. Wrana J.L. Attisano L. Massagué J. Mol. Cell. Biol. 14 1994 3810 3821 8196624 Carlsen E. Andersson A.M. Petersen J.H. Skakkebaek N.E. Hum. Reprod. 18 2003 2089 2092 14507826 Caussanel V. Tabone E. Hendrick J.C. Dacheux F. Benahmed M. Biol. Reprod. 56 1997 357 367 9116134 Cavallini L. Malendowicz L.K. Mazzocchi G. Belloni A.S. Nussdorfer G.G. Virchows Arch. B Cell Pathol. Mol. Pathol. 58 1990 215 220 Celik-Ozenci C. Sahin Z. Ustunel I. Akkoyunlu G. Erdogru T. Korgun E.T. Baykara M. Demir R. Fertil. Steril. 85 Suppl 1 2006 1168 1178 16616089 Chang H. Lau A.L. Matzuk M.M. Mol. Cell. Endocrinol. 180 2001 39 46 11451570 Chen J.J. Sun Y. Nabel G.J. Science 282 1998 1714 1717 9831564 Cheng C.Y. Mruk D.D. Physiol. Rev. 82 2002 825 874 12270945 Christeff N. Auclair M.C. Benassayag C. Carli A. Nunez E.A. J. Steroid Biochem. 26 1987 67 71 3546947 Chung J.Y. Park Y.C. Ye H. Wu H. J. Cell Sci. 115 2002 679 688 11865024 Clermont Y. Physiol. Rev. 52 1972 198 236 4621362 Clifton V.L. Husband A.J. Kay D.J. Immunol. Cell Biol. 70 1992 301 307 1478695 Cohen P.E. Hardy M.P. Pollard J.W. Mol. Endocrinol. 11 1997 1636 1650 9328346 Com E. Bourgeon F. Evrard B. Ganz T. Colleu D. Jégou B. Pineau C. Biol. Reprod. 68 2003 95 104 12493700 Constant S.L. Bottomly K. Annu. Rev. Immunol. 15 1997 297 322 9143690 Cooke B.A. Dirami G. Chaudry L. Choi M.S. Abayasekara D.R. Phipp L. J. Steroid Biochem. Mol. Biol. 40 1991 465 471 1659882 Cooper I. Kelly R.W. Prostaglandins 10 1975 507 514 1197784 Corrigan A.Z. Bilezikjian L.M. Carroll R.S. Bald L.N. Schmelzer C.H. Fendly B.M. Mason A.J. Chin W.W. Schwall R.H. Vale W. Endocrinology 128 1991 1682 1684 1900235 Cousins S.W. McCabe M.M. Danielpour D. Streilein J.W. Invest. Ophthalmol. Vis. Sci. 32 1991 2201 2211 2071334 Creasy D.M. Foster J.R. Foster P.M. J. Pathol. 139 1983 309 321 6834175 Cresswell P. Bangia N. Dick T. Diedrich G. Immunol. Rev. 172 1999 21 28 10631934 Croset M. Brossard N. Polette A. Lagarde M. Biochem. J. 345 2000 61 67 10600639 Cudicini C. Kercret H. Touzalin A.M. Ballet F. Jégou B. Endocrinology 138 1997 2863 2870 9202229 Cudicini C. Lejeune H. Gomez E. Bosmans E. Ballet F. Saez J. Jégou B. J. Clin. Endocrinol. Metab. 82 1997 1426 1433 9141528 Cupp A.S. Kim G. Skinner M.K. Biol. Reprod. 60 1999 1304 1313 10330085 Cutolo M. Sulli A. Capellino S. Villaggio B. Montagna P. Seriolo B. Straub R.H. Lupus 13 2004 635 638 15485092 Czerkinsky C. Anjuere F. McGhee J.R. George-Chandy A. Holmgren J. Kieny M.P. Fujiyashi K. Mestecky J.F. Pierrefite-Carle V. Rask C. Immunol. Rev. 170 1999 197 222 10566152 D’Abrizio P. Baldini E. Russo P.F. Biordi L. Graziano F.M. Rucci N. Properzi G. Francavilla S. Ulisse S. Int. J. Androl. 27 2004 304 310 15379972 D’Alessio A. Riccioli A. Lauretti P. Padula F. Muciaccia B. De Cesaris P. Filippini A. Nagata S. Ziparo E. Proc. Natl. Acad. Sci. USA 98 2001 3316 3321 11248076 Dal Secco V. Riccioli A. Padula F. Ziparo E. Filippini A. Biol. Reprod. 78 2008 234 242 17989360 Datto M.B. Frederick J.P. Pan L. Borton A.J. Zhuang Y. Wang X.F. Mol. Cell. Biol. 19 1999 2495 2504 10082515 de Caestecker M.P. Parks W.T. Frank C.J. Castagnino P. Bottaro D.P. Roberts A.B. Lechleider R.J. Genes Dev. 12 1998 1587 1592 9620846 De Cesaris P. Filippini A. Cervelli C. Riccioli A. Muci S. Starace G. Stefanini M. Ziparo E. Biochem. Biophys. Res. Commun. 186 1992 1639 1646 1510687 De Cesaris P. Starace D. Riccioli A. Padula F. Filippini A. Ziparo E. J. Biol. Chem. 273 1998 7566 7571 9516459 De Cesaris P. Starace D. Starace G. Filippini A. Stefanini M. Ziparo E. J. Biol. Chem. 274 1999 28978 28982 10506145 de Kretser D.M. Buzzard J.J. Okuma Y. O’Connor A.E. Hayashi T. Lin S.Y. Morrison J.R. Loveland K.L. Hedger M.P. Mol. Cell. Endocrinol. 225 2004 57 64 15451568 de Kretser D.M. Hedger M.P. Loveland K.L. Phillips D.J. Hum. Reprod. Update 8 2002 529 541 12498423 de Kretser D.M. Huidobro C. Southwick G.J. Temple-Smith P.D. J. Reprod. Fertil. Suppl. 53 1998 271 275 10645286 de Miguel M.P. de Boer-Brouwer M. de Rooij D.G. Paniagua R. van Dissel-Emiliani F.M. Cell Growth Differ. 8 1997 611 618 9149912 de Miguel M.P. de Boer-Brouwer M. Paniagua R. van den Hurk R. de Rooij D.G. van Dissel-Emiliani F.M. Endocrinology 137 1996 1885 1893 8612528 De S.K. Chen H.L. Pace J.L. Hunt J.S. Terranova P.F. Enders G.C. Endocrinology 133 1993 389 396 8319585 de Winter J.P. Themmen A.P. Hoogerbrugge J.W. Klaij I.A. Grootegoed J.A. de Jong F.H. Mol. Cell. Endocrinol. 83 1992 R1 R8 1312957 DeFranco A.L. Annu. Rev. Cell Biol. 3 1987 143 178 2961351 Dejucq N. Dugast I. Ruffault A. van der Meide P.H. Jegou B. Endocrinology 136 1995 4925 4931 7588226 Dejucq N. Lienard M.O. Guillaume E. Dorval I. Jégou B. Endocrinology 139 1998 3081 3087 9645679 Dejucq N. Liénard M.O. Jégou B. J. Reprod. Immunol. 41 1998 291 300 10213317 Del Punta K. Charreau E.H. Pignataro O.P. Endocrinology 137 1996 5337 5343 8940355 Delfino F. Walker W.H. Mol. Endocrinol. 12 1998 1696 1707 9817596 Delfino F.J. Boustead J.N. Fix C. Walker W.H. Mol. Cell. Endocrinol. 201 2003 1 12 12706288 Dias V. Meachem S. Rajpert-De Meyts E. McLachlan R. Manuelpillai U. Loveland K.L. Hum. Reprod. 23 2008 412 420 18077314 Dickson C. Webster D.R. Johnson H. Cecilia Millena A. Khan S.A. Mol. Cell. Endocrinol. 195 2002 65 77 12354673 Dinarello C.A. Blood 87 1996 2095 2147 8630372 Ditzian-Kadanoff R. Scand. J. Immunol. 50 1999 150 158 10447919 Dobrinski I. Anim. Reprod. Sci. 89 2005 137 145 16055282 Du X. Everett E.T. Wang G. Lee W.H. Yang Z. Williams D.A. J. Cell. Physiol. 168 1996 362 372 8707872 Duckett R.J. Hedger M.P. McLachlan R.I. Wreford N.G. J. Androl. 18 1997 417 423 9283955 Duckett R.J. Wreford N.G. Meachem S.J. McLachlan R.I. Hedger M.P. J. Androl. 18 1997 656 662 9432138 Dunn E. Sims J.E. Nicklin M.J. O’Neill L.A. Trends Immunol. 22 2001 533 536 11574261 Dutton R.W. Bradley L.M. Swain S.L. Annu. Rev. Immunol. 16 1998 201 223 9597129 Dym M. Fawcett D.W. Biol. Reprod. 3 1970 308 326 4108372 Dym M. Romrell L.J. J. Reprod. Fertil. 42 1975 1 7 45940 Ebner R. Chen R.H. Shum L. Lawler S. Zioncheck T.F. Lee A. Lopez A.R. Derynck R. Science 260 1993 1344 1348 8388127 Eggert-Kruse W. Boit R. Rohr G. Aufenanger J. Hund M. Strowitzki T. Hum. Reprod. 16 2001 517 528 11228223 Eggert-Kruse W. Probst S. Rohr G. Tilgen W. Runnebaum B. Fertil. Steril. 65 1996 1202 1209 8641498 Eisenhauer K.M. McCue P.M. Nayden D.K. Osawa Y. Roser J.F. Domest. Anim. Endocrinol. 11 1994 291 298 7956176 Ekwere P.D. Br. J. Urol. 76 1995 366 370 7551848 el-Demiry M.I. Hargreave T.B. Busuttil A. James K. Chisholm G.D. Urology 28 1986 492 496 3538613 Demiry M.I. Hargreave T.B. Busuttil A. James K. Ritchie A.W. Chisholm G.D. Br. J. Urol. 57 1985 769 774 3910154 Erämaa M. Hurme M. Stenman U.H. Ritvos O. J. Exp. Med. 176 1992 1449 1452 1402687 Ethier J.F. Findlay J.K. Reproduction 121 2001 667 675 11427154 Fabriek B.O. Dijkstra C.D. van den Berg T.K. Immunobiology 210 2005 153 160 16164022 Fauci A.S. Haynes B. Katz P. Ann. Int. Med. 89 1978 660 676 31121 Fawcett D.W. Neaves W.B. Flores M.N. Biol. Reprod. 9 1973 500 532 4203289 Feng Z.M. Madigan M.B. Chen C.L. Endocrinology 132 1993 2593 2600 7916681 Fijak M. Iosub R. Schneider E. Linder M. Respondek K. Klug J. Meinhardt A. J. Pathol. 207 2005 127 138 16092147 Fiszer D. Ulbrecht M. Fernandez N. Johnson J.P. Weiss E.H. Kurpisz M. Eur. J. Immunol. 27 1997 1691 1695 9247579 Flemming P.K. Dedman A.M. Xu S.Z. Li J. Zeng F. Naylor J. Benham C.D. Bateson A.N. Muraki K. Beech D.J. J. Biol. Chem. 281 2006 4977 4982 16368680 Flickinger C.J. Herr J.C. Caloras D. Sisak J.R. Howards S.S. Biol. Reprod. 43 1990 34 45 2393691 Flickinger C.J. Herr J.C. Howards S.S. Sisak J.R. Gleavy J.M. Fusia T.J. Vailes L.D. Handley H.H. Anat. Rec. 227 1990 37 46 2368925 Forman H.J. Torres M. Am. J. Resp. Crit. Care Med. 166 2002 S4 S8 12471082 Foulds L.M. Boysen R.I. Crane M. Yang Y. Muir J.A. Smith A.I. de Kretser D.M. Hearn M.T. Hedger M.P. Biol. Reprod. 79 2008 525 536 18509166 Fournel S. Aguerre-Girr M. Huc X. Lenfant F. Alam A. Toubert A. Bensussan A. Le Bouteiller P. J. Immunol. 164 2000 6100 6104 10843658 Frungieri M.B. Calandra R.S. Lustig L. Meineke V. Kohn F.M. Vogt H.J. Mayerhofer A. Fertil. Steril. 78 2002 298 306 12137866 Frungieri M.B. Gonzalez-Calvar S.I. Parborell F. Albrecht M. Mayerhofer A. Calandra R.S. Endocrinology 147 2006 4476 4485 16740978 Fujisawa M. Okuda Y. Fujioka H. Kamidono S. Endocrine Res. 28 2002 1 8 12108784 Furbeth C. Hubner G. Thoenes G.H. Virchows Arch. B Cell Pathol. 57 1989 37 45 Galli S.J. Nakae S. Tsai M. Nat. Immunol. 6 2005 135 142 15662442 Gallucci S. Matzinger P. Curr. Opin. Immunol. 13 2001 114 119 11154927 Garrido F. Ruiz-Cabello F. Cabrera T. Pérez-Villar J.J. López-Botet M. Duggan-Keen M. Stern P.L. Immunol. Today 18 1997 89 95 9057360 Gautier C. Levacher C. Avallet O. Vigier M. Rouiller-Fabre V. Lecerf L. Saez J. Habert R. Mol. Cell. Endocrinol. 99 1994 55 61 8187961 Gaytan F. Bellido C. Aceitero J. Aguilar E. Sanchez-Criado J.E. Biol. Reprod. 43 1990 665 671 1963094 Gaytan F. Bellido C. Aguilar E. van Rooijen N. J. Reprod. Fertil. 102 1994 393 399 7861393 Gaytan F. Bellido C. Morales C. Reymundo C. Aguilar E. van Rooijen N. J. Reprod. Fertil. 101 1994 175 182 8064678 Gaytan F. Bellido C. Romero J.L. Morales C. Reymundo C. Aguilar E. J. Endocrinol. 140 1994 399 407 8182367 Gaytan F. Carrera G. Pinilla L. Aguilar R. Bellido C. J. Androl. 10 1989 351 358 2592265 Georgiou M. Perkins L.M. Payne A.H. Endocrinology 121 1987 1390 1399 2820696 Gérard N. Syed V. Bardin W. Genetet N. Jégou B. Mol. Cell. Endocrinol. 82 1991 R13 R16 1761160 Gérard N. Syed V. Jégou B. Biochem. Biophys. Res. Commun. 185 1992 154 161 1599451 Gerdprasert O. O’Bryan M.K. Muir J.A. Caldwell A.M. Schlatt S. de Kretser D.M. Hedger M.P. Cell Tissue Res. 308 2002 277 285 12037584 Gerdprasert O. O’Bryan M.K. Nikolic-Paterson D.J. Sebire K. de Kretser D.M. Hedger M.P. Mol. Hum. Reprod. 8 2002 518 524 12029068 Gerena R.L. Eguchi N. Urade Y. Killian G.J. J. Androl. 21 2000 848 854 11105911 Gilliet M. Liu Y.J. J. Exp. Med. 195 2002 695 704 11901196 Goddard I. Bouras M. Keramidas M. Hendrick J.C. Feige J.J. Benahmed M. Endocrinology 141 2000 2068 2074 10830292 Godfrey D.I. Hammond K.J. Poulton L.D. Smyth M.J. Baxter A.G. Immunol. Today 21 2000 573 583 11094262 Gomez E. Morel G. Cavalier A. Lienard M.O. Haour F. Courtens J.L. Jégou B. Biol. Reprod. 56 1997 1513 1526 9166705 Gould D.S. Auchincloss H. Jr. Immunol. Today 20 1999 77 82 10098326 Gracie J.A. Robertson S.E. McInnes I.B. J. Leuk. Biol. 73 2003 213 224 Gribi R. Tanaka T. Harper-Summers R. Yu J. Mol. Cell. Endocrinol. 180 2001 163 167 11451587 Griffith T.S. Yu X. Herndon J.M. Green D.R. Ferguson T.A. Immunity 5 1996 7 16 8758890 Griswold M.D. Int. Rev. Cytol. 110 1988 133 156 3053498 Groisman G.M. Amar M. Schafer I. Appl. Immunohistochem. Mol. Morph. 10 2002 205 209 Grossman C.J. Nathan P. Taylor B.B. Sholiton L.J. Steroids 34 1979 539 553 516117 Gruber S.A. Transplantation 54 1992 1 11 1631917 Gruschwitz M.S. Brezinschek R. Brezinschek H.P. J. Androl. 17 1996 158 163 8723440 Haas G.G. Jr. D’Cruz O.J. De Bault L.E. Am. J. Reprod. Immunol. Microbiol. 18 1988 47 51 2467568 Hakovirta H. Kaipia A. Söder O. Parvinen M. Endocrinology 133 1993 1664 1668 8404607 Hakovirta H. Pentitilä T.L. Pöllänen P. Fröysa B. Söder O. Parvinen M. Int. J. Androl. 16 1993 159 164 8514429 Hakovirta H. Syed V. Jégou B. Parvinen M. Mol. Cell. Endocrinol. 108 1995 193 198 7758835 Hales D.B. Endocrinology 131 1992 2165 2172 1425417 Hales D.B. Payne A.H. Endocrinology 124 1989 2099 2104 2539967 Haour F. Kouznetzova B. Dray F. Saez J.M. Life Sci. 24 1979 2151 2158 481105 Hardy M.P. Gao H.B. Dong Q. Ge R. Wang Q. Chai W.R. Feng X. Sottas C. Cell Tissue Res. 322 2005 147 153 16079965 Hardy M.P. Zirkin B.R. Ewing L.L. Endocrinology 124 1989 762 770 2912699 Harris C.L. Mizuno M. Morgan B.P. Mol. Immunol. 43 2006 57 67 16023728 Hata K. Zhang X.R. Iwatsuki S. Van Thiel D.H. Herberman R.B. Whiteside T.L. Clin. Immunol. Immunopathol. 56 1990 401 419 1697226 Hayes R. Chalmers S.A. Nikolic-Paterson D.J. Atkins R.C. Hedger M.P. J. Androl. 17 1996 41 49 8833740 Head J.R. Billingham R.E. Transplantation 40 1985 269 275 3898493 Head J.R. Neaves W.B. Billingham R.E. Transplantation 36 1983 423 431 6353710 Head J.R. Neaves W.B. Billingham R.E. Transplantation 35 1983 91 95 6823694 Heath W.R. Carbone F.R. Annu. Rev. Immunol. 19 2001 47 64 11244030 Hedger M.P. Reproductive and Endocrine Toxicology Boekelheide K. Chapin R.E. Hoyer P.B. Harris C. 1997 Elsevier Oxford, UK 203 215 Hedger M.P. J. Reprod. Immunol. 57 2002 19 34 12385831 Hedger M.P. Halberstadt C.R. Emerich D.F. Cellular Transplantation from Laboratory to Clinic 2007 Elsevier Amsterdam, The Netherlands 567 590 Hedger M.P. Drummond A.E. Robertson D.M. Risbridger G.P. de Kretser D.M. Mol. Cell. Endocrinol. 61 1989 133 138 2501119 Hedger M.P. Eddy E.M. Endocrinology 121 1987 1824 1838 2822376 Hedger M.P. Hales D.B. Neill J.D. Knobil and Neill’s Physiology of Reproduction Vol. 1 2006 Elsevier Amsterdam, The Netherlands 1195 1286 Hedger M.P. Khatab S. Gonzales G. de Kretser D.M. Reprod. Fertil. Dev. 7 1995 1101 1109 8848577 Hedger M.P. Meinhardt A. J. Reprod. Immunol. 48 2000 69 80 11011073 Hedger M.P. Nikolic-Paterson D.J. Hutchinson P. Atkins R.C. de Kretser D.M. Biol. Reprod. 58 1998 927 934 9546722 Hedger M.P. Qin J.X. Robertson D.M. de Kretser D.M. Reprod. Fertil. Dev. 2 1990 263 280 2201062 Hedger M.P. Wang J. Lan H.Y. Atkins R.C. Wreford N.G. Biol. Reprod. 58 1998 935 942 9546723 Heinrich P.C. Behrmann I. Haan S. Hermanns H.M. Muller-Newen G. Schaper F. Biochem. J. 374 2003 1 20 12773095 Hellema H.W. Samuel T. Rümke P. Clin. Exp. Immunol. 38 1979 31 36 393440 Helliwell R.J. Adams L.F. Mitchell M.D. Prostaglandins Leukot. Essent. Fatty Acids 70 2004 101 113 14683687 Herlong J.L. Scott T.R. Immunol. Lett. 102 2006 121 131 16310861 Hertzog P.J. O’Neill L.A. Hamilton J.A. Trends Immunol. 24 2003 534 539 14552837 Hill J.A. Haimovici F. Politch J.A. Anderson D.J. Fertil. Steril. 47 1987 460 465 3104098 Hjertkvist M. Läckgren G. Plöen L. Bergh A. J. Pediatr. Surg. 28 1993 254 258 8094747 Hoeben E. Van Damme J. Put W. Swinnen J.V. Verhoeven G. Endocrinology 137 1996 514 521 8593797 Hoeben E. Wuyts A. Proost P. Van Damme J. Verhoeven G. Mol. Cell. Endocrinol. 132 1997 149 160 9324056 Hoek A. Allaerts W. Leenen P.J. Schoemaker J. Drexhage H.A. Eur. J. Endocrinol. 136 1997 8 24 9037117 Hsu H. Shu H.B. Pan M.G. Goeddel D.V. Cell 84 1996 299 308 8565075 Hu J. You S. Li W. Wang D. Nagpal M.L. Mi Y. Liang P. Lin T. Endocrinology 139 1998 3637 3645 9681518 Hudson M.M. Frankel L.S. Mullins J. Swanson D.A. J. Pediatr. 107 1985 50 53 3859628 Huleihel M. Lunenfeld E. Horowitz S. Levy A. Potashnik G. Mazor M. Glezerman M. Andrologia 31 1999 283 288 10526637 Hume D.A. Halpin D. Charlton H. Gordon S. Proc. Natl. Acad. Sci. USA 81 1984 4174 4177 6377311 Hunt J.S. Immunol. Rev. 213 2006 36 47 16972895 Hurtenbach U. Shearer G.M. J. Exp. Med. 155 1982 1719 1729 6978923 Hutson J.C. Cell Tissue Res. 267 1992 385 389 1600565 Imade G.E. Baker H.W. de Kretser D.M. Hedger M.P. Hum. Reprod. 12 1997 256 262 9070706 Isaacs J.D. Semin. Immunol. 2 1990 449 456 2104281 Ishikawa T. Hwang K. Lazzarino D. Morris P.L. Endocrinology 146 2005 5100 5111 16123165 Ishikawa T. Morris P.L. Endocrinology 147 2006 5424 5430 16887914 Ishitani A. Sageshima N. Hatake K. J. Reprod. Immunol. 69 2006 101 113 16487601 Itoh M. De-Rooij D. Takeuchi Y. J. Anat. 187 1995 671 679 8586566 Itoh M. De Rooij D.G. Jansen A. Drexhage H.A. J. Reprod. Immunol. 28 1995 217 232 7473432 Itoh M. Hiramine C. Tokunaga Y. Mukasa A. Hojo K. Autoimmunity 10 1991 89 97 1782329 Itoh M. Li X.Q. Yano A. Xie Q. Takeuchi Y. J. Androl. 19 1998 466 472 9733149 Itoh M. Xie Q. Miyamoto K. Takeuchi Y. Am. J. Reprod. Immunol. 42 1999 321 326 10584988 Itoh M. Yano A. Xie Q. Iwahashi K. Takeuchi Y. Meroni P.L. Nicoletti F. Clin. Exp. Immunol. 111 1998 513 520 9528891 Jalkanen J. Huhtaniemi I. Poutanen M. Biochim. Biophys. Acta 1730 2005 22 30 16023745 Janeway C.A. Jr. Annu. Rev. Immunol. 10 1992 645 674 1534242 Jarow J.P. Hum. Reprod. Update 7 2001 59 64 11212076 Jenab S. Morris P.L. Endocrinology 139 1998 1883 1890 9528974 Jiang C. Ting A.T. Seed B. Nature 391 1998 82 86 9422509 Jones K.L. Mansell A. Patella S. Scott B.J. Hedger M.P. de Kretser D.M. Phillips D.J. Proc. Natl. Acad. Sci. USA 104 2007 16239 16244 17911255 Jonsson C.K. Zetterström R.H. Holst M. Parvinen M. Söder O. Endocrinology 140 1999 3755 3761 10433236 Joyce C.L. Nuzzo N.A. Wilson L. Jr. Zaneveld L.J. J. Androl. 8 1987 74 82 3108222 Ju S.T. Panka D.J. Cui H. Ettinger R. el-Khatib M. Sherr D.H. Stanger B.Z. Marshak-Rothstein A. Nature 373 1995 444 448 7530337 Kabarowski J.H. Xu Y. Witte O.N. Biochem. Pharmacol. 64 2002 161 167 12123735 Kaipia A. Parvinen M. Toppari J. Endocrinology 132 1993 477 479 8380387 Kaipia A. Penttila T.L. Shimasaki S. Ling N. Parvinen M. Toppari J. Endocrinology 131 1992 2703 2710 1332846 Kanai T. Fujii T. Unno N. Yamashita T. Hyodo H. Miki A. Hamai Y. Kozuma S. Taketani Y. Am. J. Reprod. Immunol. 45 2001 94 99 11216880 Kang S.M. Schneider D.B. Lin Z. Hanahan D. Dichek D.A. Stock P.G. Baekkeskov S. Nat. Med. 3 1997 738 743 9212099 Kanzaki M. Morris P.L. Endocrinology 139 1998 2636 2644 9564881 Kapasi K. Albert S.E. Yie S. Zavazava N. Librach C.L. Immunology 101 2000 191 200 11012772 Kapcala L.P. Chautard T. Eskay R.L. Ann. N. Y. Acad. Sci. 771 1995 419 437 8597419 Kaplan H.J. Streilein J.W. J. Immunol. 120 1978 689 693 632581 Kappler J.W. Roehm N. Marrack P. Cell 49 1987 273 280 3494522 Karikó K. Ni H. Capodici J. Lamphier M. Weissman D. J. Biol. Chem. 279 2004 12542 12550 14729660 Kelly R.W. Holland P. Skibinski G. Harrison C. McMillan L. Hargreave T. James K. Clin. Exp. Immunol. 86 1991 550 556 1747961 Kelsall B.L. Rescigno M. Nat. Immunol. 5 2004 1091 1095 15496943 Kern S. Maddocks S. J. Reprod. Immunol. 28 1995 189 201 7473430 Kern S. Robertson S.A. Mau V.J. Maddocks S. Biol. Reprod. 53 1995 1407 1416 8562698 Kerr J.B. Sharpe R.M. Cell Tissue Res. 257 1989 163 169 2752405 Kerr J.B. Sharpe R.M. J. Endocrinol. 121 1989 285 292 2754362 Khan S. Teerds K. Dorrington J. Biol. Reprod. 46 1992 335 341 1617007 Khan S.A. Khan S.J. Dorrington J.H. Endocrinology 131 1992 1853 1857 1396331 Khaselev N. Murphy R.C. J. Am. Soc. Mass Spectrom. 11 2000 283 291 10757164 Kim H.C. Byun J.S. Lee T.K. Jeong C.W. Ahn M. Shin T. Anat. Histol. Embryol. 36 2007 135 138 17371387 Kohno S. Munoz J.A. Williams T.M. Teuscher C. Bernard C.C. Tung K.S. J. Immunol. 130 1983 2675 2682 6682874 Kohno S. Ziparo E. Marek L.F. Tung K.S. J. Reprod. Immunol. 5 1983 339 350 6580444 Kojima A. Spencer C.A. Biol. Reprod. 29 1983 195 205 6615965 Konrad L. Albrecht M. Renneberg H. Aumüller G. Endocrinology 141 2000 3679 3686 11014222 Kopf M. Baumann H. Freer G. Freudenberg M. Lamers M. Kishimoto T. Zinkernagel R. Bluethmann H. Kohler G. Nature 368 1994 339 342 8127368 Koumantakis E. Matalliotakis I. Kyriakou D. Fragouli Y. Relakis K. Andrologia 30 1998 339 343 9835948 Krause W. Bohring C. Gueth A. Horster S. Krisp A. Skrzypek J. Andrologia 35 2003 279 282 14535855 Krieger J.N. Sex. Transm. Dis. 11 1984 173 181 6390741 Kudo I. Murakami M. Prostaglandins Other Lipid Mediat. 68–69 2002 3 58 Kühn R. Lohler J. Rennick D. Rajewsky K. Müller W. Cell 75 1993 263 274 8402911 Kuhnlein P. Park J.H. Herrmann T. Elbe A. Hunig T. J. Immunol. 153 1994 979 986 8027567 Kumar S. McDonnell P.C. Lehr R. Tierney L. Tzimas M.N. Griswold D.E. Capper E.A. Tal-Singer R. Wells G.I. Doyle M.L. J. Biol. Chem. 275 2000 10308 10314 10744718 Langenbach R. Loftin C. Lee C. Tiano H. Biochem. Pharmacol. 58 1999 1237 1246 10487525 Lanier L.L. Nat. Immunol. 2 2001 23 27 11135574 Laouar Y. Sutterwala F.S. Gorelik L. Flavell R.A. Nat. Immunol. 6 2005 600 607 15852008 Lauw F.N. Caffrey D.R. Golenbock D.T. Trends Immunol. 26 2005 509 511 16111920 Lazarus M. Eguchi N. Matsumoto S. Nagata N. Yano T. Killian G.J. Urade Y. Prostaglandins Leukot. Essent. Fatty Acids 71 2004 233 240 15301794 Lazarus M. Munday C.J. Eguchi N. Matsumoto S. Killian G.J. Kubata B.K. Urade Y. Endocrinology 143 2002 2410 2419 12021206 Le Magueresse-Battistoni B. Morera A.M. Goddard I. Benahmed M. Endocrinology 136 1995 2788 2791 7750505 Le Magueresse-Battistoni B. Pernod G. Kolodié L. Morera A.M. Benahmed M. Endocrinology 138 1997 1097 1105 9048615 Lee H.M. Oh B.C. Lim D.P. Lee D.S. Cho J. Lee G. Lee J.R. J. Korean Med. Sci. 22 2007 277 282 17449937 Lee J. Richburg J.H. Younkin S.C. Boekelheide K. Endocrinology 138 1997 2081 2088 9112408 Lee N.P. Cheng C.Y. Endocrinology 144 2003 3114 3129 12810568 Lee N.P. Cheng C.Y. Biol. Reprod. 70 2004 267 276 14522829 Lee N.P. Mruk D.D. Wong C.H. Cheng C.Y. Biol. Reprod. 73 2005 458 471 15858215 Légrádi A. Chitu V. Szukacsov V. Fajka-Boja R. Székely Szücs K. Monostori E. Immunol. Lett. 91 2004 17 21 14757365 Levy B.D. Clish C.B. Schmidt B. Gronert K. Serhan C.N. Nat. Immunol. 2 2001 612 619 11429545 Levy S. Robaire B. Biol. Reprod. 60 1999 1392 1401 10330098 Lewis K.A. Gray P.C. Blount A.L. MacConell L.A. Wiater E. Bilezikjian L.M. Vale W. Nature 404 2000 411 414 10746731 Li H. Ren J. Dhabuwala C.B. Shichi H. Ocul. Immunol. Inflamm. 5 1997 75 84 9234371 Li L. Itoh M. Ablake M. Macri B. Bendtzen K. Nicoletti F. Clin. Immunol. 102 2002 135 137 11846454 Li M.W. Xia W. Mruk D.D. Wang C.Q. Yan H.H. Siu M.K. Lui W.Y. Lee W.M. Cheng C.Y. J. Endocrinol. 190 2006 313 329 16899565 Li P. Chan H.C. He B. So S.C. Chung Y.W. Shang Q. Zhang Y.D. Zhang Y.L. Science 291 2001 1783 1785 11230693 Li X. Strauss L. Kaatrasalo A. Mayerhofer A. Huhtaniemi I. Santti R. Mäkelä S. Poutanen M. Endocrinology 147 2006 1271 1277 16306085 Li X. Youngblood G.L. Payne A.H. Hales D.B. Endocrinology 136 1995 3519 3526 7628389 Licona-Limón P. Soldevila G. Immunol. Lett. 109 2007 1 12 17287030 Lim H. Paria B.C. Das S.K. Dinchuk J.E. Langenbach R. Trzaskos J.M. Dey S.K. Cell 91 1997 197 208 9346237 Lin P. Ye R.D. J. Biol. Chem. 278 2003 14379 14386 12586833 Lin S.J. Lerch T.F. Cook R.W. Jardetzky T.S. Woodruff T.K. Reproduction 132 2006 179 190 16885528 Ling N. Ying S.Y. Ueno N. Shimasaki S. Esch F. Hotta M. Guillemin R. Nature 321 1986 779 782 3086749 Lissbrant E. Löfmark U. Collin O. Bergh A. Biol. Reprod. 56 1997 1221 1227 9160722 Liston A. Lesage S. Wilson J. Peltonen L. Goodnow C.C. Nat. Immunol. 4 2003 350 354 12612579 Lizama C. Alfaro I. Reyes J.G. Moreno R.D. Apoptosis 12 2007 499 512 17195944 Loras B. Vételé F. El Malki A. Rollet J. Soufir J.C. Benahmed M. Hum. Reprod. 14 1999 1534 1539 10357971 Lue Y. Sinha Hikim A.P. Wang C. Leung A. Swerdloff R.S. Endocrinology 144 2003 3092 3100 12810565 Lui W.Y. Lee W.M. Cheng C.Y. Int. J. Androl. 26 2003 147 160 12755993 Lustig L. Lourtau L. Perez R. Doncel G.F. Int. J. Androl. 16 1993 279 284 8262661 Lysiak J.J. Reprod. Biol. Endocrinol. 2 2004 9 15012831 Lysiak J.J. Bang H.J. Nguyen Q.A. Turner T.T. J. Androl. 26 2005 129 135 15611577 Lysiak J.J. Turner S.D. Nguyen Q.A. Singbartl K. Ley K. Turner T.T. Biol. Reprod. 65 2001 718 725 11514333 Maccioni M. Riera C.M. Rivero V.E. J. Reprod. Immunol. 50 2001 133 149 11334995 MacDonald T.T. Curr. Opin. Immunol. 10 1998 620 627 9914215 Maddocks S. Setchell B.P. Immunol. Cell Biol. 66 1988 1 8 3372004 Maegawa M. Kamada M. Irahara M. Yamamoto S. Yoshikawa S. Kasai Y. Ohmoto Y. Gima H. Thaler C.J. Aono T. J. Reprod. Immunol. 54 2002 33 42 11839394 Mahi-Brown C.A. Tung K.S. Cell. Immunol. 124 1989 368 379 2573435 Mahi-Brown C.A. Yule T.D. Tung K.S. Cell. Immunol. 106 1987 408 419 2952288 Mahi-Brown C.A. Yule T.D. Tung K.S. Am. J. Reprod. Immunol. Microbiol. 16 1988 165 170 3048131 Mak T.W. Yeh W.C. Arthritis Res. 4 Suppl 3 2002 S243 S252 12110144 Makanji Y. Walton K.L. Wilce M.C. Chan K.L. Robertson D.M. Harrison C.A. J. Biol. Chem. 283 2008 16743 16751 18397882 Malmgaard L. J. Interferon Cytokine Res. 24 2004 439 454 15320958 Mantovani A. Sica A. Locati M. Immunity 23 2005 344 346 16226499 Martín-Villa J.M. Luque I. Martínez-Quiles N. Corell A. Regueiro J.R. Timón M. Arnaiz-Villena A. Biol. Reprod. 55 1996 620 629 8862780 Massagué J. Andres J. Attisano L. Cheifetz S. López-Casillas F. Ohtsuki M. Wrana J.L. Mol. Reprod. Dev. 32 1992 99 104 1322148 Mather J.P. Attie K.M. Woodruff T.K. Rice G.C. Phillips D.M. Endocrinology 127 1990 3206 3214 2249646 Matthiesson K.L. McLachlan R.I. O’Donnell L. Frydenberg M. Robertson D.M. Stanton P.G. Meachem S.J. J. Clin. Endocrinol. Metab. 91 2006 3962 3969 16895950 Matzinger P. Annu. Rev. Immunol. 12 1994 991 1045 8011301 Mauduit C. Besset V. Caussanel V. Benahmed M. Biochem. Biophys. Res. Commun. 224 1996 631 637 8713100 Mauduit C. Chauvin M.A. de Peretti E. Morera A.M. Benahmed M. Biol. Reprod. 45 1991 101 109 1831673 Mauduit C. Gasnier F. Rey C. Chauvin M.A. Stocco D.M. Louisot P. Benahmed M. Endocrinology 139 1998 2863 2868 9607795 Mauduit C. Hartmann D.J. Chauvin M.A. Revol A. Morera A.M. Benahmed M. Endocrinology 129 1991 2933 2940 1659519 Mauduit C. Jaspar J.M. Poncelet E. Charlet C. Revol A. Franchimont P. Benahmed M. Endocrinology 133 1993 69 76 8319591 McGhee J.R. Fujihashi K. Xu-Amano J. Jackson R.J. Elson C.O. Beagley K.W. Kiyono H. Semin. Hematol. 30 1993 3 12 discussion 3–5 McLachlan R.I. Wreford N.G. O’Donnell L. de Kretser D.M. Robertson D.M. J. Endocrinol. 148 1996 1 9 8568455 Medzhitov R. Preston-Hurlburt P. Kopp E. Stadlen A. Chen C. Ghosh S. Janeway C.A. Jr. Mol. Cell 2 1998 253 258 9734363 Meehan T. Schlatt S. O’Bryan M.K. de Kretser D.M. Loveland K.L. Dev. Biol. 220 2000 225 237 10753512 Meineke V. Frungieri M.B. Jessberger B. Vogt H. Mayerhofer A. Fertil. Steril. 74 2000 239 244 10927038 Meinhardt A. Bacher M. McFarlane J.R. Metz C.N. Seitz J. Hedger M.P. de Kretser D.M. Bucala R. Endocrinology 137 1996 5090 5095 8895383 Meinhardt A. Bacher M. Metz C. Bucala R. Wreford N. Lan H. Atkins R. Hedger M. Biol. Reprod. 59 1998 371 378 9687310 Meinhardt A. McFarlane J.R. Seitz J. de Kretser D.M. Mol. Cell. Endocrinol. 168 2000 111 117 11064157 Meistrich M.L. Biomed. Pharmacother. 38 1984 137 142 6478053 Melaine N. Lienard M.O. Dorval I. Le Goascogne C. Lejeune H. Jégou B. Biol. Reprod. 67 2002 1699 1707 12444043 Mellor S.L. Ball E.M. O’Connor A.E. Ethier J.F. Cranfield M. Schmitt J.F. Phillips D.J. Groome N.P. Risbridger G.P. Endocrinology 144 2003 4410 4419 12960042 Mendis-Handagama S.M. Risbridger G.P. de Kretser D.M. Int. J. Androl. 10 1987 525 534 3610361 Merkler D. Horvath E. Bruck W. Zinkernagel R.M. de la Torre J.C. Pinschewer D.D. J. Clin. Invest. 116 2006 1254 1263 16604192 Mestecky J. Moldoveanu Z. Russell M.W. Am. J. Reprod. Immunol. 53 2005 208 214 15833098 Meunier H. Rivier C. Evans R.M. Vale W. Proc. Natl. Acad. Sci. USA 85 1988 247 251 2829170 Miller L. Hunt J.S. Life Sci. 59 1996 1 14 8684265 Miller L.J. Fischer K.A. Goralnick S.J. Litt M. Burleson J.A. Albertsen P. Kreutzer D.L. J. Urol. 167 2002 753 756 11792966 Miller S.C. Bowman B.M. Roberts L.K. J. Leuk. Biol. 36 1984 679 687 Miller S.C. Bowman B.M. Rowland H.G. Am. J. Anat. 168 1983 1 13 6685429 Mizuno M. Harris C.L. Morgan B.P. J. Reprod. Immunol. 69 2006 23 34 16380167 Mocikat R. Braumuller H. Gumy A. Egeter O. Ziegler H. Reusch U. Bubeck A. Louis J. Mailhammer R. Riethmuller G. Immunity 19 2003 561 569 14563320 Moldoveanu Z. Huang W.Q. Kulhavy R. Pate M.S. Mestecky J. J. Immunol. 175 2005 4127 4136 16148163 Moller R. Andrologia 12 1980 564 576 6162406 Monder C. Miroff Y. Marandici A. Hardy M.P. Endocrinology 134 1994 1199 1204 8119160 Moon C. Ahn M. Kim S. Yasuzumi F. Shin T. J. Vet. Med. Sci. 67 2005 453 456 15876800 Mori K.L. Egashira M. Oshimi K. Br. J. Haematol. 115 2001 225 228 11722437 Moser B. Loetscher P. Nat. Immunol. 2 2001 123 128 11175804 Moser M. Murphy K.M. Nat. Immunol. 1 2000 199 205 10973276 Muguruma K. Komatz Y. Ikeda M. Sugimoto T. Saito K. Biol. Reprod. 48 1993 386 392 8439628 Mullaney B.P. Skinner M.K. Mol. Endocrinol. 7 1993 67 76 8446109 Nagai T. Takaba H. Miyake K. Hirabayashi Y. Yamada K. Fertil. Steril. 57 1992 1331 1336 1376286 Nakamura K. Kitani A. Strober W. J. Exp. Med. 194 2001 629 644 11535631 Nakamura T. Sonoda K.H. Faunce D.E. Gumperz J. Yamamura T. Miyake S. Stein-Streilein J. J. Immunol. 171 2003 1266 1271 12874214 Nakamura T. Sugino K. Titani K. Sugino H. J. Biol. Chem. 266 1991 19432 19437 1918055 Nakano H. Trends Immunol. 25 2004 402 405 15275637 Nathan C. Science 312 2006 1874 1875 Naz R.K. Evans L. J. Androl. 19 1998 302 307 9639047 Nehar D. Mauduit C. Boussouar F. Benahmed M. Endocrinology 138 1997 1964 1971 9112394 Nehar D. Mauduit C. Boussouar F. Benahmed M. Biol. Reprod. 59 1998 1425 1432 9828188 Nes W.D. Lukyanenko Y.O. Jia Z.H. Quideau S. Howald W.N. Pratum T.K. West R.R. Hutson J.C. Endocrinology 141 2000 953 958 10698170 Ness R.B. Markovic N. Carlson C.L. Coughlin M.T. Fertil. Steril. 68 1997 205 213 9240243 Nishimura M. Naito S. Biol. Pharmaceut. Bull. 28 2005 886 892 Nistal M. Santamaria L. Paniagua R. Acta Anat. 119 1984 155 160 6464648 Nistal M. Santana A. Paniaqua R. Palacios J. Arch. Pathol. Lab. Med. 110 1986 744 746 3755328 Nocera M. Chu T.M. Am. J. Reprod. Immunol. 30 1993 1 8 8260018 Nossal G.J. Cell 76 1994 229 239 8293461 Nusinow S.R. Izuno G.T. Curd J.G. Postgrad. Med. 78 1985 122 124 2863815 O’Bryan M.K. Gerdprasert O. Nikolic-Paterson D.J. Meinhardt A. Muir J.A. Foulds L.M. Phillips D.J. de Kretser D.M. Hedger M.P. Am. J. Physiol. 288 2005 R1744 R1755 O’Bryan M.K. Hedger M.P. Adv. Exp. Med. Biol. 636 2008 92 114 19856164 O’Bryan M.K. Schlatt S. Gerdprasert O. Phillips D.J. de Kretser D.M. Hedger M.P. Biol. Reprod. 63 2000 1285 1293 11058531 O’Bryan M.K. Schlatt S. Phillips D.J. de Kretser D.M. Hedger M.P. Endocrinology 141 2000 238 246 10614644 O’Neill L.A. Bowie A.G. Nat. Rev. Immunol. 7 2007 353 364 17457343 O’Neill L.A. Dinarello C.A. Immunol. Today 21 2000 206 209 10782049 Oboki K. Ohno T. Saito H. Nakae S. Allergol. Int. 57 2008 121 134 18427165 Ochsenkühn R. O’Connor A.E. Hirst J.J. Baker H.W.G. de Kretser D.M. Hedger M.P. J. Reprod. Immunol. 71 2006 57 74 16712948 Ogawa K. Funaba M. Chen Y. Tsujimoto M. J. Immunol. 177 2006 6787 6794 17082592 Ogi S. Tanji N. Yokoyama M. Takeuchi M. Terada N. Urol. Res. 26 1998 17 21 9537691 Okuda Y. Bardin C.W. Hodgskin L.R. Morris P.L. Rec. Prog. Horm. Res. 50 1995 367 372 7740168 Okuda Y. Sun X.R. Morris P.L. Endocr. J. 2 1994 617 624 Okuma Y. O’Connor A.E. Hayashi T. Loveland K.L. de Kretser D.M. Hedger M.P. J. Endocrinol. 190 2006 331 340 16899566 Okuma Y. O’Connor A.E. Muir J.A. Stanton P.G. de Kretser D.M. Hedger M.P. J. Endocrinol. 187 2005 125 134 16214948 Okuma Y. Saito K. O’Connor A.E. Phillips D.J. de Kretser D.M. Hedger M.P. J. Endocrinol. 185 2005 99 110 15817831 Olaso R. Gautier C. Levacher C. Durand P. Saez J. Habert R. Mol. Cell. Endocrinol. 126 1997 165 172 9089654 Olaso R. Pairault C. Boulogne B. Durand P. Habert R. Endocrinology 139 1998 733 740 9449647 Onichtchouk D. Chen Y.G. Dosch R. Gawantka V. Delius H. Massague J. Niehrs C. Nature 401 1999 480 485 10519551 Orava M. Cantell K. Vihko R. Biochem. Biophys. Res. Commun. 127 1985 809 815 2985059 Orava M. Cantell K. Vihko R. Int. J. Cancer 38 1986 295 296 3089946 Orava M. Voutilainen R. Vihko R. Mol. Endocrinol. 3 1989 887 894 2544801 Ouyang W. Kolls J.K. Zheng Y. Immunity 28 2008 454 467 18400188 Padmanabhan R. Singh S. Z. Mikrosk. Anat. Forsch. 95 1981 1057 1064 6121427 Palladino M.A. Johnson T.A. Gupta R. Chapman J.L. Ojha P. Biol. Reprod. 76 2007 958 964 17314314 Papadopoulos V. Carreau S. Drosdowsky M.A. Med. Sci. Res. 15 1987 11 12 Parvinen M. Söder O. Mali P. Fröysa B. Ritzén E.M. Endocrinology 129 1991 1614 1620 1874191 Patrizio P. Silber S.J. Ord T. Moretti-Rojas I. Asch R.H. Fertil. Steril. 58 1992 1006 1010 1426350 Pattinson H.A. Mortimer D. Fertil. Steril. 48 1987 466 469 3305089 Pedersen N.C. Morris B. J. Exp. Med. 131 1970 936 969 4910145 Pelletier R.M. Am. J. Anat. 175 1986 91 117 3953473 Pelletier R.M. In Cereijido M. Anderson J. Tight Junctions 2001 CRC Press Boca Raton, FL 599 628 Pentikäinen V. Erkkilä K. Suomalainen L. Otala M. Pentikäinen M.O. Parvinen M. Dunkel L. J. Clin. Endocrinol. Metab. 86 2001 4480 4488 11549697 Pentikäinen V. Suomalainen L. Erkkilä K. Martelin E. Parvinen M. Pentikäinen M.O. Dunkel L. Am. J. Pathol. 160 2002 205 218 11786414 Petersen C. Svechnikov K. Fröysa B. Söder O. Cytokine 32 2005 51 59 16181786 Philippidis P. Mason J.C. Evans B.J. Nadra I. Taylor K.M. Haskard D.O. Landis R.C. Circ. Res. 94 2004 119 126 14656926 Phillips D.J. Jones K.L. Scheerlinck J.Y. Hedger M.P. de Kretser D.M. Mol. Cell. Endocrinol. 180 2001 155 162 11451586 Piccirillo C.A. Letterio J.J. Thornton A.M. McHugh R.S. Mamura M. Mizuhara H. Shevach E.M. J. Exp. Med. 196 2002 237 246 12119348 Piccirillo C.A. Thornton A.M. Trends Immunol. 25 2004 374 380 15207505 Picker L.J. Butcher E.C. Annu. Rev. Immunol. 10 1992 561 591 1590996 Politch J.A. Tucker L. Bowman F.P. Anderson D.J. Hum. Reprod. 22 2007 2928 2935 17855405 Pöllänen P. Maddocks S. J. Reprod. Fertil. 82 1988 437 445 3163001 Pöllänen P. Niemi M. Int. J. Androl. 10 1987 37 42 3294605 Pöllänen P. Söder O. Parvinen M. Reprod. Fertil. Dev. 1 1989 85 87 2496437 Pöllänen P. Söder O. Uksila J. J. Reprod. Immunol. 14 1988 125 138 2976828 Pöllänen P. von Euler M. Jahnukainen K. Saari T. Parvinen M. Sainio-Pöllänen S. Söder O. J. Reprod. Immunol. 24 1993 123 137 7901411 Pudney J. Anderson D.J. Am. J. Pathol. 147 1995 155 165 7604877 Quinn P.G. Payne A.H. J. Biol. Chem. 259 1984 4130 4135 6584429 Quintar A.A. Roth F.D. De Paul A.L. Aoki A. Maldonado C.A. Biol. Reprod. 75 2006 664 672 16870940 Raburn D.J. Coquelin A. Reinhart A.J. Hutson J.C. J. Reprod. Immunol. 24 1993 139 151 8229992 Radu C.G. Yang L.V. Riedinger M. Au M. Witte O.N. Proc. Natl. Acad. Sci. USA 101 2004 245 250 14681556 Raeside J.I. Renaud R.L. Biol. Reprod. 28 1983 727 733 6221767 Rahman F. Christian H.C. Trends Endocrinol. Metab. 18 2007 371 378 17997105 Rajasekaran M. Hellstrom W. Sikka S. Am. J. Reprod. Immunol. 36 1996 90 95 8862252 Raleigh D. O’Donnell L. Southwick G.J. de Kretser D.M. McLachlan R.I. Fertil. Steril. 81 2004 1595 1603 15193483 Rasoulpour R.J. Boekelheide K. Biol. Reprod. 72 2005 479 486 15496515 Raulet D.H. Nat. Immunol. 5 2004 996 1002 15454923 Regner M. Lambert P.H. Nat. Immunol. 2 2001 185 188 11224510 Restifo N.P. Nat. Med. 6 2000 493 495 10802692 Riccioli A. Starace D. D’Alessio A. Starace G. Padula F. de Cesaris P. Filippini A. Ziparo E. J. Immunol. 165 2000 743 749 10878347 Riccioli A. Starace D. Galli R. Fuso A. Scarpa S. Palombi F. De Cesaris P. Ziparo E. Filippini A. J. Immunol. 177 2006 7122 7130 17082629 Riera M.F. Meroni S.B. Gómez G.E. Schteingart H.F. Pellizzari E.H. Cigorraga S.B. Gen. Comp. Endocrinol. 122 2001 88 97 11352557 Ritchie A.W. Hargreave T.B. James K. Chisholm G.D. Br. J. Urol. 56 1984 79 83 6365234 Riteau B. Menier C. Khalil-Daher I. Sedlik C. Dausset J. Rouas-Freiss N. Carosella E.D. J. Reprod. Immunol. 43 1999 203 211 10479056 Rival C. Guazzone V.A. von Wulffen W. Hackstein H. Schneider E. Lustig L. Meinhardt A. Fijak M. Mol. Hum. Reprod. 13 2007 853 861 17884838 Rival C. Lustig L. Iosub R. Guazzone V.A. Schneider E. Meinhardt A. Fijak M. Cell Tissue Res. 324 2006 311 318 16432710 Rival C. Theas M.S. Guazzone V.A. Lustig L. J. Reprod. Immunol. 70 2006 43 58 16458979 Roach J.C. Glusman G. Rowen L. Kaur A. Purcell M.K. Smith K.D. Hood L.E. Aderem A. Proc. Natl. Acad. Sci. USA 102 2005 9577 9582 15976025 Robertson D.M. de Vos F.L. Foulds L.M. McLachlan R.I. Burger H.G. Morgan F.J. Hearn M.T. de Kretser D.M. Mol. Cell. Endocrinol. 44 1986 271 277 3082696 Robertson S.A. Bromfield J.J. Tremellen K.P. J. Reprod. Immunol. 59 2003 253 265 12896827 Robson N.C. Phillips D.J. McAlpine T. Shin A. Svobodova S. Toy T. Pillay V. Kirkpatrick N. Zanker D. Wilson K. Blood 111 2008 2733 2743 18156495 Rodrigues A. Queiroz D.B. Honda L. Silva E.J. Hall S.H. Avellar M.C. Biol. Reprod. 79 2008 1135 1147 18703421 Rodriguez M.G. Rival C. Theas M.S. Lustig L. Asian J. Androl. 8 2006 576 583 16847529 Rogers A.M. Boime I. Connolly J. Cook J.R. Russell J.H. Eur. J. Immunol. 28 1998 3479 3487 9842890 Romagnani S. Arthritis Res. Ther. 10 2008 206 18466633 Roper R.J. Doerge R.W. Call S.B. Tung K.S. Hickey W.F. Teuscher C. Am. J. Pathol. 152 1998 1337 1345 9588902 Rosenberg H.F. Gallin J.I. Fundamental Immunology Paul W.E. 2003 Lippincott, Williams and Wilkins Philadelphia, PA 1151 1169 Roussel J.D. Stallcup O.T. Austin C.R. Fertil. Steril. 18 1967 509 516 4961516 Russell C.E. Hedger M.P. Brauman J.N. de Kretser D.M. Phillips D.J. Mol. Cell. Endocrinol. 148 1999 129 136 10221778 Ruwanpura S.M. McLachlan R.I. Stanton P.G. Meachem S.J. Biol. Reprod. 78 2008 705 713 18094353 Ryan A.F. Grendell R.L. Geraghty D.E. Golos T.G. J. Immunol. 169 2002 673 683 12097369 Saas P. Walker P.R. Hahne M. Quiquerez A.L. Schnuriger V. Perrin G. French L. Van Meir E.G. de Tribolet N. Tschopp J. J. Clin. Invest. 99 1997 1173 1178 9077524 Sainio-Pöllänen S. Saari T. Simell O. Pöllänen P. J. Reprod. Immunol. 31 1996 145 163 8905549 Sales K.J. Jabbour H.N. Prostaglandins Other Lipid Mediat. 71 2003 97 117 14518555 Samuelsson B. Dahlén S.E. Lindgren J.A. Rouzer C.A. Serhan C.N. Science 237 1987 1171 1176 2820055 Sanberg P.R. Borlongan C.V. Saporta S. Cameron D.F. Nat. Biotechnol. 14 1996 1692 1695 9634853 Sant A.J. Beeson C. McFarland B. Cao J. Ceman S. Bryant P.W. Wu S. Immunol. Rev. 172 1999 239 253 10631950 Santoro G. Romeo C. Impellizzeri P. Ientile R. Cutroneo G. Trimarchi F. Pedale S. Turiaco N. Gentile C. BJU Int. 88 2001 967 973 11851622 Sanyal S. Patra P.B. Nag S. Biswas N.M. Andrologia 12 1980 179 185 7386900 Sapolsky R.M. Romero L.M. Munck A.U. Endocr. Rev. 21 2000 55 89 10696570 Sarkar O. Mathur P.P. Cheng C.Y. Mruk D.D. Biol. Reprod. 78 2008 445 454 18057314 Sasson S. Mayer M. J. Steroid Biochem. 14 1981 509 517 7242083 Schaloske R.H. Dennis E.A. Biochim. Biophys. Acta 1761 2006 1246 1259 16973413 Schittek B. Rajewsky K. Nature 346 1990 749 751 2388695 Schmidt H.H. Walter U. Cell 78 1994 919 925 7923361 Schoenborn J.R. Wilson C.B. Adv. Immunol. 96 2007 41 101 17981204 Schrag S.D. Dixon R.L. Annu. Rev. Pharmacol. Toxicol. 25 1985 567 592 2408559 Schuppe H.C. Meinhardt A. Chem. Immunol. Allergy 88 2005 1 14 16129933 Schuppe H.C. Meinhardt A. Allam J.P. Bergmann M. Weidner W. Haidl G. Andrologia 40 2008 84 91 18336456 Schütze S. Tchikov V. Schneider-Brachert W. Nat. Rev. Mol. Cell Biol. 9 2008 655 662 18545270 Schwartz G.G. J. Clin. Epidemiol. 43 1990 1433 2254783 Seethalakshmi L. Flores C. Carboni A.A. Bala R. Diamond D.A. Menon M. J. Androl. 11 1990 17 24 2312396 Selawry H.P. Cameron D.F. Cell Transplant. 2 1993 123 129 8143079 Selawry H.P. Whittington K. Diabetes 33 1984 405 406 6423432 Selawry H.P. Whittington K.B. Horm. Metab. Res. 20 1988 562 565 3143654 Selsted M.E. Ouellette A.J. Nat. Immunol. 6 2005 551 557 15908936 Seo N. Hayakawa S. Takigawa M. Tokura Y. Immunology 103 2001 449 457 11529935 Setchell B.P. Granholm T. Ritzén E.M. J. Reprod. Immunol. 28 1995 75 80 7738917 Setchell B.P. Maddocks S. Brooks D.E. The Physiology of Reproduction Knobil E. Neill J.D. 1994 Raven Press New York 1063 1173 Setchell B.P. Rommerts F.F. Int. J. Androl. 8 1985 436 440 3011682 Setchell B.P. Sharpe R.M. J. Endocrinol. 91 1981 245 254 7299325 Setchell B.P. Voglmayr J.K. Waites G.M. J. Physiol. 200 1969 73 85 4973530 Sharma A.C. Sam A.D. 2nd Lee L.Y. Hales D.B. Law W.R. Ferguson J.L. Bosmann H.B. Shock 9 1998 416 421 9645493 Shiraishi K. Naito K. BJU Int. 99 2007 1086 1090 17346270 Shiraishi K. Naito K. Yoshida K. Biol. Reprod. 65 2001 514 521 11466220 Sica A. Larghi P. Mancino A. Rubino L. Porta C. Totaro M.G. Rimoldi M. Biswas S.K. Allavena P. Mantovani A. Semin. Cancer Biol. 18 2008 349 355 18467122 Sipione S. Simmen K.C. Lord S.J. Motyka B. Ewen C. Shostak I. Rayat G.R. Dufour J.M. Korbutt G.S. Rajotte R.V. J. Immunol. 177 2006 5051 5058 17015688 Siu M.K. Lee W.M. Cheng C.Y. Endocrinology 144 2003 371 387 12488366 Skibinski G. Kelly R.W. Harrison C.M. McMillan L.A. James K. J. Reprod. Immunol. 22 1992 185 195 1501205 Slukvin I.I. Watkins D.I. Golos T.G. Tissue Antigens 53 1999 282 291 10203022 Smith W.L. DeWitt D.L. Garavito R.M. Annu. Rev. Biochem. 69 2000 145 182 10966456 Snyder F. Am. J. Physiol. 259 1990 C697 C708 2240190 Söder O. Syed V. Callard G.V. Toppari J. Pöllänen P. Parvinen M. Fröysa B. Ritzén E.M. Int. J. Androl. 14 1991 223 231 2066166 Soga T. Ohishi T. Matsui T. Saito T. Matsumoto M. Takasaki J. Matsumoto S. Kamohara M. Hiyama H. Yoshida S. Biochem. Biophys. Res. Commun. 326 2005 744 751 15607732 Sonoda K.H. Faunce D.E. Taniguchi M. Exley M. Balk S. Stein-Streilein J. J. Immunol. 166 2001 42 50 11123275 Spiess A.N. Feig C. Schulze W. Chalmel F. Cappallo-Obermann H. Primig M. Kirchhoff C. Hum. Reprod. 22 2007 2936 2946 17921478 Spörri R. Reis e Sousa C. Nat. Immunol. 6 2005 163 170 15654341 Springer T.A. Cell 76 1994 301 314 7507411 Srivastava M.D. Lippes J. Srivastava B.I. Am. J. Reprod. Immunol. 36 1996 157 166 8874712 Starace D. Galli R. Paone A. Cesaris P.D. Filippini A. Ziparo E. Riccioli A. Biol. Reprod. 79 2008 766 775 18596219 Starace D. Riccioli A. D’Alessio A. Giampietri C. Petrungaro S. Galli R. Filippini A. Ziparo E. De Cesaris P. FASEB J. 19 2005 473 475 15601669 Stéphan J.P. Guillemois C. Jégou B. Bauché F. Biochem. Biophys. Res. Commun. 213 1995 218 224 7543752 Stéphan J.P. Syed V. Jégou B. Mol. Cell. Endocrinol. 134 1997 109 118 9426154 Strand M.L. Wahlgren A. Svechnikov K. Zetterström C. Setchell B.P. Söder O. Mol. Cell. Endocrinol. 240 2005 64 73 16002206 Streilein J.W. Curr. Opin. Immunol. 5 1993 428 432 8347303 Stuart P.M. Griffith T.S. Usui N. Pepose J. Yu X. Ferguson T.A. J. Clin. Invest. 99 1997 396 402 9022072 Suarez-Pinzon W. Korbutt G.S. Power R. Hooton J. Rajotte R.V. Rabinovitch A. Diabetes 49 2000 1810 1818 11078447 Suescun M.O. Rival C. Theas M.S. Calandra R.S. Lustig L. Biol. Reprod. 68 2003 2114 2121 12606341 Sullivan M.H. Cooke B.A. Biochem. J. 230 1985 821 824 2998334 Sun J. Wiklund F. Zheng S.L. Chang B. Bälter K. Li L. Johansson J.E. Li G. Adami H.O. Liu W. J. Natl. Cancer Inst. 97 2005 525 532 15812078 Suominen J. Soderstrom K.O. Int. J. Androl. 5 1982 461 466 7174127 Suominen J.J. Andrologia 27 1995 213 216 7486031 Suominen J.S. Wang Y. Kaipia A. Toppari J. Eur. J. Endocrinol. 151 2004 629 640 15538942 Syed V. Gerard N. Kaipia A. Bardin C.W. Parvinen M. Jegou B. Endocrinology 132 1993 293 299 8380379 Syed V. Stéphan J.P. Gérard N. Legrand A. Parvinen M. Bardin C.W. Jégou B. Endocrinology 136 1995 3070 3078 7789334 Tafuri A. Alferink J. Möller P. Hämmerling G.J. Arnold B. Science 270 1995 630 633 7570020 Takahashi N. Takeuchi K. Abe T. Murakami K. Yamaguchi M. Abe K. Endocrinology 136 1995 4143 4146 7649122 Takano T. Fiore S. Maddox J.F. Brady H.R. Petasis N.A. Serhan C.N. J. Exp. Med. 185 1997 1693 1704 9151906 Takeda A. Palfree R.G. Forsdyke D.R. Biochim. Biophys. Acta 710 1982 87 98 6173077 Takemura R. Werb Z. Am. J. Physiol. 246 1984 C1 C9 6364825 Tanabe T. Tohnai N. Prostaglandins Other Lipid Mediat. 68–69 2002 95 114 Teerds K.J. Dorrington J.H. Biol. Reprod. 48 1993 40 45 8418916 Teuscher C. Blankenhorn E.P. Hickey W.F. Cell. Immunol. 110 1987 294 304 2446778 Theyer G. Kramer G. Assmann I. Sherwood E. Preinfalk W. Marberger M. Zechner O. Steiner G.E. Lab. Invest. 66 1992 96 107 1370561 Thompson A.G. Thomas R. Immunol. Cell Biol. 80 2002 509 519 12406384 Thompson A.J. Locarnini S.A. Immunol. Cell Biol. 85 2007 435 445 17667934 Thornberry N.A. Molineaux S.M. Protein Sci. 4 1995 3 12 7773174 Tilg H. Dinarello C.A. Mier J.W. Immunol. Today 18 1997 428 432 9293158 Tomlinson M.J. Barratt C.L. Cooke I.D. Fertil. Steril. 60 1993 1069 1075 8243688 Tomlinson M.J. East S.J. Barratt C.L. Bolton A.E. Cooke I.D. Am. J. Reprod. Immunol. 27 1992 89 92 1610494 Tomlinson M.J. White A. Barratt C.L. Bolton A.E. Cooke I.D. Hum. Reprod. 7 1992 517 522 1522196 Tompkins A.B. Hutchinson P. de Kretser D.M. Hedger M.P. Biol. Reprod. 58 1998 943 951 9546724 Tsan M.F. Gao B. J. Leuk. Biol. 76 2004 514 519 Tung K.S. Clin. Exp. Immunol. 20 1975 93 104 1106922 Tung K.S. Alexander N.J. Am. J. Pathol. 101 1980 17 30 7446699 Tung K.S. Ellis L. Teuscher C. Meng A. Blaustein J.C. Kohno S. Howell R. J. Exp. Med. 154 1981 1016 1032 6116740 Tung K.S. Yule T.D. Mahi-Brown C.A. Listrom M.B. J. Immunol. 138 1987 752 759 3492532 Turek P.J. Lipshultz L.I. Urol. Clin. North Am. 21 1994 447 468 8059500 Turek P.J. Malkowicz S.B. Tomaszewski J.E. Wein A.J. Peehl D. Br. J. Urol. 77 1996 891 895 8705228 Türker Köksal I. Erdoğru T. Gülkesen H. Sezer C. Usta M. Çiftçioğlu A. Baykara M. Int. Urol. Nephrol. 36 2004 67 72 15338679 Ueno N. Takegoshi Y. Kamei D. Kudo I. Murakami M. Biochem. Biophys. Res. Commun. 338 2005 70 76 16140261 Unanue E.R. Annu. Rev. Immunol. 2 1984 395 428 6242349 Vale W. Wiater E. Gray P. Harrison C. Bilezikjian L. Choe S. Ann. N. Y. Acad. Sci. 1038 2004 142 147 15838109 van Furth R. Inflammation: Basic Principles and Clinical Correlates Gallin J.I. Goldstein I.M. Snyderman R. 1988 Raven Press New York 281 295 van Vliet J. Rommerts F.F. de Rooij D.G. Buwalda G. Wensing C.J. J. Endocrinol. 117 1988 51 57 2833552 Varma T.K. Lin C.Y. Toliver-Kinsky T.E. Sherwood E.R. Clin. Diagn. Lab. Immunol. 9 2002 530 543 11986256 Veräjänkorva E. Setälä N. Teros T. Salmi A.A. Pöllänen P. Scand. J. Immunol. 55 2002 478 483 11975759 Vergouwen R.P. Huiskamp R. Bas R.J. Roepers-Gajadien H.L. Davids J.A. de Rooij D.G. J. Reprod. Fertil. 99 1993 479 485 8107030 Veselský L. Dostál J. Kraus M. Peknicová J. Holán V. Zajícová A. Jonáková V. Železná B. Anim. Reprod. Sci. 71 2002 111 123 11988375 Vivier E. Malissen B. Nat. Immunol. 6 2005 17 21 15611777 Wahl S.M. Wen J. Moutsopoulos N. Immunol. Rev. 213 2006 213 227 16972906 Wahlsten J.L. Gitchell H.L. Chan C.C. Wiggert B. Caspi R.R. J. Immunol. 165 2000 5480 5486 11067900 Walch L. Morris P.L. Endocrinology 143 2002 3276 3283 12193539 Walker W.H. Curr. Top. Dev. Biol. 56 2003 25 53 14584725 Wallgren M. Kindahl H. Rodriguez-Martinez H. Int. J. Androl. 16 1993 235 243 8359940 Wang C.Q. Cheng C.Y. J. Cell Biol. 178 2007 549 556 17698604 Wang J. Wreford N.G. Lan H.Y. Atkins R. Hedger M.P. Biol. Reprod. 51 1994 551 561 7528551 Wang S.Y. Tai G.X. Zhang P.Y. Mu D.P. Zhang X.J. Liu Z.H. Cytokine 42 2008 85 91 18321725 Wang X. Shen C.L. Dyson M.T. Eimerl S. Orly J. Hutson J.C. Stocco D.M. Endocrinology 146 2005 4202 4208 16002525 Wang Y. Goligorsky M.S. Lin M. Wilcox J.N. Marsden P.A. J. Biol. Chem. 272 1997 11392 11401 9111048 Warren D.W. Pasupuleti V. Lu Y. Platler B.W. Horton R. J. Androl. 11 1990 353 360 2211341 Watanabe M. Kashiwakura Y. Kusumi N. Tamayose K. Nasu Y. Nagai A. Shimada T. Daida H. Kumon H. Gene Ther. 12 2005 1126 1132 15920464 Watanabe N. Kobayashi Y. Cytokine 6 1994 597 601 7893968 Wei R.Q. Yee J.B. Straus D.C. Hutson J.C. Biol. Reprod. 38 1988 830 835 2840982 Wekerle H. Sun D. Oropeza-Wekerle R.L. Meyermann R. J. Exp. Biol. 132 1987 43 57 3323405 Welch C. Watson M.E. Poth M. Hong T. Francis G.L. Metab. Clin. Exp. 44 1995 234 238 7869921 Weltzien H.U. Biochim. Biophys. Acta 559 1979 259 287 476122 Wenkel H. Streilein J.W. Young M.J. J. Immunol. 164 2000 5125 5131 10799870 Westermann J. Pabst R. Clin. Investig. 70 1992 539 544 Wetzels J.F. Neth. J. Med. 62 2004 347 352 15683089 Whalen M.M. Doshi R.N. Bader B.W. Bankhurst A.D. Cell. Physiol. Biochem. 9 1999 297 309 10749996 Whitmore I.I.I.W.F. Gittes R.F. Trans. Am. Assoc. Genitourin. Surg. 70 1978 76 80 753027 Widmark A. Bergh A. Damber J.E. Smedegård G. Mol. Cell. Endocrinol. 53 1987 25 31 3666291 Winnall W.R. Ali U. O’Bryan M.K. Hirst J.J. Whiley P.A. Muir J.A. Hedger M.P. Biol. Reprod. 76 2007 759 768 17251525 Winnall W.R. Muir J.A. Liew S. Hirst J.J. Meachem S.J. Hedger M.P. Int. J. Androl. 32 2009 542 555 18522674 Wolff H. Anderson D.J. Fertil. Steril. 49 1988 497 504 3342902 Wolff H. Politch J.A. Martinez A. Haimovici F. Hill J.A. Anderson D.J. Fertil. Steril. 53 1990 528 536 2407566 Wolkow P.P. Inflamm. Res. 47 1998 152 166 9628258 Wu H. Wang H. Xiong W. Chen S. Tang H. Han D. Endocrinology 149 2008 4402 4412 18499758 Wunderlich F. Benten W.P. Lieberherr M. Guo Z. Stamm O. Wrehlke C. Sekeris C.E. Mossmann H. Steroids 67 2002 535 538 11960632 Wyatt C.R. Law L. Magnuson J.A. Griswold M.D. Magnuson N.S. J. Reprod. Immunol. 14 1988 27 40 3199389 Xerri L. Devilard E. Hassoun J. Mawas C. Birg F. Mol. Pathol. 50 1997 87 91 9231156 Xia W. Mruk D.D. Lee W.M. Cheng C.Y. J. Biol. Chem. 281 2006 16799 16813 16617054 Xiong Y. Hales D.B. Endocrinology 133 1993 2568 2573 8243279 Xiong Y. Hales D.B. Endocrinology 132 1993 2438 2444 8504748 Xiong Y. Hales D.B. Endocr. J. 2 1994 223 228 Xiong Y. Hales D.B. Endocrine 7 1997 295 301 9657065 Xu J. Qi L. Chi X. Yang J. Wei X. Gong E. Peh S. Gu J. Biol. Reprod. 74 2006 410 416 16237152 Yamaguchi Y. Nagase T. Makita R. Fukuhara S. Tomita T. Tominaga T. Kurihara H. Ouchi Y. J. Immunol. 169 2002 2516 2523 12193721 Yamanaka K. Fujisawa M. Tanaka H. Okada H. Arakawa S. Kamidono S. Hum. Reprod. 15 2000 1543 1547 10875863 Yamashita T. Takahashi S. Ogata E. Blood 79 1992 304 307 1730078 Yang L.V. Radu C.G. Wang L. Riedinger M. Witte O.N. Blood 105 2005 1127 1134 15383458 Yasuda K. Yu P. Kirschning C.J. Schlatter B. Schmitz F. Heit A. Bauer S. Hochrein H. Wagner H. J. Immunol. 174 2005 6129 6136 15879108 Yee J.B. Hutson J.C. Endocrinology 116 1985 2682 2684 3922747 Yenugu S. Hamil K.G. Radhakrishnan Y. French F.S. Hall S.H. Endocrinology 145 2004 3165 3173 15033915 Yeung C.H. Nashan D. Sorg C. Oberpenning F. Schulze H. Nieschlag E. Cooper T.G. Biol. Reprod. 50 1994 917 926 8199271 Yin Z.Z. Xie L. Zeng M.H. Li R. Huang Y.B. Zhu M. Chen G. Chen S. Transplant. Proc. 38 2006 3309 3311 17175257 Yu E.W. Dolter K.E. Shao L.E. Yu J. Clin. Exp. Immunol. 112 1998 126 132 9566800 Yu M. Wang H. Ding A. Golenbock D.T. Latz E. Czura C.J. Fenton M.J. Tracey K.J. Yang H. Shock 26 2006 174 179 16878026 Yule T.D. Montoya G.D. Russell L.D. Williams T.M. Tung K.S. J. Immunol. 141 1988 1161 1167 3397538 Yule T.D. Tung K.S. Endocrinology 133 1993 1098 1107 8103448 Zetterström C.K. Strand M.L. Söder O. Hum. Reprod. 21 2006 2801 2809 16997939 Zeyse D. Lunenfeld E. Beck M. Prinsloo I. Huleihel M. Endocrinology 141 2000 1521 1527 10746659 Zhang D. Zhang G. Hayden M.S. Greenblatt M.B. Bussey C. Flavell R.A. Ghosh S. Science 303 2004 1522 1526 15001781 Zheng S.L. Augustsson-Balter K. Chang B. Hedelin M. Li L. Adami H.O. Bensen J. Li G. Johnasson J.E. Turner A.R. Cancer Res. 64 2004 2918 2922 15087412 Zhou C.X. Zhang Y.L. Xiao L. Zheng M. Leung K.M. Chan M.Y. Lo P.S. Tsang L.L. Wong H.Y. Ho L.S. Nat. Cell Biol. 6 2004 458 464 15122269 Zinkernagel R.M. Nat. Immunol. 1 2000 181 185 10973269